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1 Abstract 
1.1 Abstract 
Enterococcus faecalis (E. faecalis) is a common colonizer of the animal and human 
gastrointestinal tracts, also used as a probiotic mixture in health care or as a starter 
culture in food fermentation. In contrast, E. faecalis is an opportunistic pathogen and 
one of the leading causes of nosocomial infections, especially of the urinary tract, 
bacteremia and/or endocarditis. 
 With the focus on niche adaptation, this thesis presents results of the genomic 
comparison of 42 E. faecalis isolates of the most frequent multilocus sequence type 
ST40, comprising strains of various clinical origins and colonization 
(humans/animals), which also originated from different countries and isolated over a 
period of nearly 50 years. 
 We resolved the complete genome sequence of a porcine commensal ST40 
strain D32, which represents the first complete genome sequence of an animal E. 
faecalis isolate. It was further used as a template for detailed comparisons to high-
quality draft genomes of 14 related ST40 isolates. By reflecting the close relationship, 
genomic and phylogenetic analyses suggest a high level of similarity regarding the 
core genome, which was also reflected by similar carbon utilization patterns, 
analyzed by BIOLOG MicroArray™ technology. Distribution of known and putative 
virulence-associated genes does not allow any differentiation between ST40 strains 
from a commensal (animal/human) and clinical background. Further analyses of 
mobile genetic elements (MGE) revealed a large pool for genomic diversity due to: (i) 
a modular structured pathogenicity island (PAI), varying independently of the core 
genome; (ii) a site-specifically integrated and previously unknown genomic island (GI; 
138 kb) in D32, probably associated with exopolysaccharide synthesis; and (iii) a 
certain level of plasmid diversity and strain-specific phage patterns. Moreover, we 
used different cell-biological and animal experiments to compare the isolate D32 with 
a closely related clinical ST40 isolate UW7709, obtained from a patient with infective 
endocarditis and whose draft genome sequence was also generated within this 
project. The porcine colonizing strain D32 generally showed a greater capacity of 
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adherence and an increased pathogenic potential in combination with an even faster 
growth in vivo (not in vitro). 
In general, these findings emphasized the crucial role of MGEs in niche 
adaptation by transferring virulence-associated features, which enable isolates of the 
commensal microflora to be a potential source of infections in humans. 
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1.2 Zusammenfassung 
Enterococcus faecalis (E. faecalis) gehören zur natürlichen Flora des tierischen und 
menschlichen Verdauungstraktes, werden aber auch als Probiotika oder als 
Starterkulturen in der Lebensmittelfermentation eingesetzt. Als opportunistischer 
Krankheitserreger ist E. faecalis jedoch auch einer der häufigsten Ursachen für 
nosokomiale Infektionen, was insbesondere Harnwegsinfektionen, Bakteriämien 
und/oder Endokarditiden betrifft. 
 Grundlegend geht es in dieser Arbeit um den genomischen Vergleich von 42 
eng verwandten E. faecalis Isolaten, die dem am weitesten verbreiteten MLST 
Sequenztyp ST40 angehören. Unsere Sammlung zeichnet sich durch eine breite 
Diversität aus und umfasst Stämme verschiedener klinischer Herkunft und 
Besiedlung (Mensch/Tier), die weltweit über einen Zeitraum von fast 50 Jahren 
gesammelt wurden und wodurch eine mögliche Anpassung an ökologische Nischen 
am ehesten nachvollzogen werden sollte. 
 Es ist uns gelungen die vollständige Genomsequenz des ST40 Stammes D32 
darzustellen, der als Kommensale eines Schweins isoliert wurde und damit die als 
erstes veröffentlichte vollständige Genomsequenz eines tierischen E. faecalis Isolats 
repräsentiert. Diese Sequenzinformation nutzten wir dann als Grundlage für 
detaillierte Genomvergleiche mit den 14 ebenfalls sequenzierten und de novo 
assemblierten ST40 Isolaten. In diesen genomischen und phylogenetischen 
Analysen spiegelte sich die enge genetische Verwandtschaft durch ein stark 
konserviertes Kern- („core“) Genom wider, was zudem durch ähnliche Kohlenstoff-
Verwertungsmuster in den durchgeführten BIOLOG MicroArray™ Analysen 
verdeutlicht werden konnte. Bereits beschriebene und vermeintliche virulenz-
assoziierte Gene erlauben keine Differenzierung zwischen den ST40 Stämmen mit 
kommensalen (Tier/Mensch) und klinischen Hintergrund. Weitere Untersuchungen 
hinsichtlich des Vorkommens und der Zusammensetzung von  mobilen genetischen 
Elementen (MGE) offenbarten jedoch einen umfangreichen Pool an genomischer 
Diversität, dargestellt durch: (i) eine modular aufgebaute Pathogenitätsinsel (PAI), 
deren Zusammensetzung unabhängig vom Kern-Genom variierte; (ii) im D32 eine 
positions-spezifisch integrierte und bislang unbeschriebene genomische Insel (GI; 
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138kb), die vermutlich mit der Synthese von Exopolysacchariden in Verbindung 
gebracht werden kann; sowie (iii) einen gewissen Grad an Plasmid-Diversität sowie 
Stamm-spezifisches Phagenmuster. Darüber hinaus haben wir zellbiologische 
Assays und verschiedene Tiermodelle verwendet, um dieses Isolat mit dem sehr eng 
verwandten klinischen ST40 Isolat UW7709 zu vergleichen, das von einem Patienten 
mit einer infektiösen Endokarditis isoliert wurde und während dieser Arbeit ebenfalls 
sequenziert wurde. Bei diesen Vergleichen zeigte der Schweine-kolonisierende 
Stamm D32 ein stärkeres Adhärenzverhalten und eine höhere Pathogenität 
kombiniert mit einem schnelleren in vivo (nicht aber in vitro) Wachstum. 
Bezüglich der Anpassung an ökologische Nischen, weisen diese Erkenntnisse 
auf eine maßgebliche Rolle der MGE hin, durch die die Übertragung von virulenz-
assoziierten Eigenschaften vermittelt wird und wodurch Isolate der Mikroflora als eine 
mögliche Quelle für nosokomiale Infektionen des Menschen befähigt werden. 
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2 Introduction 
2.1 Genus Enterococcus 
Belonging to the third-largest genus of lactic acid bacteria (LAB), enterococci are 
commensals of the gastrointestinal tracts (GIT) of animals and humans and also well 
adapted to survive in diverse environmental and animal-associated habitats 
(reviewed in (67, 100, 117, 165)). 
 
Enterococci are Gram-positive, catalase-negative, non-spore-forming, facultative 
anaerobic bacteria, formerly classified as group D streptococci. In 1984, DNA-DNA 
and DNA-rRNA hybridization studies (210) resulted in the re-classification into the 
new genus Enterococcus (reviewed in (67, 165)). 
 
 
Figure 2.1: Scanning Electron microscopy of E. faecalis strain OG1RF (Image: G. Holland, Dr. 
N. Bannert, Robert Koch Institute, Berlin). 
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By now, more than 48 species of Enterococcus were described 
(http://www.bacterio.cict.fr/e/enterococcus.html), whereby E. faecalis and E. faecium 
have an outstanding position as common colonizers of the GIT and the cause of a 
wide range of infections, especially among hospitalized patients. 
 
2.1.1 Ecology 
Enterococci can grow at high salt concentrations, variable temperatures between 10 
to 45°C. Also being resistant to desiccation, they occur in many natural habitats, like 
soil, water, sewage, plants and animals (reviewed in (64, 67)). 
 
Enterococci play a crucial role as common colonizers of animals and humans. On the 
one hand, small numbers of enterococci occur in vaginal flora or on the skin and are 
rarely observed in oropharyngeal secretions (reviewed in (117)). But more important 
is their ability to colonize the gastrointestinal tracts of animals and humans, possible 
due to toleration and growth in the presence of 40% (w/v) bile acids. In healthy 
human feces, bacterial counts of E. faecalis range from 105 – 107 colony forming 
units (CFU) per gram and E. faecium counts range from 104 – 105 CFU per gram 
(reviewed in (64)). But in summary, human feces are mainly composed of anaerobic 
Gram-negative species ((186), reviewed in (117)). The suspected health-promoting 
effects explain, why some E. faecalis and E. faecium strains have been used as 
probiotics in health care (reviewed in (67, 278)). 
 
Because of their further beneficial impact on ripening and aroma production of 
cheese and fermented meat, vegetables and olives, enterococci are also used as 
starter cultures or co-starter cultures in food fermentation. Thereby, production of a 
variety of bacteriocins with inhibitory activity against food spoilage or foodborne 
pathogens, such as Listeria monocytogenes, Staphylococcus aureus, Vibrio 
cholerae, Clostridium spp., and Bacillus spp., is a particularly advantageous 
(reviewed in (67, 79)). 
 
On the contrary, enterococci are also opportunistic pathogens, especially associated 
with hospital-acquired infections. Thereby, E. faecalis is responsible for the major of 
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60 – 95% of nosocomial infections, while E. faecium is diagnosed in 5-40% of the 
cases (120). Hospitalized patients, especially premature newborns, 
immunocompromised and / or elderly patients, seem to have a greater incidence of 
enterococcal infections, particularly of surgical wounds, the urinary tract, bacteremia 
and/or endocarditis (reviewed in (64, 117, 278)). Moreover, enterococci are also able 
to survive for long periods on environmental surfaces and especially robustness on 
the surface of medical devices is one of the major problems, when preventing 
nosocomial transmission in hospital milieu (reviewed in (7)). 
 
2.2 Antibiotic resistance 
In context of enterococcal colonization of the gastrointestinal tract, antibiotic 
treatment plays a significant role. By destabilization of the intestinal microbial 
consortium, especially due to antibiotics with activity against anaerobic bacteria, new 
niches for colonization by resistant enterococci are opened ((78), reviewed in (7, 99, 
120)). An association between predominantly colonization with vancomycin-resistant 
enterococci (VRE) was demonstrated, which could also be associated with its 
invasion into the bloodstream in combination with the spread within the host 
organism (259). Primarily, hospital milieu holds various risk factors for an infection: 
long period of hospitalization in combination with multiple antibiotic treatments, 
immunosuppression, surgical interventions and / or contact with colonized medical 
devices or infected patients and accordingly medical personnel (reviewed in (7, 99, 
120)). In that context, it was demonstrated that intensive care units (ICU) are a 
reservoir for transmission of infections (76). 
 
2.2.1 Intrinsic resistance 
Intrinsic resistance mechanisms are naturally encoded on the host´s chromosome 
(reviewed in (3)). 
 
A characteristic feature of enterococci is resistance to ß-lactams (particularly 
cephalosporins, semi-synthetic penicillins and monobactams) due to expression of 
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chromosomal-encoded penicillin binding proteins (PBPs; PBP5 in E. faecium and 
PBP4 in E. faecalis) with a low affinity to bind ß-lactam antibiotics (reviewed in (120)). 
Additionally in E. faecalis, tolerance to ß-lactams is also induced by removal of 
reactive oxygen species by superoxide dismutase activity (19). 
 
Aminoglycosides act as 30S ribosome inhibitors and consequently inhibit protein 
synthesis (121). In enterococci, low-level intrinsic resistance to aminoglycosides is 
due to the low uptake of the drugs. To counteract, a combined therapy, consisting of 
cell wall active agents and aminoglycosides, is preferred to utilize bactericidal 
synergism (reviewed in (99)). 
 
An ABC-efflux pump mechanism is suggested to be responsible for intrinsic 
resistance of E. faecalis to lincosamides and streptogramins of class A and B, like 
quinupristin/dalfopristin. Due to expression of a differently encoded ABC-efflux pump, 
E. faecium only show low-level resistance to streptogramins of class B (reviewed in 
(99)). 
 
Only isolates of E. gallinarum and E. casseliflavus show low level intrinsic resistance 
to vancomycin, but are still susceptible for teicoplanin. In detail, expression of VanC 
phenotype is induced by replacing of the D-Ala ending of the peptidoglycan precursor 
to D-Ser resulted in a lower binding affinity to vancomycin (43). 
 
Wide spectrum activity of fluoroquinolones does not apply to enterococci because 
resistance is generally encoded by the transmissible qnr gene (9). 
 
2.2.2 Acquired resistance 
Resistance to antibiotics is also evolved by sporadic mutations in genes targeted by 
the antibiotic, as well as, by incorporation of mobile genetic elements (MGE) acquired 
of other bacteria of the environment. In fact, horizontal gene transfer (HGT) of 
resistance determinants mainly occurs through transfer of plasmids, bacteriophages 
and transposons. Consequently, spread of multidrug resistance (MDR) is one of the 
biggest challenges nowadays (reviewed in (3, 99, 278)). In the following, a selection 
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of acquired resistance mechanisms against clinically relevant enterococci is 
described. 
 
High-level resistance (HLR) to penicillins is associated with acquisition of ß-
lactamases.  The vast majority of resistance to ampicillin is found in E. faecium, but 
rarely in E. faecalis, and is associated with point mutations in the binding region of 
PBP5 (reviewed in (7, 99, 120)). 
 
The synergistic therapy is limited due to the acquisition of mobile genetic elements, 
harboring genes that encode for HLR to aminoglycosides (especially gentamicin and 
streptomycin). Resistance to gentamicin bases on the enzymatically inactivation of 
gentamicin and its structural homologs, induced by the bifunctional 6´-
aminoglycoside acetyltransferase 2´´ phosphotransferase enyzme. HLR to 
streptomycin is due to ribosomal mutations or antibiotic inactivation by 
adenylyltransferases Ant(6´)-Ia and Ant(3´´)-Ia ((63), reviewed in (8, 99)). 
 
In 1988, the first vancomycin resistant clinical isolates of E. faecium were reported in 
France (134) and the United Kingdom (260). At the same time, E. faecalis V583 was 
the first vancomycin resistant clinical isolate reported in the US (202). Nowadays, 
vancomycin resistant enterococci (VRE) are widely distributed and especially 
acquired vancomycin resistance in clinical E. faecium isolates is a major problem in 
hospital milieu (284). In this context, highly transferable plasmids (like broad host-
range Inc18 plasmid) play an important role in horizontal transfer of vancomycin 
determinants between enterococcal species (reviewed in (99)). However, presence of 
vanA resistance cluster in methicillin-resistant S. aureus (MRSA) was detected 
(reviewed in (185)), but Werner et al. also demonstrated that mobility across species- 
or genus-barriers seemed to be of lower frequency in vitro (281). Up to now, nine 
different vancomycin operons (vanA, vanB, vanD, vanE, vanG, vanL, vanM, vanN 
and the intrinsic vanC genotype) are described in enterococci, at which vanA and 
vanB gene clusters are most frequently (reviewed in (99)). Resistance mechanism 
bases on the modification of the C-terminus of the cell wall precursor, resulting in a 
less affinity to glycopeptides (reviewed in (43)). 
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Alternatively, the clinically relevant group of macrolide-lincosamide-streptogramin 
(MLS) antibiotics is characterized due to the similar antibacterial mechanism. 
Acquired resistance showed the following characteristics: (a) enzymatically 
methylation of rRNA, resulting from the expression of the erythromycin-resistant 
methylase (erm) genes; (b) presence of efflux pumps; or (c) enzymatically 
modification of the antibiotic, avoiding interaction to the ribosome (reviewed in (195)). 
 
Furthermore, tetracyclines are the first broad spectrum class of antibiotics and they 
are frequently used in livestock production. The acquired resistance mechanisms are 
based on (a) the inhibition of protein synthesis by preventing the attachment of tRNA 
to the ribosome, especially encoded by tetM gene; (b) tetL encoded efflux pumps, 
which remove the drug out of the cell; or enzymatically deactivation of the 
tetracyclines (reviewed in (35, 195)). 
 
 
2.3 Population structure and genomic diversity of E. faecalis 
Nowadays, sequence-based tools, like multilocus sequence typing (MLST) (142) or 
multiple-locus variable-number tandem repeat analysis (MLVA) (257) in combination 
with genome sequencing, are the “gold-standard” to obtain insights into the 
population structure of enterococci to pursue adaption to ecological niches (287) 
(reviewed in (278)). 
In 2006, Ruiz-Garbajosa and colleagues developed an MLST scheme for E. faecalis, 
based on sequencing of seven housekeeping genes. In comparison to the publicly 
available MLST database (http://efaecalis.mlst.net/), sequence of each locus resulted 
in a distinct allele number and combination of the allele numbers of all the seven loci 
assigned a sequence type (ST) (199). 
MLST analysis of a diverse collection of 110 E. faecalis isolates revealed four major 
clonal complexes (CC; CC2, CC9, CC10 and CC21), combining closely related 
sequence types (ST) (199). 
On the basis of this MLST scheme, widely distributed CC2 and CC9 were mainly 
characterized by containing hospital-associated strain types (125, 199, 200). But their 
characterization as high-risk enterococcal clonal complexes (HiRECCs) (133) is not 
Introduction 
7 
 
so strict, because isolates of these CCs were also found in feces of healthy infants 
(227), as well as, in pigs (68). Furthermore, other CCs – especially the CC40/ST40 – 
include strains of various clinical origins, from colonization and food (199). In this 
context, presence of antibiotic resistance and “virulence traits” can not only be 
correlated with adaption to hospital environment, because they were also found in 
livestock- and community-associated isolates (46, 128, 129, 227) and were spread 
over many diverse lineages of E. faecalis (129, 149). One important example is the 
so-called pathogenicity island (PAI), not limited to clinical strains (129, 149, 216). 
Probably, community could be a reservoir for transmission of E. faecalis clones. 
Further within this pool it is suggested, that MGEs, harboring genes with a proposed 
role in virulence, are spread between swine and humans (68, 129, 216). Types of 
MGEs with relevance in enterococci are discussed in section 2.6. 
 
Until now, five complete genome sequences (24, 28, 71, 184, 300), and, numerous 
draft genome sequences of E. faecalis are publicly available (179, 181, 229, 267). 
First, the VRE isolate V583, belonging to ST6/CC2, was completely sequenced in 
2003. In addition to the occurrence of a large pathogenicity island (PAI), more than a 
quarter of the genome comprises of MGEs, including three plasmids and seven 
integrated putative phages. Vancomycin resistance is mediated by integration of a 
vanB conjugative transposon (184). 
With a size of 2.74Mbp, the genome of the strain OG1RF, a derivate of the human 
colonizer OG1, was also sequenced (24).  Probably due to the presence of the 
CRISPR-cas system, a bacterial defense mechanisms against invading DNA, this 
strain lacks plasmids, was well as, phages. But the putative role of CRISPR-cas will 
be described in part 2.5.1.4 in more detail. In comparison to V583, the OG1RF 
contains an inositol iol operon at the same attL/R site, which explained its ability to 
utilize m-inositol (27). 
Furthermore, genome sequence of the commensal strain 62 (2.99Mbp), isolated from 
a healthy Norwegian infant, harbored genes involved in lactose and other 
carbohydrate metabolism, but also lacks virulence-associated traits. This suggested 
its adaption to the environment of the GIT (28). 
During this thesis, the first complete genome sequence of an animal E. faecalis strain 
was resolved (300) and a detailed analysis of its sequence data will be presented. 
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At the beginning of 2013, the complete genome sequence of the probiotic E. faecalis 
Symbioflor 1 clone DSM 16431 was reported by Fritzenwanker et al. (71). With a 
genome size of 2.81Mbp, the absence of putative virulence traits and the previously 
described vanB transposon emphasize its non-pathogenic characteristics (53, 71). 
 
 
2.4 Important aspects of metabolism of E. faecalis 
Within the complex ecosystem of the intestine, enterococci are well adapted to the 
harsh conditions, where nutrients are limited. Thereby, a large spectrum of 
substrates, like diverse carbohydrates, organic acids, and amino acids, are 
catabolized to pyruvate. Catalyzed by the NADH-dependent L-(+)-lactate 
dehydrogenase (ldh), pyruvate is mainly reduced to lactate, the major end-product of 
LAB fermentation (reviewed in (107),(137)). But among enterococci, only E. faecalis 
is able to utilize pyruvate for growth (reviewed in (107)). 
However, it was also demonstrated that certain conditions, probably such as the 
NADH/NAD ratio, can regulate a shift from homolactic to mixed-acid fermentation, 
where pyruvate is also fermented to other end-products, such as formate, ethanol, 
acetate, CO2, diacetyl, acetoin, and 2,3-butanediol (116, 137, 153). 
Hexoses and pentoses are primary key components of pyruvate formation. Especially 
substrates, like D-glucose, D-fructose, lactose, maltose, D-mannose, trehalose, 
sucrose, mannitol, and N-acetylglucoseamine, could be sensed and effectively 
transported into the bacterial cell by the phosphoenolpyruvate phosphotransferase 
system (PTS), where they are further channeled into glycolysis, Entner-Doudoroff, 
and pentose phosphate pathways, respectively (reviewed in (107)) (226). E. faecalis 
and other enterococci lack a tricarboxylic acid cycle and, consequently, enhanced 
pyruvate metabolism plays a key role within energy metabolism. Additionally, this 
also explains the disability to produce the porphyrin precursors resulting in the lack of 
heme synthesis (reviewed in (107)). Besides, only E. faecalis is able to ferment the 
sugar alcohol component glycerol to pyruvate in absence of oxygen, and not only 
under the ordinary aerobic and microaerophilic conditions (reviewed in (107)). 
Organic acids, like malate and oxaloacetate, generated from citrate, aspartate or 
tartrate, can also be decarboxylated to pyruvate (reviewed in (137)). However, there 
Introduction 
9 
 
are several other potential possibilities for energy gain in E. faecalis, like catabolism 
of arginine and its derivate agmatine, oxidation of lactate and heme-dependent 
respiration by cytochrome bd, as well as, energy-yielding by ion transport (reviewed 
in (107)). 
In context of the diverse microbial colonization of the intestine, the effective uptake of 
energy sources in combination with their efficient metabolism implicate bacterial 
fitness.  On the other side, these mechanisms could also be used for regulation of 
expression of virulence genes.  For example, activity of the major virulence regulator 
PrfA in Listeria monocytogenes is affected by the phosphorylation state of the PTS 
components ((54), reviewed in (188), (65)). 
 
 
2.5 Pathogenicity of E. faecalis 
In close association with the host immune system, the normal microflora represents 
the essential barrier defending several potential pathogens (62). But potential danger 
also lurks in their own lines – concretely in form of E. faecalis, for example. As an 
extremely robust opportunistic pathogen, E. faecalis is one of the leading causes of 
nosocomial infections (120), especially of the urinary tract, bacteremia and/or 
endocarditis. 
 
2.5.1 Virulence determinants 
According to Pillar et al., four steps from bacterial colonization up to the point of host 
damage have been described, including phases of (i) colonization, (ii) bacterial 
spread, (iii) persistence and growth, and (iv) tissue damage (186). Special 
environmental conditions could enable antibiotic resistant, opportunistic pathogens, 
like vancomycin resistant enterococci (VRE), to “overgrowth” normal commensal 
microbiota (259). 
Several recent studies have identified putative enterococcal virulence traits. Their 
relevance in enhanced adherence was investigated in several cell culture assays (75, 
94, 208, 248, 249) and their role in virulence was also estimated in various animal 
Introduction 
10 
 
infection models (Table 2.1) (reviewed in (41, 74, 90, 194, 218, 255), reviewed in 
(178, 207)). 
 
At this point, importance of biofilm formation by E. faecalis should be emphasized 
because of its clinical relevance in enterococcal growth on medical devices, 
catheters, implants, or heart valves. These infections are extremely hard to treat 
because biofilms protect bacteria against antibiotics or host defense strategies, like 
phagocytosis (reviewed in (98, 178)). 
In general, biofilms are a three-dimensional structured consortium of attached 
populations of microbes, surrounded by an extracellular polymeric substance (EPS) 
matrix. This EPS matrix consists of polysaccharides, proteins and extracellular DNA 
(eDNA) (reviewed in (73, 98)). Moreover, analyses of early biofilm formation by 
Barnes and colleagues also revealed a cell lysis-independent mechanism of eDNA 
release by living bacterial cells (13). 
Mature biofilms are characterized by a concentration gradient of metabolic substrates 
and products, such as oxygen. Adaption to the local environment within the biofilm 
can be effected by various responses, like regulation of gene expression, genetic 
variation through mutation or recombination (reviewed in (236)). 
In the following parts, the most important virulence factors, focused in this study, will 
be described and their role in biofilm formation will be discussed (Table 2.1) 
 
2.5.1.1 Bacterial colonization and fitness 
Components of the cell envelope play a crucial role in fitness and virulence, 
especially biofilm formation, because they enhance the bacterial ability to adhere to 
host cells and the extracellular matrix (ECM), as well as, to neighboring cells 
(reviewed in (178)). 
For example, the enterococcal surface protein (Esp) is discussed to be one of the 
biofilm-enhancing factors (241) and seemed to be highly associated with the ability of 
E. faecalis to form biofilms on polystyrene surfaces (256), as well as, with the 
colonization of the urinary tract (218). But other data indicated that biofilm formation 
is independent form esp presence (60, 105, 124, 159). However, an advantage 
concerning to the bacterial fitness might be conceivable (51). 
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Furthermore, there are several other enterococcal adhesion factors, such as the 
members of the MSCRAMM (microbial surface component recognizing adhesive 
matrix molecule proteins) family, like aggregation substance and Ace (adhesion to 
collagen in E. faecalis), promoting adherence to the ECM. Furthermore, the 
enterococcal glycopolymers lipoteichoic acids (LTA) and peptidoglycan-attached wall 
teichoic acids (WTA) are responsible for binding to epithelial and endothelial cells, 
but also to biomaterials, and are also important for host cell invasion. It was also 
demonstrated that biochemical modifications resulted in a reduced sensitivity against 
cationic antimicrobial peptides by changes in the membrane charge (reviewed in 
(178, 194)). 
 
Analyzes of pathogenicity, for example using a rat endocarditis and a murine urinary 
tract infection (UTI) model, described the role of endocarditis and biofilm associated 
pilus operon ebpABC, encoding pilus structures, in an increased attachment and 
biofilm formation (27, 221). Furthermore, expression of this locus could be controlled 
by RNA processing, as well as, the two regulators ebpR and fsr and could be 
enhanced by environmental conditions, like bicarbonate concentration (reviewed in 
(178)). 
 
In summary, enriched presentation of surface-related structures seemed to be 
associated with virulence, demonstrated for strains of MLST CC2 (229). 
 
2.5.1.2 fsr-regulated proteolytic activity 
A complex interplay between the zinc metalloprotease gelatinase (GelE) and the 
serine protease (SprE) plays a major role in biofilm formation by causing cell lysis (6, 
88, 251, 252). The co-located and co-expressed gelE and sprE genes are tightly 
regulated by the upstream fsrABDC quorum sensing locus (189, 251) and their 
relevance for virulence in E. faecalis was determined in different animal models (168, 
220, 224, 255). GelE-mediated cell death resulted in eDNA release, which stabilizes 
the EPS biofilm (reviewed in (178)). Cell lysis is primary induced by modifying cell 
wall affinity of the proteolytically processed autolysin AtlA/Atn. However, autolysis is 
negatively affected by sprE, acting as an immunity protein against lysis (251, 252). 
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2.5.1.3 Toxicity by cytolysin 
Both, hemolytic and bactericidal activities are induced by the quorum-sensing 
regulated cytolysin expression (84, 85). The mainly responsible cytolysin (cyl) operon 
is encoded within the E. faecalis PAI in close association with the esp gene (215, 
217) or also on large pheromone-responsive plasmids (36, 110). Its role in 
contribution of virulence in E. faecalis was demonstrated in different infection models, 
ranging from C. elegans to rabbits (reviewed in (41)). 
 
2.5.1.4 Strategies of self-protection against hosts defense mechanisms 
Persistence due to evasion of the host immune system also plays a major role in 
virulence. Additionally to the formation of protective biofilms, especially encapsulation 
by capsular polysaccharides has been shown to cause resistance to complement-
mediated opsonophagocytosis by masking LTA (87, 103, 106, 253, 254). There are 
two well-studied enterococcal cell wall polysaccharides: (i) a rhamnopolysaccharide 
Epa (244, 245, 293) and (ii) a MLST-specific capsular polysaccharide cps (87, 103, 
150). 
The former is supported for a key role in bacterial fitness. But nevertheless, behavior 
of tested mutants was demonstrated to be associated with pathogenicity, such as 
resistance to PMN-killing, biofilm formation, and virulence in a mouse peritonitis 
model, but needs more investigations (159, 194, 244, 245, 293). Two glycosyl 
transferases, which are encoded by ef2167 and ef2170 and are enriched in strains of 
MLST CC2, are suspected to have an effect to the structural diversity of Epa (194, 
229). 
Concerning the E. faecalis capsule, a serotyping scheme was defined by the 
presence of the 11 open-reading frames (ORF) of the cps locus (cpsA to cpsK) (87, 
104). Strains of serotypes A and B possessed only the cpsA and cpsB genes, 
defined by the absence of a capsule (Maekawa/CPS type 1). Presence of capsular 
polysaccharides depends on the presence of cpsC to cpsK genes. Serodiversity 
between serotype C (Maekawa/CPS type 2) and D (Maekawa/CPS type 5) is 
attributed to the presence or absence of the putative glycosyltransferase encoded by 
cpsF gene (104, 141, 150, 253). In a large-scale study with respect to genetic 
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diversity of a diverse E. faecalis strain collection, CPS type 1 was most common, 
while CPS type 2 was associated with the accumulation of virulence traits and 
antibiotic resistances (150). 
 
Table 2.1: Putative virulence factors present in E. faecalis. 
Putative virulence factors Pathophysiology/Virulence Reference(s) 
Secreted factors:   
Cytolysin 
(hemolysin/bacteriocin) 
Lyses a broad range of eukaryotic and 
Gram-positive cells 
(36, 40, 41) 
Gelatinase / serine protease, 
regulated by fsrABDC quorum 
sensing locus  
Biofilm formation, host tissue damage, 
immune evasion by degradation of 
complement peptide C3; Pathogenesis 
of Endocarditis  
(25, 183, 190, 220, 
255) 
Autolysins: AtlA/Atn, AtlB, AtlC  Cell lysis and biofilm formation by 
releasing of eDNA  
(83, 251, 252) 
Reactive oxygen species Extracellular superoxide and hydrogen 
peroxide; oxidative stress to damage 
other bacteria or host cells 
(108, 109, 240) 
Cell envelope bound factors:   
LPxTG surface proteins: 
 
 (Reviewed in (95)) 
(a) Aggregation substance, 
AS: Asa1, Asp1, Asc10  
Promotes conjugation by directing 
aggregation, adherence to ECM, 
internalization; pathogenesis of 
endocarditis 
(36, 97, 123, 176, 
191, 197, 206, 211, 
238, 263, 271, 277) 
(b) Collagen-binding 
MSCRAMMs: Ace 
Binding to collagen type I, collagen type 
IV, laminin and dentin; unclear 
relevance in endocarditis 
(122, 169, 170, 193, 
225) 
(c) Enterococcal surface 
protein Esp 
Biofilm enhancing factor; Role in murine 
UTI 
(218, 241, 242, 256) 
(d) Pili ebpABC locus Three pilus subunits (EbpA, B and C) 
with a role in initial attachment during 
the process of biofim formation; 
assembly and cell wall anchoring by 
sortase SrtA; role in pathogenesis of 
endocarditis and UTI; antigenic in 
humans 
(27, 38, 171, 173, 
221, 223) 
(e) bee locus Biofilm formation (among 5% of E.fs) (243) 
(f) EF3314 Putative adhesion (45) 
Introduction 
14 
 
Capsular polysaccharides, cps 
locus 
Immune evasion due to resistance to 
complement and PMNs-mediated killing 
(87, 103, 254) 
Enterococcal 
rhamnopolysaccharide antigen 
Epa 
Erythrocyte translocation, resistance to 
killing by PMNs and to infection by 
phages; biofilm formation; pathogenesis 
in a mouse peritonitis model; key role in 
host adaptation and fitness 
(159, 194, 222, 244, 
245, 293, 295) 
Lipid-attached lipotechoic acids 
(LTA) 
Attachment to epithelial and endothelial 
surfaces, as well as, to biomaterials; 
involved in host cell invasion; target of 
opsonic antibodies 
(194, 247) 
Peptidoglycan-attached wall 
teichoic acids (WTA) 
Attachment to epithelial and endothelial 
surfaces, as well as, to biomaterials; 
involved in host cell invasion 
(172, 194) 
Glycolipids  
(like the bgsA-encoded 
gylcosyltransferase)  
Biofilm formation, binding to colonic 
epithelial cells; pathogenesis in murine 
bacteremia model 
(208, 248) 
  ECM, extracellular matrix; E.fs, E. faecalis; LPxTG, cell wall-anchored Leu-Pro-x-Thr-Gly proteins, 
where x denotes any amino acid; LTA, lipoteichoic acid; MSCRAMM, microbial surface component 
recognizing adhesive matrix molecules; PMNs, polymorphonuclear leukocytes; UTI, urinary tract 
infection; WTA, wall teichoic acid (Table modified and completed from (130, 178, 207)). 
 
2.5.2 Short insights into the role of differential gene expression 
Up to now, several in vitro transcriptome analyses, for example using DNA 
microarrays and RIVET, emphasized the role of the differential expression of putative 
virulence-associated genes controlled by diverse transcriptional regulators, like PerR 
(194), the PAI-encoded PerA ((140), reviewed in (178)), Fsr (reviewed in ((178)), 
AhrC (66), ebpR (27), or Rex factor (153, 268). But also, discrepancies between 
transcriptomic and proteomic data revealed further possibilities of regulation on a 
posttranscriptional or translational level (152). Thereby, a complex regulatory network 
is distinguished (56), being further regulated by environmental conditions, such as 
growing in the presence of bile (21, 228), blood (266), urine (267), metals (138, 192), 
or bicarbonate (27, 140). 
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2.6 Genome plasticity by exchange of MGEs 
Enterococcal genomes evolutionary adapt to new niches, like hospital environment, 
by the exchange of genes by HGT and homologous recombination (reviewed in 
(262)). Thereby, acquisition and spread of virulence or resistance associated genes 
by MGE, such as bacteriophages, plasmids, genomic islands (GIs) and transposable 
elements, can result in a beneficial effect under certain circumstances (reviewed in 
(52, 92, 278)). Initial fitness costs are relativized over the time and beneficial effects 
of the plasmid-bacteria association may become dominantly (234). 
Transposable elements, including transposons, insertions (IS) elements, and 
integrons, play a crucial role in genome plasticity because they move genes directly 
from one DNA site to another genomic location. Transposons in enterococci can be 
categorized as elements of Tn3-family, composite transposons and integrative 
conjugative elements (ICE). By an interplay of recombination and/or transposition, 
variability of such MGEs is increased, as well as, gene expression can be affected 
due to insertion into an ORF or into a promoter region (reviewed in (92, 278)). 
Importantly, transmission of enterococci from animal source to humans, also being 
associated with infections, was demonstrated (68, 128, 129). In this context, 
conjugative and transferable elements play an important role in spread of resistance 
genes via lateral gene transfer (reviewed in (278)). 
 
2.6.1 The pathogenicity island (PAI) 
PAIs are large genomic regions (≥10 – 200kb), whose GC-content differs from the 
core genome. Their naming bases on the presence of one or more virulence-
associated genes, which are normally absent in non-pathogenic strains. HGT and 
recombination seem to play a key role in its adaptive evolution, because PAIs are 
frequently integrated in transfer RNA (tRNA) genes and they also contain genes 
associated with mobility, like IS elements, integrases or transposases. However, 
characteristic segments of the PAI were also found in commensal, symbiotic and 
environmental bacteria (reviewed in (52, 86)). 
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E. faecalis MMH594, which caused a hospital outbreak in the mid-1980s, was the 
first enterococcal strain reported to contain a PAI, possessing a size of 153kb (215). 
Genomic analyses revealed 129 predicted ORF, encoding for several pathogenicity 
factors like cytolysin toxin, Esp, and aggregation substance (149, 215). The PAI of 
MMH594 seems to be a prototype from which strains like V586 and V583 evolved. 
The region, spanning the co-localized genes of the cytolysin operon and esp, was 
nearly identical. In V586, insertions interrupted the cylB gene, resulted in a Cyl-
negative but Esp-positive phenotype. Whereas, V583 was phenotypically Cyl- and 
Esp-negative because of a spontaneous deletion of a 17,036bp DNA segment, which 
occurred in the strain V586 (215). 
The E. faecalis PAI also contains genes encoding transcriptional regulators, such as 
quorum-sensing fsrABDC locus (described in part 2.5.1.2) or PerA (pathogenicity 
island-encoded). This araC-type regulator is suggested to coordinately regulate 
genes, involved in metabolism and pathogenicity, including biofilm formation (39, 86, 
140, 189, 215). A number of additional factors within the PAI can influence the ability 
to colonize new niches within the host GI tract and might have an impact on 
pathogenesis. Genomic comparisons of the PAI-related genes of several 
enterococcal strains demonstrated the presence of genes associated with enhanced 
intestinal fitness, like due to the expression of a putative bile acid hydrolase (encoded 
by cbh) or of proteins with a function in DNA damage repair. Furthermore, other traits 
can contribute to survival under conditions of nutrient starvation or other stresses, like 
the general stress protein Gls24-like, PTS, or alternative metabolic enzymes, for 
example responsible for utilization of xylose ((149, 215), reviewed in (186)). 
Contrasting the situation of Gram-negatives, the E. faecalis PAI shows a modular 
organization by defined gene clusters, categorized from regions A-F, and was found 
to be highly variable in gene content independently of clonal background (1, 149, 
150, 216). 
Representing a prime example (reviewed in (86)), the PAI in E. faecalis MMH594 has 
a GC-content of 32.3%, which varies to 37.38% of the remainder genome (reviewed 
in (186)). Additionally, the ends of the PAI contain phage-related integration and 
excision genes and were flanked by 10bp direct repeats (DR), resembling attachment 
sites attL/R for phage integrases (131, 215). Furthermore, several segments are 
flanked by multiple IS elements and conjugal transfer elements are also present. 
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These characteristics revealed that the PAI or segments of it could be mobilized. 
Although recombination is a key factor within the diversification of the core genome, it 
is suggested that the PAI evolves even faster most likely by HGT, which emphasized 
the variety of the PAI independently of the core genome (40, 149, 215). Previous 
studies demonstrated that segments, as well as, the PAI itself were transferable 
between E. faecalis isolates, as well as, between E. faecalis and E. faecium through 
conjugative mechanisms (40, 131, 145, 175), confirming the importance of mobile 
elements in the evolution from non-pathogenic to pathogenic E. faecalis. 
 
2.6.2 Plasmids 
As semi-autonomously replicating extra-chromosomal genetic elements, plasmids 
play a key role in bacterial adaptability and diversity of the gene pool within the 
species of many genera, mainly by HGT (reviewed in (250)). Further, stable 
inheritance can be facilitated by an acquired toxin-antitoxin (TA) system, a kind of 
selective killing machinery in case of plasmid loss (91, 162). Furthermore, Manson et 
al. demonstrated that plasmid integration into the chromosome occurs in a RecA-
dependent manner (145). 
 
2.6.2.1 Plasmid typing 
By focusing on the phylogenetic relationship, enterococcal plasmids can be classified 
by several strategies; especially typing methods based on (i) the mode of replication 
(rolling cycle replication or theta-replicating plasmids) (reviewed in (278)),  (ii) 
replication regions of various incompatibility (Inc) groups (reviewed in (30, 174)), (iii) 
homology of conserved areas of the replication initiation genes (rep) (114), or (iv) the 
specification of genes encoding for relaxases (37). 
However, plasmids of the Inc18 group, like pIP501 (rep-family 1) and the multi-
resistant plasmid pRE25 (rep-family 2), are broadly distributed among Gram-positive 
and partly Gram-negative bacteria, too (114, 127, 213, 246, 273); whereas, 
pheromone-responsive plasmids are characterized by a narrow host range (273). 
Also proposed as RepA_N plasmids (272), pheromone plasmids of E. faecalis are 
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classified to rep-family 8 and 9, represented by pAM373, as well as, pCF10 and 
pAD1 (114). Additionally, large plasmids, like the megaplasmid pLG1, are only 
described to be widespread in the hospital-associated E. faecium population (70, 
132, 196). 
In summery, classification of enterococcal plasmids is a complex matter, because (i) 
some of the rep-types are still unknown (92, 270), (ii) new plasmids are identified 
within whole genome sequencing projects (reviewed in (278)), and (iii) recombinatoric 
diversification resulted in mosaics of plasmid structures (69). 
 
2.6.2.2 Benefits resulting from the acquisition of plasmids 
Plasmids confer genomic flexibility, which enable bacteria to adapt to different 
ecological niches and to evade host defense strategies (reviewed in (278), (297)). 
Especially megaplasmids are described to confer fitness and a selective advantage 
due to (i) the expression of virulence-associated genes, such as LPxTG surface 
proteins or cytolysin, (ii) enzymes for the uptake and utilization of unusual carbon 
sources, as well as, (iii) the resistance to heavy metals and antibiotics (36, 95, 99, 
110, 132, 192, 297). 
 
2.6.3 CRISPR-cas – a prokaryotic immune system 
Within the genomic variability, bacteria and archaea have also evolved a self-defense 
mechanism, clustered regularly interspaced short palindromic repeats (CRISPR), to 
limit HGT of mobile extra-chromosomal DNA elements, mainly like plasmids or 
bacteriophages (14, 29, 31, 101, 148). Widely distributed CRISPRs are typically 
characterized by several non-contiguous direct repeats, varying in size from 24 to 
47bp, separated by stretches of variable sequences of spacers (81, 112, 160).  By 
forming the CRISPR-cas system, six “core” CRISPR-associated genes (cas1-6), 
encoding for functional proteins with homology to nucleases, helicases, polymerases, 
and polynucleotide-binding proteins, can be found in multiple subtypes (reviewed in 
(101)). 
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By describing the spectrum of immunity, many CRISPR spacers showed sequence 
homology to MGEs, especially phages (230). During a kind of immunization process, 
the Cas complex recognizes and integrates a small segment of the exogenous DNA 
as a novel repeat-spacer unit at the leader end of the CRISPR array ((14), reviewed 
in (101)). This resulted in acquired immunity against the corresponding invading 
DNA, functioning via the RNA interference (RNAi) mechanism (reviewed in (101)). 
The genome of E. faecalis OG1RF comprises only one phage remnant as part of the 
core genome and generally lacks mobile genetic elements (24, 150). Nevertheless, 
two CRISPR loci (CRISPR1 and CRISPR2) were described, while only CRISPR1 is 
associated with functional cas nuclease genes (24). However, over one quarter the 
genome of the clinical isolate V583 consists of MGE, but only harbors an orphan 
CRISPR2 locus, lacking the functional cas genes required for CRISPR defense (180, 
184). 
 
In the evolutionary context, composition of CRISPR arrays is extremely unstable, 
completely varying between closely related strains. Presumably by HGT, CRISPR 
loci evolved due to a process of adaption to rapidly changing repertoires of phages 
and plasmids (reviewed in (101), (136, 143, 230)). Furthermore, antibiotic usage 
seemed to have a negatively selective effect to CRISPR-associated immunity, 
reported by Palmer and Gilmore (180). 
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2.7 Objectives of this study 
McBride et al. analyzed the genetic diversity among a collection of 106 E. faecalis 
strains isolated over the past 100 years, demonstrating that MLST ST40 is the most 
common sequence type (150). 
According to these observations, the overall aim of this thesis is to characterize a 
heterogeneous E. faecalis ST40 strain collection, comprising randomly collected 
isolates of various clinical origins and colonization (humans/animals), which also 
originated from different countries and isolated over a period of many decades. 
The main objectives are to identify microevolutionary changes coming along with 
niche adaptation and differences in pathogenic properties between highly related 
microorganisms. 
More specifically, the following workflow is pursued: 
(i) Analysis of the presence and expression of well-known virulence-
associated markers, encoded within the E. faecalis pathogenicity 
island (PAI) and/or on the chromosome. 
(ii) Investigation of plasmid content and their characterization. 
(iii) On the basis of these previous characterizations, representative 
isolates should be chosen for de novo genome sequencing and 
comparison of these genome data sets among each other and 
with the publicly available E. faecalis complete genome 
sequences of V583 (184) and OG1RF (24) with the focus on 
niche adaptation. 
(iv) Examination of utilization of carbon sources by using Biolog 
MicroArray™ technology. 
(v) Investigation of the relationship between the genomic data and 
the in vivo pathogenic potential in selected animal models. 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Chemicals 
Table 3.1: Chemicals used in this study. 
Chemicals Manufacturer 
Agarose Sigma-Aldrich GmbH 
Agarose Life Technologies Corporation 
Amino acids (nonessential) Life Technologies Corporation 
BIOLOG Redox Dye Mix D (100x) BIOLOG Life Science Institute 
Bromphenol blue (loading) Sigma-Aldrich GmbH 
Calcium chloride dihydrate (CaCl2∙2 H2O) Merck KGaA 
Chloroform Sigma-Aldrich GmbH 
EDTA (Ethylenediaminetetraacetic acid) Serva Electrophoresis GmbH 
Ethanol (96%) Merck KGaA 
Ethidium Bromide (10mg/mL) CARL ROTH GmbH & Co. KG 
Fetal bovine serum PAA - The Cell Culture Company 
D-glucose Merck KGaA 
Distilled water Sigma-Aldrich GmbH 
Gelatin Becton, Dickinson & Co. 
Gram´s crystal violet Merck KGaA 
Heparin Sigma-Aldrich GmbH 
Hydrochloric acid 37% (HCl) CARL ROTH GmbH & Co. KG 
L-arginine Sigma-Aldrich GmbH 
Lysozyme Sigma-Aldrich GmbH 
Magnesium chloride (MgCl2) CARL ROTH GmbH & Co. KG 
Magnesium chloride hexahydrate (MgCl2∙6 H2O) CARL ROTH GmbH & Co. KG 
Maleic acid CARL ROTH GmbH & Co. KG 
N-Lauroylsarcosine Sigma-Aldrich GmbH 
Phenol/Chlorofom/Isoamyl alcohol (25:24:1) CARL ROTH GmbH & Co. KG 
Potassium chloride (KCl) CARL ROTH GmbH & Co. KG 
Potassium hydroxide (KOH) Jenapharm Laborchemie 
Potassium phosphate, monobasic (KH2PO4) Merck KGaA 
Proteinase K AppliChem GmbH 
Proteinase K Sigma-Aldrich GmbH 
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RNaseI Sigma-Aldrich GmbH 
S1 nuclease Takara Bio Inc. 
SmaI New England Biolabs Inc. 
Sodium chloride (NaCl) Sigma-Aldrich GmbH 
Sodium dodecyl sulphate (SDS) CARL ROTH GmbH & Co. KG 
Sodium hydroxide (NaOH) CARL ROTH GmbH & Co. KG 
Sodium phosphate, dibasic (Na2HPO4∙2 H2O) Merck KGaA 
Tris(hydroxymethyl)aminomethane (Tris) CARL ROTH GmbH & Co. KG 
Tris-HCl Merck KGaA 
Tri-Sodium citrate Merck KGaA 
Trypsin Life Technologies GmbH 
Triton X-100 Sigma-Aldrich GmbH 
Trypton Becton, Dickinson & Co. 
Tween 20 CARL ROTH GmbH & Co. KG 
 
Table 3.2: Molecular markers and their sizes. 
DNA Molecular Size markers Manufacturer 
GeneRuler 100bp DNA-Ladder Plus Thermo Fisher Scientific Inc. 
GeneRuler 1kb DNA-Ladder Plus Thermo Fisher Scientific Inc. 
DIG III DNA-Ladder DIG III DNA-Ladder 
 
3.1.2 Kits 
Table 3.3: Kits used during this work. 
Kit Manufacturer 
Cycle Sequencing Kit B3.1 (BigDye) Applied Biosystems 
DIG High-Prime F. Hoffmann-La Roche AG 
DIG Nucleic Acid Detection Kit F. Hoffmann-La Roche AG 
DNAeasy Blood and Tissue kit QIAGEN GmbH 
Expand Long Template PCR F. Hoffmann-La Roche AG 
Genomic Tipp 100 DNA isolation QIAGEN GmbH 
PCR Master Mix Thermo Fisher Scientific Inc. 
Quant-iTTM PicoGreen® dsDNA Assay Kit Life Technologies GmbH   
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3.1.3 Media 
Table 3.4: Media used for culturing of bacteria and cell-lines. 
Medium Manufacturer 
BIOLOG IF-0a GN/GP Base inoculating fluid (1.2x) BIOLOG Life Science Institute 
Brain-Heart Infusion (BHI) agar Oxoid GmbH 
Brain-Heart Infusion (BHI) medium Oxoid GmbH 
Dubelco`s Modified Eagle`s Medium (DMEM) Difco® labs 
de Man, Rogosa and Sharpe (MRS) Agar OXOID GmbH 
de Man, Rogosa and Sharpe (MRS) Broth OXOID GmbH 
Mueller-Hinton (MH) Agar with sheep blood OXOID GmbH 
Nutrient Agar OXOID GmbH 
Nutrient Broth Becton, Dickinson & Co. 
Todd-Hewitt agar  OXOID GmbH 
Tryptic Soy Agar (TSA) Becton, Dickinson & Co 
Tryptic Soy Broth (TSB) Becton, Dickinson & Co 
 
3.1.4 Standard solutions 
Gram positive cell-lysis buffer 
 Tris, pH 8.0       20mM 
EDTA       2mM 
Triton X-100       1.2% 
added before usage: 
Lysozym       20 mg/mL 
 
Phosphate buffered saline (PBS) 
 NaCl       137mM 
 KCl       2.7mM 
 Na2HPO4∙2 H2O     10mM 
 KH2PO4      2mM 
pH 7.4 
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Tris-EDTA (TE) buffer 
 Tris-HCl      200mM 
EDTA       20mM 
pH 7.5 
 
TES buffer 
 Tris-HCl pH 8.0     10mM 
 Trypton pH 8.0     1mM 
 
Tris-Borat-EDTA (TBE) buffer 
Tris       10,78 g 
Sodium EDTA (Celaplex III)    0,1 g 
Boric acid      5,4 g 
pH 8.0 
 
3.1.5 Software and Internet resources 
Table 3.5: Software tools and publicly available web tool used for data analysis. 
Program Manufacturer Type of application 
AIDA Image Analyzer 
Version 3.52 
Raytest Evaluation of fluorometric analysis 
Artemis 12 Sanger Institute DNA sequence edition 
BioNumerics 
Version 6.0 
Applied Maths PFGE analysis 
BLAST Ring Image Generator 
(BRIG) 
Sourceforge/Dice 
Holdings, Inc. (4) 
Image generation of a multiple E. faecalis 
genome comparison 
Celera Assembler Version 6.1 
Celera Genomics, Inc. 
(156, 167) 
Hybrid de novo assembly using reads 
gathered by 454 and long paired-end 
sequencing technologies  
CRISPRFinder 
Institut de Génétique et 
Microbiologie (82) 
Web tool to identify clustered regularly 
interspaced short palindromic repeats 
(CRISPR) 
DS Gene Software Accelrys, Inc. 
Analysis of DNA sequences; primer 
design 
EDGAR CeBiTec (20) VENN diagram 
EndNote® X5 Thomas Reuters Reference library 
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GeCo 
University Giessen 
(126) 
Comparative genome analysis 
GenDB CeBiTec (155) Genome annotation 
GraphPad Prism 5.01 software 
package 
GraphPad Software, 
Inc. 
Statistical analysis 
Kodon Software 
Version 3.61 
Applied Maths 
DNA sequence alignments and 
comparisons 
Lasergene 8 (Seqman) DNAStar Evaluation of DNA sequences 
MAUVE (progressive ~) (47, 48) Genome alignment 
Microsoft office package 
Version 7 and Version 10 
Microsoft Word, Excel, PowerPoint 
MiniMap 
University Giessen 
(Kuenne, C.T., 
unpublished software) 
Primer design for gap closing 
Mira Assembler 
Version 3.4.0.1 
Sourceforge/Dice 
Holdings, Inc. (33, 34) 
Hybrid de novo assembly using reads 
generated by 454 and Illumina/Solexa 
sequencing technologies  
Mugsy (5) MCL clustering and alignment 
NCBI BLAST NCBI (209) Alignment search tool 
NCBI ORF Finder NCBI (209) ORF Finder 
Newbler Assembler 
Version 2.5.3 
F. Hoffmann-La Roche 
AG 
Assembly of data generated by 454 
pyrosequencing 
OmniLog Kinetic and 
Parametric analysis software 
version 2005 
BIOLOG Life Science 
Institute 
Analysis of Biolog MicroArray® data 
PHAge Search Tool (PHAST) 
Free Software 
Foundation, Inc. (299) 
Identification of prophages integrated into 
the genome 
Prophage Finder (23) Identification of integrated prophages 
Quantity One 
Version 4.6.6 
BioRad 
Laboratories 
Documentation of gel images and 
Southern hybridization membranes 
RAST Server  (10) Genome annotation 
RAxML (233) Generation of the phylogenetic tree 
Sequin 9.0 NCBI DNA sequence edition 
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3.1.6 Bacterial strains 
Altogether 42 isolates of E. faecalis MLST type ST40 were collected from commensal 
and pathogenic (stool, blood, urine, swab) sources and originating from many 
different countries and years. 
 
Table 3.6: E. faecalis ST40 strain collection used in this study. 
Isolate Country (City) Year Origin 
UW1833 (U 09508/98)* D (Berlin) 1998 H, U 
UW5212 D (Köln) 2004 H, U 
UW5744 D (Köln) 2004 H, U 
UW6530 D (Augsburg) 2006 H, U 
UW6756 D (Leezen) 2006 H, U 
UW6724 (Ba7514)* D (Wernigerode) 2006 H, C 
UW6727 (Ba7517)* D (Wernigerode) 2006 H, C 
UW7775 D (Heidelberg) 2004 H, C 
UW7776 D (Heidelberg) 2004 H, C 
UW7777 (AK-EF 29)* D (Heidelberg) 2004 H, C 
UW7778 D (Heidelberg) 2004 H, C 
UW7779 (AK-EF 92)* D (Heidelberg) 2004 H, C 
UW2860 (3803)* D (Gera) 2000 H, B 
UW2861 D (Gera) 2000 H, B 
UW4340 D (Berlin) 2003 H, B 
UW4889 D (Augsburg) 2004 H, B 
UW5209 D (Augsburg) 2004 H, B 
UW5213 D (Augsburg) 2004 H, B 
UW5345 D (Augsburg) 2004 H, B 
UW6149 (AB 5093-231) D (Augsburg) 2005 H, B 
UW7800 (ATCC 27275) Unknown ≤1962 Unknown 
UW7801 (ATCC 27959)* USA (Iowa) ≤1975 A1, M 
UW7729 (LMGT 2333)* IS (Reijkjavik) 1990 A2, C 
UW7730 (LMGT 3209) GR (Athens) <2004 F 
UW7709 (5)* DK 1997 H, E 
UW7710 DK Unknown 
(after 2000) 
H, U 
UW7742 (D1)* DK 2001 A3, C 
UW7743 (D27) DK 2001 A3, C 
UW7744 (D32)▲ DK 2001 A3, C 
UW7745 (D37) DK 2001 A3, C 
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UW7761 (DQ213/C003-e)* Cuba (Havana) 2008 H, B 
UW7753 (HC 24)* ESP (Madrid) 2001 H, B 
UW7780 (402/96)* PL (Warsaw) 1996 H, C 
UW7781 PL (Warsaw) 1996 H, PF 
UW7782 PL (Warsaw) 1996 H, U 
UW7784 PL (Grajewo) 1999 H, U 
UW7785 PL (Zawiercie) 2000 H, W 
UW7787 PL (Zamość) 2002 H, CSF 
UW7788 PL (Bytom) 2003 H, B 
UW7789 PL (Biała Podlaska) 2004 H, U 
UW7790 PL (Wołomin) 2007 H, C 
UW7791 PL (Maków Maz.) 2007 H, C 
  E. faecalis strain collection comprises 42 ST40 strains. * draft genomes; ▲ ST40 complete reference 
genome; A, animal (1 cow, 2 fish, 3 pig); B, blood culture; C, colonizer; CSF, cerebrospinal fluid; E, 
endocarditis; F, food (cheese); H, human; M, bovine mastitis; PF, peritoneal fluid; U, urine; W, wound. 
 
 
Table 3.7: Bacteria strains and plasmids used as references. 
Strain MLST Resistance Plasmids Description References 
E. faecalis:      
V583 CC2 
(ST6) 
VAN pTEF1, 
pTEF2 and 
pTEF3 
ATCC700802; 
first sequences 
E. faecalis 
genome 
(150, 184, 
202) 
MMH594 CC2 
(ST6) 
  Contents the first 
identified 
complete PAI 
(149, 150, 
215) 
OG1RF ST1 RAM, FUS Plasmid-free ATCC 47077; 
mutant of OG1 
(150, 166) 
UW7770 ST6 VAN 85kb vanA Epidemic strain  
UW1873  TET     
UW1965  ERY, STR    
UW18912  GEN    
E. faecium:      
64/3 ST21 RAM, FUS   (118) 
Staphylococcus 
aureus: 
     
NCTC8325    Size marker in 
PFGE 
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Plasmids:      
pAD1    Isolated from E. 
faecalis 
OG1::pAD1 
(161) 
pCF10    Isolated from E. 
faecalis 
OG1::pCF10 
(58) 
pRE25    Isolated from E. 
faecalis 
RE25::pRE25 
(213) 
  CC, clonal complex; ST, sequence type; only antibiotic resistances relevant for this study are 
presented: ERY, erythromycin; FUS, fusidic acid; GEN, gentamicin; RAM, rifampicin; STR, 
streptomycin; TET, tetracycline; VAN, vancomycin 
 
3.1.7 Cell-line 
For adhesion studies, the human epithelial colorectal adenocarcinoma Caco-2 cell 
line, was used. 
 
3.1.8 Animals 
Table 3.8: Animals used for the assessment of the pathogenic potential. 
Animal Company Model 
BALB/c mouse 
(female; 5-6 weeks old) 
Charles River Laboratories 
International, Inc. 
Murine bacteremia 
Chicken egg 
(day 5 and day 10-12 after 
fertilization) 
VALO BioMedia GmbH Chicken embryo 
infection 
Galleria mellonella larva Reptilienkosmos.de G. mellonella infection 
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3.1.9 Consumables 
Table 3.9: Devices and materials used in this study. 
Consumables Manufacturer 
Centrifuge tubes (15mL, 50mL) CARL ROTH GmbH & Co. KG 
CO2 Gene Compact sachets Thermo Fisher Scientific Inc. 
Eppendorf tubes (0.2, 0.5mL, 1.5mL, 2.0mL) Eppendorf AG 
Filter, Rotilabo® (0.22µm, 0.45µm) CARL ROTH GmbH & Co. KG 
LongSwabs, cotton, sterile BIOLOG Life Science Institute 
Nylon membranes F. Hoffmann-La Roche AG GmbH 
Petri plates Sterilin Ltd. 
Pipette tips (0.1µL, 0.5µL, 2µL, 100µL, 1000µL) Eppendorf AG 
PM panels (PM01, PM02) BIOLOG Life Science Institute 
Polystyrene cell culture microplates, 24-well Greiner bio-one AG 
Polystyrene microtiter plates flat bottom, 96-well Greiner bio-one AG 
Polystyrene semi-micro cuvette Greiner bio-one AG 
Polystyrene semi-micro cuvette VWR 
Reagent reservoirs, sterile VWR 
Syringes (5mL, 10mL) CARL ROTH GmbH & Co. KG 
Thermal paper, Mitsubishi MS Laborgeräte GmbH 
Whatman paper, 3MM Whatman Ltd. 
 
3.1.10 Equipment 
Table 3.10: Instruments used during this work. 
Equipment Manufacturer 
Autoclave, Biomedis H+P Labortechnik 
Biodocumentation luminescence detector  
ChemiDocXR Bio-Rad Laboratories 
Centrifuge Sartoris 3-30K (Rotor 19776-H) Sigma-Aldrich GmbH 
Centrifuge 5804R (Rotor F-34-6-38) Eppendorf AG 
Centrifuge 5417 R (Rotor FA) Eppendorf AG 
Centrifuge, mini spin plus (Rotor) Eppendorf AG 
Electrophoresis chambers, Sub Cell Mini 
And Mini Wide 
Bio-Rad Laboratories 
Electrophoresis Power supply Bio-Rad Laboratories 
ELISA reader, Sunrise Tecan Group 
Fluorescence reader, Fluorimeter FLA-200 Fujifilm 
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Freezer (-20°C), LIEBHERRcomfort Liebherr-holding GmbH 
Hamilton MICROLITER® syringe series 700 (10µL) CARL ROTH GmbH & Co. KG 
Hybridization oven and flasks, Techne Biostep GmbH 
Incubator Binder GmbH 
Incubator Jamesway Incubator Company Inc. 
Incubator, HERAcool Thermo Scientific Inc. 
Incubator shaker, Innova® 42 Eppendorf AG 
Laminator Severin Elektrogeräte GmbH 
Mercury vapor lamp MJR Norddeutsche Laborbau GmbH & Co. KG 
Microbiological Safety Cabinet HERAsafe Thermo Scientific Inc. 
Microwave oven, Severin CARL ROTH GmbH & Co. KG 
Multicanal-pipette (8 and 12 canals), Research Eppendorf AG 
Multistep-pipette, Research pro Eppendorf AG 
OmniLog PM BIOLOG Life Science Institute 
pH-meter, HANNA instruments neolab GmbH 
Pipettes, Reference, variable Eppendorf AG 
Pipettes, Research, variable Eppendorf AG 
Pipettes, Research plus, variable Eppendorf AG 
Platform shaker, Heidolph Polymax 1040 neolab GmbH 
Precision scale, Kern 440-43 N Sartorius GmbH 
Refrigerator, Bosch Robert Bosch GmbH 
Spectrophotometer, Biophotometer plus Eppendorf AG 
Spectrophotometer, NanoDrop® Thermo Scientific Inc. 
Spectrophotometer, NoaspecII Pharmacia Biotech Inc. 
Spectrophotometer, VP Jouan S.A. 
Thermocycler, Gene Amp 9700 Applied Biosystems 
Thermocycler, SensoQuest SensoQuest GmbH 
Thermomixer, Comfort Eppendorf AG 
Thermal printer, Mitsubishi Bio-Rad Laboratories 
Turbidimeter BIOLOG Life Science Institute 
Ultraviolet irradiator, Bio-Link Cross linker  
BLX 365nm 
Viler Lourmat 
Vacuum blotter, TDNA, Model 230600 Appligene Oncor 
Vacuum centrifuge, concentrator 5301 Eppendorf AG 
Variable speed pump Bio-Rad Laboratories 
Vortex Genie 2 Scientific Industries 
Water bath GFL GmbH 
Water purification system SG Reinstwasser GmbH 
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3.1.11 Primer 
All primers used in this study were purchased from Life Technologies Corporation 
and are listed in (Table 6.1 - Table 6.12). 
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3.2 Methods 
3.2.1 Antibiotic resistance profile 
Before starting this project, all ST40 strains were tested for their antibiotic 
susceptibilities by the routine laboratory of the RKI. According to the EUCAST clinical 
breakpoint table (version 2007), the following reference ranges (in micrograms per 
milliliter) for susceptibility (s) and resistance (r) were applied to the MIC tests: 
penicillin and ampicillin, s ≤ 8, r ≥ 16; gentamicin (high-level, HL), HLr ≥ 1024; 
streptomycin, HLr ≥ 512; glycopeptides, s ≤ 4, r ≥ 16; erythromycin and tetracycline, s 
≤ 4, r ≥ 8; chloramphenicol, s ≤ 8, r ≥ 16 (285). 
 
3.2.2 Cytolysin/hemolysin assay 
According to Solheim et al., in vitro ß-hemolytic activity was qualitatively analyzed by 
the use of MH agar plates containing 5% human blood in combination with 1% 
glucose and 0.03% L-arginine. Overnight cultures were diluted 1:100 and spotted 
onto fresh plates. After incubation at 37°C overnight, zones of clearing around the 
colonies indicated production of cytolysin (227). 
 
3.2.3 Gelatinase assay 
In vitro gelatinase expression was determined using Todd-Hewitt agar plates 
containing 3% gelatin. Overnight cultures were diluted 1:100, spotted onto fresh 
plates and incubated at 37°C overnight. After plates were placed at 4°C for 5 hours 
(h), expression of gelatinase resulted in hydrolysis of gelatin, identified by zones of 
turbidity around the colonies (adapted from the protocol described in (227)). 
 
3.2.4 Isolation of the whole cell DNA 
Genomic DNA was isolated by using the DNAeasy Blood and Tissue kit following the 
manufacturer protocol with an additional step for an efficient lysis of the Gram 
positive cell wall. 
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1mL of an overnight culture in BHI broth at 37°C, was centrifuged and re-suspended 
into 180µL lysis buffer (not included into the kit), containing 1µL RNase. After 
incubation for 60 minutes (min) at 37°C, 25µL of the Proteinase K solution and 200µL 
Buffer AL were added and further incubated at 70°C for another 60min. Then 200µL 
of 96% ethanol were added, mixed and the whole content was pipetted into a 
DNAeasy Mini spin column. After a centrifugation step at 8,000rpm for 1min, 200µL 
of the washing buffer AW1 were added to the columns and centrifuged again. 200µL 
of buffer AW2 were added and centrifuged again at 14,000rpm for 3min. DNA was 
eluted from the column by incubating with 20µL of buffer AE for 1min at room 
temperature and centrifuging again at 8,000rpm for 1min. The final DNA 
concentration was determined using PicoGreen and could also be visualized by gel 
electrophoresis using 0.8% agarose. 
 
3.2.5 Plasmid isolation 
Preparation of plasmid DNA was done using the method of Woodford et al. (290) with 
some modifications (283)). 
Cells were grown on BHI agar plate at 37°C and were re-suspended in 1mL of TES 
buffer. After centrifugation at 8,000rpm for 5min, the pellet was re-suspended and 
incubated for 60min at 37°C in 200µL of TES buffer containing 10mg/mL lysozyme 
and 1µL RNase. Afterwards, 400µL of 0,2N NaOH/1% SDS were added, the tube 
was inverted gently and then incubated at 56°C for 60min, again. For protein 
precipitation, 300µL of 3M potassium acetate were added. The tube was kept on ice 
for 20min and subsequently centrifuged at 15,000rpm for 15min. The supernatant 
was washed two times by adding one volume of phenol/chloroform/isoamyl alcohol 
(25:24:1) and once again with one volume of chloroform, inverting it 30 times, 
centrifuged it at 12,000rpm for 10min and collecting the upper, aqueous phase. 
Finally, the interphase would be clear. The plasmid DNA-containing phase was 
precipitated with two volumes of ethanol (96%) overnight at -20°C and was 
centrifuged at 14,000rpm for 10min at 4°C. The pellet was washed with 500µL of 
70% ethanol, centrifuged, and finally dried at 37°C for 15 to 30min. Subsequently, the 
pellet was dissolved in 20µL water for 20min at room temperature. The final DNA 
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concentration was determined using PicoGreen and plasmid DNA could be visualized 
by gel electrophoresis using 0.8% agarose. 
 
3.2.6 Determination of DNA concentration 
DNA average concentration was determined by using a NanoDrop® 
spectrophotometer by using default measurement conditions for dsDNA 
quantification. 
For a more specific quantification, DNA concentration was measured by an ultra-
sensitive Quant-iT PicoGreen® system using the AIDA image Analyzer. First, a 
standard curve using the provided lambda DNA was prepared, as well as, 
appropriate dilutions of the samples, as shown in Table 3.11. 50µL of a prepared 
1:200 solution of PicoGreen in TE were added into each flat-bottomed well (A1 until 
Bx) of a polystyrene black microtiter plate. Additionally, 50µL of each dilution A1 until 
A8 and B1 until Bx was diluted into the wells and the microtiter plate was scanned on 
a florescence reader at 480-520nm. 
 
Table 3.11: Scheme for PicoGreen DNA quantification. 
Tube Type Amount – DNA 
Amount - TE 
[µL] 
Concentration 
[µg/mL] 
1   5µL lambda DNA 95 5.0 
2   50µL of 1 50 2.5 
A1 Standard 40µL of 2 60 1.0 
A2 Standard 50µL of A1 50 0.5 
A3 Standard 40µL of A2 60 0.25 
A4 Standard 50µL of A3 50 0.1 
A5 Standard 40µL of A4 60 0.05 
A6 Standard 50µL of A5 50 0.025 
A7 Standard 40µL of A6 60 0.01 
A8 Standard - 100 0.0 
B1 DNA sample 1 1µL of DNA sample 99 unknown 
B2 DNA probe 1 10µL of B1 90 unknown 
  (A) Standard curve preparation and (B) investigated sample dilutions are indicated. 
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3.2.7 Multilocus sequence typing (MLST) 
On the basis of seven housekeeping genes, an E. faecalis MLST scheme was 
developed by Ruiz-Garbajosa and colleagues (199). 
Primers used for amplification and sequencing of the gene fragments are listed in 
Table 6.1. After sequencing, sequences of the internal fragments of the seven loci 
were uploaded and compared with the MLST database (http://efaecalis.mlst.net/). 
According to the similarity to the database entries, each locus got an allele number 
and finally the sequence type (ST) arose from a combination of all of the allele 
numbers. 
 
3.2.8 Pulse field gel electrophoresis and Southern hybridization 
The Pulse field gel electrophoresis (PFGE) was used for molecular typing of 
Enterococcus and related Gram-positive bacteria (285). This method is generally 
based on an alternating electric field generated by hexagonal-arranged electrode 
pairs. Thus, DNA fragments of a few kilobases (kb) to some megabases (Mbp) are 
separated with a high resolution (164, 212). 
In advance of this dissertation, clonal relatedness of the ST40 strain collection was 
analyzed via macrorestriction patterns, generated by several PFGE techniques. 
a) SmaI PFGE 
Bacterial DNA fingerprints were generated by digestion of the DNA using the 
rare-cutting restriction endonuclease SmaI, which has a GC-rich recognition 
sequence (164, 165). 
All strains of the ST40 collection were prepared for macrorestriction analysis 
as previously described (285). By using the CHEF III apparatus, PFGE was 
done by medical technical assistants U. Geringer (RKI) and C. Günther (RKI) 
as described elsewhere (131, 279). Subsequently, Southern hybridization and 
immunological detection were practiced as described below. As an external 
size standard, SmaI-digested S. aureus NCTC8325 strain was used to 
calculate the fragment sizes applying BioNumerics version 6.0 software (164). 
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b) S1 nuclease PFGE 
Briefly, plasmid content of the ST40 strains was analyzed after specific S1 
nuclease digestion of the genomic DNA, as previously described (15, 70, 131). 
Subsequent Southern hybridization onto a nylon membrane and 
immunological detection, which were described in detail in the following part, 
were used to visualize the linearized plasmids as detectable bands on a faint 
genomic background (15). PFGE was done by medical technical assistant C. 
Fleige (RKI). 
 
3.2.8.1 Vacuum Southern blotting 
In general, DNA is first separated in an agarose gel (232). Then, the DNA fragments 
are transferred onto a nylon membrane using Southern blotting. The surface of the 
nylon membrane is positively charged, so that a stable complex with the negatively 
charged phosphate of the DNA backbone is formed (203, 231). 
Here, Vacuum blotting was used to transfer DNA form plasmid preparation onto the 
nylon membrane. According to the instructions of the manufacturer of the Vacuum 
blotter device, the blot was constructed by placing the gel on the surface of the nylon 
membrane. The transfer was performed by adjusting the vacuum to 50mbar. The gel 
was completely covered with the Blot buffers I to III for respective 30min. Next, the 
whole blot was incubated with SSC for 120min. After the entire blot was 
disassembled, the DNA was cross-linked by 150mJoule of ultraviolet irradiation 
exposure for 30 seconds (s). Finally, the membrane was washed with water for 
10min and was dried at room temperature. 
 
Blot buffer I 
 HCl      0.25M 
 
Blot buffer II 
 NaOH      0.5M 
 NaCl      1.5M 
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Blot buffer III 
 Tris       1M 
 NaCl      2M 
 
SSC (stock solution, 20x) 
 NaCl      3M 
 Sodium citrate    0.3M 
 
3.2.8.2 Probe labeling 
Using PCR-based Digoxigenin- (DIG) High Prime system, DNA probes were non-
radioactive labeled with alkali-labile DIG-11-dUTP. According to the manufacturer 
recommendations regarding the random primer labeling technique, 40µL of the PCR 
product were denatured at 96°C for 10min. After immediately cooling down on ice, 
10µL of DIG High-Prime solution were added and incubated overnight at 37°C. The 
reaction was stopped by heating at 65°C for 10min. Before Southern hybridization, 
DNA probe was denatured by heating for 10min, followed by immediate cooling down 
on ice. Primers used in that study were listed in Table 6.9. 
 
3.2.8.3 Southern hybridization 
The previously to the nylon membrane blotted plasmid DNA was hybridized with the 
DIG-labeled DNA probe by using the DIG system kit. First, the nylon membrane was 
pre-hybridized by incubation with 25mL of Hybridization buffer I at 37°C for 2h. The 
solution was replaced with 12mL Hybridization buffer I containing 5µL freshly 
denatured probe and was incubated at 37°C for 12h. Then, the membrane was 
washed twice with 50mL SSC buffer I at room temperature for 5min, followed by 
twice washing with 50mL SSC buffer II at 37°C for 15min. During this process, dry 
out of the membrane had to be prevented. By doing this, transferred plasmid DNA 
was prepared for the final immunological detection.  
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Hybridization buffer I 
 SSC      5x 
 Blocking reagent    1x 
 N-lauroylsarcosine    0.1% 
 SDS      0.02% 
 Solution was heated at 50 – 70°C for 1h. 
 
SSC buffer I 
 SSC      2x 
 SDS      0.1% 
 
SSC buffer II 
 SSC      0.1x 
 SDS      0.1% 
 
3.2.8.4 Immunochemical detection 
Generally, immunochemical detection was performed by an enzyme-linked assay 
using Roche´s DIG Nucleic Acid Detection Kit. 
Alkaline phosphatase-conjugated antibody binds selectively to the DIG-labeled DNA, 
whereby phosphatase activity could be detected with CDP-Star by 
chemiluminescence. 
First, the membrane was washed briefly with Detection buffer I, where 0.3% Tween 
was previously added. To prevent undesired non-specific interactions with the 
antibody, membrane was incubated with 60mL Detection buffer II at room 
temperature for 30min. Then, 8µL of the anti-DIG antibody (1:10,000) were diluted in 
40mL Detection buffer II and the membrane was incubated with this solution for 
30min. The unbound antibody was removed by washing twice with 50mL of Detection 
buffer I for 15min and membrane was equilibrated for 2min with 20mL of Detection 
buffer III. After these steps, membrane was placed into a hybridization bag and 
10.5µL CDP-Star solution in 1.5mL Detection buffer III was added. Air bubbles were 
removed and it was left 5min in darkness. After removing the CDP-Star solution, light 
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emission was documented within the ChemiDoc instrument by exposure within 10, 
30, 60 and 120min. 
The membrane was re-hybridized after removing the label. Therefor, the membrane 
was incubated twice with 50mL 0.2N NaOH with 0.1% SDS at 37°C for 30min. Then, 
a washing step with SSC solution (2x) followed. Before re-hybridization, the 
membrane was dried, in the end. 
 
Blocking reagent (stock solution) 
 Blocking reagent (Roche)    10% 
in Hybridization buffer I 
 
Detection buffer I 
 Maleic acid     0.1M 
 NaCl      0.15M 
 pH 7.5 
 
Detection buffer II 
 Blocking reagent (Roche)   1x 
 Detection buffer I    9x 
 
Detection buffer III 
 Tris-HCl     0.1M 
 NaCl      0.1M 
 MgCl2 x 6 H2O    50mM 
 pH 9.5 
 
3.2.9 Polymerase chain reaction (PCR) 
The standard PCR reactions were performed using PCR Master mix containing Taq 
Polymerase, nucleotides and PCR buffer. This PCR Master mix was mixed with 
primer pair, DNA template, and water to a final volume of 25µL, as presented in 
Table 3.12. Used primers are listed in section 6.  
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Table 3.12: Regular PCR reaction setting. 
Substrate Amount 
PCR Master mix 12.5µL 
Primer pair Each 200nM 
Genomic DNA (DNeasy) 10ng 
Nuclease-free water Up to 25µL 
 
Cycling conditions were used in accordance to the manufacturer’s instructions and 
were dependent on the annealing temperature of the used primer pair and expected 
amplicon size. In general, the following conditions were used: An initial denaturation 
step at 95°C, was followed by 30 to 35 cycles of denaturation (94°C for 30s), 
annealing (50-58°C for 30s) and extension (72°C for 30s), and finally one step of 
10min at 72°C. Then the PCR amplificates were resolved in a 1.4% agarose gel and 
subsequently stained with ethidium bromide for 15min, washed for other 15min and 
finally visualized in UV light. 
 
3.2.10 Long template PCR 
According to Laverde-Gomez et al., long template PCR was used to amplify 
integration of a PAI at the known genomic integration site, as well as, to analyze its 
structure using MMH594 PAI as a reference (131, 149, 215). 
Primers used in this study had been previously described in (131) and are listed in 
Table 6.7 and Table 6.8. 
According to the manufacturer´s recommendations, two master mixes were prepared 
separately on ice and were mixed to a final volume of 50µL as presented in Table 
3.13.  
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Table 3.13: Setting of long template PCR. 
Master mix I Concentration 
dNTP mix 10mM 
Primer – forward 300nM 
Primer – reverse 300nM 
Template DNA 300ng 
Nuclease-free water Up to 25µL 
Master mix II Amount 
Buffer III (10x) 5µL 
Expand Long Enzyme mix 0,75µL 
Nuclease-free water Up to 25µL 
 
Cycling conditions were used as followed: After an initial denaturation step at 92°C 
for 2min, 10 cycles were run for 10s at 92°C, 30s at 60°C, followed by elongation with 
10min at 68°C. Then, additional 25 cycles passed through with 10s at 92°C, 30s at 
60°C and 10min at 68°C. Corresponding to the expected length of the amplicon, 
extension time of the elongation step was increased by 20s for each successive 
cycle. A temperature of 68°C for 10min was used for the final elongation step. 
 
3.2.11 Sequencing 
3.2.11.1 Amplicon Sequencing by Sanger ABI Big Dye technology 
The classical method of determining DNA nucleotide sequences is Sanger 
sequencing, also described as chain termination method (205). 
PCR products were amplified by using fluorescently labeled ddNTPs, lacking a 
3´hydroxyl-group, which prevents a further elongation of the amplicon. Incorporation 
of ddNTPs occurs with the same probability just as the dNTPs, also contained in the 
used BigDye mix. By capillary electrophoresis, DNA fragments are separated by 
length and the respective fluorescence of the incorporated base is detected. Data 
analysis resulted in the corresponding electropherogram, which represents the final 
DNA sequence (according to http://www.lifetechnologies.com/de/en/home.html). 
 
According to the recommendations of Applied Biosystems, PCR mix was prepared as 
presented in Table 3.14 and used primers are listed in section 6.  
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Table 3.14: Setting of sequencing PCR. 
Substrate Amount 
PCR product 5ng 
Primer (0.8µM) 2µL 
BigDye 1µL 
Nuclease-free water Up to 10µL 
 
PCR was done using the following cycling conditions: a 2min denaturation step at 
96°C, following by 25 cycles with 10s at 96°C, 5s at 45°C - 60°C and 4min at 60°C. 
Amplicons were sequenced at the sequencing laboratory of the RKI in Berlin. Finally, 
Sanger reads were analyzed by SeqMan (Lasergene 5) or DS Gene software 
package. 
 
3.2.11.2 De novo genome sequencing of selected E. faecalis ST40 
strains 
On the basis of the previous characterizations, 15 representative isolates were 
selected for de novo sequencing by Roche/GS-FLX 454 technology (Table 3.6; 12 
isolates at the RKI and three isolates at GATC). 
(i) Roche/454 FLX pyrosequencing 
Roche/454 FLX pyrosequencing was chosen for de novo genome sequencing. 
Despite of the relatively error-prone raw data sequence (for example due to “InDel” 
errors), this NGS technology ensures long sequence reads. Until today, this 
sequencer can produce an average read length of 400bp (296). 
In general, the process can be described as follows: First, a library of adapter-linked 
DNA fragments is constructed. During emulsion PCR as a key procedure, single-
stranded DNA coupled to beads is clonally amplified. Then, beads are loaded into the 
picotiter plate (PTP) and pyrosequencing started, using Roche 454´s Titanium kit. 
Basically, this sequencing-by-synthesis technology uses bioluminescence to detect 
incorporation of a nucleotide by DNA polymerase (146, 147, 154, 296). 
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Finally, usage of this classical sequencing strategy revealed only two strains – D32 
(UW7744) and UW7709 – with <100 genomic fragments. 
Because no complete ST40 genome was previously sequenced, D32 was chosen to 
generate a template for a detailed genome comparison. This strain was isolated form 
pig feces in 2001 as part of the Danish Integrated Antimicrobial Resistance 
Monitoring and Research Programme (216, 300). Additional to the data of 454 
sequencing, long paired-end (LPE) sequencing was used as a complementary 
technology. 
 
(ii) LPE sequencing 
Performed by the service platform of Eurofins MWG-Operon, an 8-kb LPE library was 
constructed and sequenced on Roche/GS-FLX 454 system. Generally, this means 
sequencing of the ends of two adaptor-linked DNA fragments, which were originally 
located approximately 8-kb apart from each other in the genome (113). 
 
This sequencing approach was also used to resolve the additional genomes of both 
strains UW1833 and UW7709, in more detail. But until now, neither the gap closing 
nor the genome annotation is completely finished. 
 
(iii) Assembly and Mapping 
Eurofins MWG-Operon used Celera Assembler software for assembly and 
scaffolding. In detail, sequence information of the paired end reads was used to 
bridge gaps and to determine the orientation and relative position of the contigs 
derived from 454 pyrosequencing (113). 
After receiving these data sets, contig orientation within the chromosomal scaffold 
was compared to that of E. faecalis strain V583 (184) by progressive Mauve 
alignment (48), which was done by C. Kuenne, staff of the working group of Dr. T. 
Hain at the Institute of Medical Microbiology of Giessen University. 
A total number of 33 remaining gaps within the chromosomal scaffold, as well as, 
assembly ambiguities (“InDel” errors) were corrected by sequencing of PCR 
amplicons. Therefor, specific primer pairs, listed in Table 6.10 to Table 6.12, were 
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identified by MiniMap (Kuenne, C.T., unpublished software), which basically 
combines BLASTN and Primer3. The remaining five intra-chromosomal contigs were 
ordered and again orientated in comparison to the E. faecalis strain V583 (184) by 
progressive Mauve alignment (also done by C. Kuenne), again. Hereafter, intra-
chromosomal gaps were closed, as well as, inversions within the sequence and 
overlapping regions were identified and corrected by sequencing. 
Data management and sequence analysis were done with DS Gene as well as 
KODON software package. 
 
(iv) Genome Annotation 
Basically, ORF prediction and automatic annotation was performed by GenDB 
annotation pipeline (155) and RAST annotation services (10) at CeBiTec of the 
University of Bielefeld. 
Subsequently, frame-shift mutations, modification of Start-/Stop codons and 
annotations were checked and manually corrected using online tools, like NCBI ORF 
Finder and BLAST comparisons (209) against completed and publicly available E. 
faecalis genomes. 
 
A brief report about the complete genome sequence of this porcine E. faecalis isolate 
D32 was published in the Journal of Bacteriology (300), and whole sequence data 
have been deposited in GenBank under accession numbers CP003726 to 
CP003728. 
 
(v) Illumina/Solexa sequencing 
To improve the accuracy of the sequencing data, genomes of the 14 E. faecalis 
strains were additionally sequenced by using Illumina´s Genome Analyzer IIx at the 
department of “Genomic and Applied Microbiology” of the Georg-August University of 
Göttingen. 
In each channel of the flow cell, solid-phase amplification produces randomly 
distributed, clonally amplified clusters of adapter-linked single DNA templates. Based 
on sequencing-by-synthesis approach, one of four fluorescently labeled nucleotides 
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is incorporated and emitted fluorescence of each cluster is imaged to identify the 
complementary base. To allow base-by-base sequencing, fluorophore is separated 
from the nucleotide by enzymatically cleaving after each sequencing cycle. That 
implies that raw error rates are greatly reduced (111, 154, 296). 
 
(vi) Hybrid assembly 
The hybrid assembly was done by Dr. S. Voget, staff of the working group of Prof. Dr. 
R. Daniel, at the department of “Genomic and Applied Microbiology” of the Georg-
August University of Göttingen. 
De novo sequences, generated by both Roche/454 FLX pyrosequencing and 
Illumina/Solexa sequencing, were assembled in a single run (hybrid assembly) by 
using Mira assembler software. Here, advantages of the individual sequencing 
methods are combined: 454 pyrosequencing generated long contigs and using 
Illumina/Solexa sequencing solved the problem concerning the homopolymers. 
 
3.2.11.3 Genomic comparisons and phylogenetic analyses 
Circular map (Figure 4.6), visualizing the E. faecalis ST40 genome comparison 
against the D32 reference genome, as well as, the phylogenetic tree (Figure 4.10) 
were generated by Dr. S. Voget, staff of the working group of Prof. Dr. R. Daniel at 
the department of “Genomic and Applied Microbiology” of the Georg-August 
University of Göttingen. The alignment was calculated with Mugsy (5) and only 
aligned regions present in all analyzed strains were extracted (“core genome”). 
These regions were concatenated and positions with gaps removed (201). The 
resulting core alignment (126.7 kb) was used to infer a Maximum Likelihood tree with 
RAxML (233). The GTRGAMMA model for nucleotide substitution and rate 
heterogeneity was utilized, bootstrap support values of 1000 replicates are shown at 
the nodes. M plutonius was used as an outgroup. 
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3.2.12 Biolog Phenotyping Microarrays 
Biolog Phenotyping Microarrays (PM01 and PM02A MicroPlate™) were used to 
analyze the metabolic phenotype with focus on utilization of different carbon sources 
under aerobic conditions. In context of the BMBF “UroGenOmics” consortium (grant 
no: 0315833C), these assays were done in cooperation with the working group of 
Prof. Dr. D. Schomburg at Braunschweig University. 
 
Aerobic conditions 
Bacteria were incubated on fresh MH agar plates at 37°C for 24h. All microbial 
following steps were carried out under laminar flow to prevent contaminations. Using 
a sterile swab, bacteria were transferred into a sterile tube, containing 10mL IF-0a 
medium (1.2x), and cell suspension were adjusted to 81% transmittance by using the 
Biolog turbidimeter. Analog to the manufacturer´s recommendations, 20mL of the IF-
0a Base (1.2x) were mixed with 0.24mL Redox Dye Mix D (100x) and 2.0mL of a 12x 
additive solution, containing 24mM MgCl2 x 6H2O and 12mM CaCl2 x 2 H2O. Finally, 
1.76mL of cell suspension was added. 100µL of the final suspension was added to 
each well of the 96-well Biolog PM01 and PM02A plates. The panels were placed 
into the OmniLog instrument and incubated at 37°C for 72h, where the utilization of 
different carbon sources was measured spectrophotometrically and recorded every 
15min over the whole incubation period. All assays were repeated for at least three 
times on different days. 
 
Data evaluation 
Data sets were evaluated by the OmniLog Kinetic and Parametric analysis software 
version 2005. The area under the kinetic curve (area values) was used to compare 
the utilization of different carbon sources between the strains. Calculation of the 
arithmetic averages with the corresponding standard deviations was done with 
Microsoft Excel. Color code, used in Table 4.13 and Table 4.14, was chosen 
according to Gripp et al. (80). 
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3.2.13 Growth kinetics 
To determine the bacterial growth rates, overnight cultures were diluted 1:50 in TS 
broth and grown at 37°C with shaking. Optical density at 600nm was measured at 
different time points and the corresponding CFU were calculated by plating serial 
dilutions of the cultures onto LB agar plates in duplicate. 
 
3.2.14 Biofilm plate assay 
E. faecalis also play a significant role in the context of nosocomial infections. During 
the infections process, the formation of a slime matrix (biofilm) can be assigned an 
important role. 
The potential of selected strains to produce biofilm on flat bottom polystyrene 
microtiter plates was tested by following the methodology previously described (11, 
93, 248) with slight modifications. MH blood agar plate-grown bacteria were re-
suspended in TS broth supplemented with 0.25% glucose to a concentration of 5 x 
108 CFU/mL. 100µL of bacterial suspension was filled in triplicates to each well of the 
microtiter plate and incubated at 37°C for 24h. After incubation, bacteria were 
removed and the wells were washed with 200µL PBS for three times. The plates 
were dried for 1h at 60°C and stained by adding 100µL of 0.2% Gram´s crystal violet 
solution to each well. After 10min incubation step at room temperature, the stain was 
removed and the wells were washed again with 200µL PBS for three times. The 
plates were dried for 10min at 60°C and Gram´s crystal violet was re-suspended by 
adding 100µL ethanol and shaking for 30min. Finally, optical density (OD) of 595nm 
was measured in an ELISA reader. Biofilm plate assay for each of the strains was 
done in triplicate and repeated again. 
 
Statistical analysis 
Statistical comparisons were done by unpaired two-tailed t-test using GraphPad 
Prism 5.01 software package. A P-value of <0.05 was considered statistically 
significant. 
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3.2.15 Adherence assay 
Adherence of Enterococci to the colonic epithelial cells is essential to colonize the 
gastrointestinal tract as a commensal, but it is also supposed to play an important 
role in biofilm formation and in translocation across the intestinal barrier. 
 
In context of the BMBF “UroGenOmics” consortium (grant no: 0315833C), assays 
were done in cooperation with the working group of Prof. Dr. J. Hübner at Freiburg 
University. 
 
Adherence to human epithelial colorectal adenocarcinoma Caco-2 cells was 
investigated using a protocol previously described (208, 248) with slight 
modifications. Caco-2 cells between the 15th – 25th passages were cultivated in 24-
well plates to a density of 1 x 105 cells/well for 13 – 15 days. The confluent 
monolayers were incubated with a bacterial cell to epithelial cell ratio of 100:1, as well 
as, 1000:1 for 2h. After infection, Caco-2 cells were washed with PBS five times, and 
subsequently lysed with 0.25% Triton X-100 at 37°C for 20min. To quantitatively 
determine the amount of attached bacterial cells, lysates were diluted in PBS and 
plated onto LB agar plates. 
Statistical analysis 
Statistical comparisons were done by unpaired two-tailed t-test using GraphPad 
Prism 5.01 software package. 
 
3.2.16 Animal models 
Below, different animal models are presented which were used for a comparative 
assessment of the pathogenic potential of the selected enterococcal strains D32 and 
UW7709. Besides, E. faecalis strains V583 and OG1RF, as well as, E. faecium 64/3 
served as controls. 
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3.2.16.1 Pathogenicity studies by using the model organism Galleria 
mellonella 
Because of its simplicity, G. mellonella insect model is attractive to study bacteria to 
host interactions. 
 
Assay of G. mellonella infection 
Accordingly to previously described protocols (163, 182), assays were done with 
some modifications. 
100µL of TSB overnight culture were added to 5mL of fresh TSB medium and were 
cultured at 37°C for 3h. After centrifugation for 5min at 8,000rpm, cell pellet was 
resuspended in 1mL sterile PBS. Cell concentration was photometrically measured 
and cell density of the inoculum was adjusted to 107 cells/500µL. Groups of 15 larvae 
with a weight of about 200mg were separated. Then, 5µL of the bacterial inoculum 
were microinjected at the base of the last proleg, corresponding to an infective dose 
of 105 CFU/larvae. A control group of larvae was infected with PBS only. The real 
infective dose was determined by serial dilution, which has been plated on PBS agar 
plates. Groups of infected larvae were kept per Petri dish at 37°C and the number of 
dead larvae was checked for a time interval of 18, 24, 42, 48, 66 and 70h. This 
experiment was repeated at least three times for each of the selected bacterial strain. 
 
Statistical analysis 
Using the nominal values of survival and dead, the diagram presented the death 
rates were calculated by Kaplan-Meier plot method in GraphPad Prism 5.01 software 
version. 
 
3.2.16.2 Pathogenicity studies by using the chicken embryos as model 
organisms 
In cooperation with the working group of Prof. Dr. H. M. Hafez at the Institute of 
Poultry Diseases of FU Berlin, pathogenicity of E. faecalis isolates was tested in a 
chicken embryo model (198, 291). By using embryonated chicken eggs, this model 
could be an interesting alternative in comparison to other complex model systems of 
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vertebrates. To test the functionality of this assay, infective doses were implemented 
into yolk sack at day five after fertilization and into allantoic cavity at day 10 to 12 
after fertilization, respectively. 
 
Assay of chicken embryo infection 
Accordingly to the previously described protocol (198), overnight cultures of the E. 
faecalis isolates were used to generate a cell suspension with 107CFU/mL. Test 
groups of four eggs were separated and unfertilized eggs were sorted out by 
schiering using a mercury vapor lamp. 
a) Infective dose into the yolk sack 
At day five after fertilization, infective dose of 103 CFU was injected into the yolk 
sack. Therefore, surface of the eggs was disinfected with 70% ethanol and the 
eggshell was carefully opened at the blunt pole by the use of a needle. 0.2mL of the 
infective dose was injected with a sterile disposable syringe and the hole was sealed 
with liquid paraffin. 
 
b) Infective dose into the allantoic cavity 
At day 10 to 12 after fertilization, 0.2mL of each bacterial inoculum (~105 CFU) was 
injected into the allantoic cavity. For it, the surface of the eggs was disinfected with 
70% ethanol and the eggshell was carefully opened at the blunt pole by the use of a 
needle. Finally, the hole was also sealed with liquid paraffin. 
A control group of three eggs received saline solution only. Infected eggs were 
incubated at 37°C for four days. Every day, eggs were screened using the mercury 
vapor lamp and already dead embryos were discarded. At the end of the test, 
surviving embryos were killed by the storage at 4°C for 48h and all of the embryos 
were bacteriological screened. 
 
Statistical analysis 
Using the nominal values of survival and dead, the curve presented the death rates 
was constructed by Kaplan-Meier plot method in GraphPad Prism 5.01 software 
version. 
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3.2.16.3 Murine bacteremia model 
Murine bacteremia model was used to evaluate the pathogenic potential of selected 
E. faecalis strains by analysis of bacterial growth in blood, liver, kidney and spleen 
after an intravenous infection via tail vein. 
In context of the BMBF “UroGenOmics” consortium (grant no: 0315833C), these 
experiments were done in cooperation with the working group of Prof. Dr. J. Hübner 
at Freiburg University, wherein the previously described protocol has been used 
(105, 248). The animal assays described in the present study were reviewed and 
approved by the International Animal Care and Use Committee at Harvard University. 
 
For preparation of the inoculum, bacteria were grown in TSB at 37°C overnight. Next, 
cell suspension was centrifuged and the cell pellet was dissolved in 5mL PBS, spun 
down again and resolved in 5mL of sterile 0.9% NaCl. Aliquots of 550µL were shock 
frozen and stored at -80°C. 
Eight female six to eight weeks-old BALB/c mice were inoculated intravenously in the 
tail vein with 108 and 5x108 CFU respectively. A control group of mice were injected 
with sterile saline only. Actual used inoculum was once verified by viable counts on 
TSA. 48h after infection, mice were sacrificed by CO2 inhalation and exsanguination. 
Blood was obtained by cardiac puncture and 100µL were plated on TSA. 
Furthermore, liver, kidney and spleen were taken out and homogenized in TSB. To 
verify bacterial counts serial dilutions of these samples were also plated on TSA. 
Statistical analysis 
Statistical comparisons were done by Mann-Whitney test (non-parametric data) using 
GraphPad Prism 5.01 software package. 
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4 Results 
4.1 Comparative genomics of E. faecalis ST40 
Forty-two isolates of E. faecalis MLST type ST40 were collected from commensal 
and pathogenic sources (humans/animals) originating from different countries and 
years. A detailed listing of the ST40 strains with the corresponding background 
information is described in Table 3.6. 
 
4.1.1 Pre-characterization of the ST40 strain collection 
First of all, the strain collection was checked with respect to several phenotypic and 
genotypic characteristics, to select representative isolates for genome sequencing. 
 
4.1.1.1 Genomic profile by SmaI macrorestriction patterns 
Strains were typed by SmaI macrorestriction in PFGE identifying sub-clusters of 
closely related strains, which were independent from their geographical and temporal 
origin or clinical/non-clinical context (Figure 4.1). 
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Figure 4.1: SmaI macrorestriction patterns in PFGE of 44 E. faecalis isolates. 
  Certain sub-clusters indicated a comparably high level of clonal relatedness. Displayed collection 
comprises 42 ST40 isolates and 2 isolates, belonging to the CC40 (1 ST268 and 2 ST220). Sequenced 
isolates are marked with a blue square; 3 reference strain; 4 unknown; 5 unknown (after 2000); AC, 
animal colonizer; B, blood culture; CSF, cerebrospinal fluid; E, endocarditis; HC, human colonizer; M, 
bovine mastitis; PF, peritoneal fluid; U, urine; W, wound. 
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4.1.1.2 Antibiotic resistance profile 
Distribution of phenotypic antibiotic susceptibilities was completed by determination 
of the corresponding genotype by PCR. 
 
Table 4.1: Distribution of antibiotic resistances. 
Antibiotic resistance Phenotype [%]  Resistance gene Genotype [%] 
Vancomycin (VanA-type) 2.4 (1/42) vanA 2.4 (1/42) 
Erythromycin 19.1 (8/42) ermB 21.4 (9/42) 
Tetracycline 81.0 (34/42) tetM 81.0 (34/42) 
Streptomycin (high-level) 28.6 (12/42) aadE 33.3 (14/42) 
Gentamicin (high-level) 2.4 (1/42) aac6'-aph2" 0 (0/42) 
  Broth microdilution assay was used to determine phenotypic antibiotic susceptibilities. Resistance 
genes (aac6‘-aph2“, aadE, ermB, tetM, vanA) were determined by PCR. 
 
4.1.1.3 Assessment of putative virulence-associated markers 
Presence and expression of putative virulence-associated genes encoded within the 
E. faecalis PAI (149) and/or on the chromosome were investigated by PCR and 
confirmed by phenotypic in vitro assays (Table 4.2). PAI associated aggregation 
substance asc-10 gene was found in 16.7% of the isolates. Prevalence of the 
cytolysin (cyl) operon in 33.3% of the strains was associated with the evidence of β-
hemolysis in vitro (Figure 4.2). The enterococcal surface protein (esp) gene was 
detected in 78.6% of the ST40 collection. All isolates harbored the gelE (gelatinase) 
and fsr (major accessory gene regulator) genes and showed in vitro gelatinase 
expression (Figure 4.3). 
 
The capsule locus (cps) consists of 11 known open reading frames, namely cpsA-K. 
There are three known capsule operon polymorphisms: (1) cps type 2, which 
includes all 11 genes (e.g. V583); (2) cps type 5, which includes all genes except for 
cpsF (like strains of the CC9); and (3) cps type 1, where only cpsA and cpsB are 
present (e.g. OG1RF) (87, 141, 150). Capsule locus type 1 was verified for all ST40 
isolates (Table 4.2). 
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Table 4.2: Presence of putative virulence factors. 
Putative virulence 
factor 
Putative function % of positive 
isolates 
Comment 
Pathogenicity island    
asc-10 (EF0005) Aggregation substance 16.7 (7/42)  
cylM (EF0046) Cytolysin subunit modifier 33.3 (14/42) Expression of  
ß-hemolysis in vitro 
esp (EF0056) Enterococcal surface 
protein 
78.6 (33/42)  
xyl kinase (EF0083) Xylose kinase 4.8 (2/42)  
gls24-like (EF0117) General stress protein 0 (0/42)  
Other    
gelE (EF1818) Gelatinase/coccolysin 100 (42/42)  
fsrB (EF1821) Accessory gene regulator B 100 (42/42)  
cps type 1 Capsular polysaccharide 100 (42/42)  
  Presence of putative virulence-associated genes (in italics) was examined by PCR. Numbers in bold 
represent percentage of positive tested isolates, calculated from the number of the positive genotypes 
versus the whole strain collection (in parentheses). 
 
 
Figure 4.2: Hemolytic activity tested in human blood agar plates. 
  Human blood agar plate was used to show ß-hemolysis in vitro. Here, a representative example is 
shown: top, non-hemolytic strain OG1RF, bottom, hemolytic E. faecalis strain 3114. 
Expression of  
gelatinase in vitro 
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Figure 4.3: Expression of gelatinase in vitro. 
  Expression of gelatinase was visualized by hydrolysis of gelatin, indicated by turbid zones around the 
colony. Here, two examples are shown, which illustrate possible phenotypes in this experiment: (A) E. 
faecium 64/3 did not expressed gelatinase in vitro, (B) expression of an active metalloprotease GelE 
by E. faecalis strain UW7709. 
 
We also tested the ability of the ST40 strains to form biofilms on polystyrene plates. 
In vitro biofilm formation was independently of the presence of putative biofilm-
enhancing genes, like esp and asc-10, and was also inhomogeneous between 
closely related strains (data not shown). Because of high standard derivations, further 
studies are necessary.  
 
4.1.1.4 Analysis of plasmid content 
Results of plasmid isolation in combination with previously performed S1 nuclease 
PFGE indicated diversity in plasmid content, varying from none to two plasmids. To 
exemplify the S1 nuclease analyses, one of the gels is shown in Figure 4.4. 
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Figure 4.4: S1 nuclease analysis resolving plasmid content of 20 E. faecalis isolates. 
  This representative gel of S1 nuclease PFGE showed the presence of none to two linearized 
plasmids. Displayed collection comprises 18 ST40 isolates and 2 isolates, belonging to the CC40 (1 
ST220 and 2 ST268). A red arrow points at a plasmid of the sequenced E. faecalis strain D32, 
revealing its size of circa 75kb. The upper bands (migrating at an apparent size of 674kb), visible in all 
lanes, correspond to undigested chromosomal DNA. 
 
The detailed properties of the plasmids of the 15 de novo sequenced ST40 strains 
are described in Table 4.11. 
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4.1.2 Genome sequencing strategies 
4.1.2.1 De novo 454 genome sequencing of 15 representative E. 
faecalis ST40 isolates 
On the basis of these previous characterizations, a subset of 15 strains (Figure 4.1), 
representing the diversity of the ST40 collection and some pairs of related isolates, 
was de novo sequenced by Roche GS FLX 454 technology (12 isolates at the Robert 
Koch Institute and 3 isolates at GATC). Genomic contigs were generated and 
assembled by using the Newbler assembler software (Table 4.3). 
 
Table 4.3: Quality report of 454 sequencing data assembled with Newbler software. 
Isolate Origin GC content 
[%] 
Number of  
contigs 
Calculated genome 
size [bp] 
Coverage 
[n-fold] 
UW6149 B 37.51 163 3,239,149 13.92 
UW2860 B 37.51 104 3,062,478 15.78 
UW6724 HC 37.31 298 3,050,235 10.04 
UW7761 B 37.51 178 2,912,463 11.60 
UW7777 HC 37.55 133 2,945,792 34.32 
UW7780 HC 37.35 267 3,059,826 15.60 
UW7753 B 37.32 148 3,158,895 13.54 
UW1833 U 37.10 228 3,190,695 17.29 
UW7779 HC 37.21 143 3,024,279 22.45 
UW7729 AC 37.26 370 2,946,024 11.16 
UW7801 M 37.51 218 2,900,593 10.55 
UW6727 HC 37.02 236 3,275,508 18.39 
UW7744 (D32) AC 37.63 71 2,840,807 24.36 
UW7709 E 37.26 94 2,921,715 23.13 
UW7742 AC 37.34 124 2,889,018 22.59 
  Genomes were de novo sequenced and assembly was done with Newbler assembler software. 
Assembly of only two strains D32 and UW7709 resulted in less than 100 contigs. Genome size varied 
between 2.8 to 3.3Mbp, irrespective of the clinical or non-clinical background of the isolates. Coverage 
of the genomes was between 10 to 34-fold; AC, animal colonizer; B, blood culture; E, endocarditis; 
HC, human colonizer; M, bovine mastitis; U, urine. 
 
Although in principle suitable for de novo genome assemblies, classical 454 
sequencing revealed only two strains (D32 and UW7709) with less than 100 genomic 
fragments. Independent from a supposed pathogenic potential, the calculated 
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genome size varied from 2.8 to 3.3Mbp. For the majority of the genomes, only a low 
coverage of less than 20 was achieved. To improve the accuracy of the sequencing 
data, the following workflow was pursued: 
(i) Representing the first finished ST40 genome, D32 was chosen to generate 
a template for a detailed genome comparison (see part 4.1.2.2). 
(ii) Genomes of the other 14 E. faecalis strains were additionally sequenced 
by using Illumina´s Genome Analyzer IIx (see part 4.1.2.3). 
 
4.1.2.2 Generation of a ST40 template for a detailed genome 
comparison 
To resolve the complete genome of E. faecalis ST40 isolate D32, a classical short 
read library and a Long Paired End (LPE) library were prepared and 454 sequenced 
(see part 3.2.11.2). As previously described in part 4.1.2.1, de novo genome 
sequencing of D32 generated 71 contigs and also resulted in 125,952 reads with an 
average length of 392bp. Additional sequencing of an 8-kb LPE library generated 
97,660 reads with an average read length of 346bp. Using Celera Assembler 
software, both data sets were assembled into three scaffolds. One chromosomal 
scaffold comprised of 28 contigs and the other two scaffolds suggested a plasmid 
origin. On the basis of the E. faecalis strain V583, chromosomal contigs were 
orientated by progressive Mauve alignment (48). Remaining gaps and assembly 
ambiguities (“InDel” errors) were resolved in detail and corrected by sequencing of 
PCR amplicons. ORF prediction and definition of the coding sequences (CDS) were 
performed by GenDB annotation pipeline (155).  Frame-shift mutations, modification 
of Start-/Stop codons and annotations were checked and manually corrected using 
online tools, like NCBI ORF Finder and BLAST comparisons (209) against finished E. 
faecalis genomes (V583, OG1RF and 62). 
 
4.1.2.3 Solexa sequencing and hybrid assembly strategy 
For detailed comparisons with the D32 reference genome, quality and coverage of 
the 14 selected and already pyrosequenced ST40 strains had to be improved. For 
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that purpose, strains were additionally sequenced at the working group of Prof. Dr. 
Rolf Daniel (department of “Genomic and Applied Microbiology” of the Georg-August 
University of Göttingen) by using Illumina´s Solexa technology. 
Generally, 454 pyrosequencing generates long reads, while the “InDel” problem in 
regions can be corrected by Solexa generated sequences. By using Mira assembler 
software (33, 34), reads of both sequencing strategies were hybrid assembled and 
thus, the even described advantages of both technologies were usefully combined 
(Table 4.4). 
 
Table 4.4: Quality report of hybrid assemblies considering of 454 and Solexa sequencing data. 
Isolate 
No. of 
assembled 
reads 
Coverage 
(454) 
[n-fold] 
Coverage 
(Solexa) 
[n-fold] 
No. 
Scaffolds 
Genome 
size 
[bp] 
GC content 
[%] 
UW6149 5,060,490 12.78 166.36 72 3,011,563 37.46 
UW2860 5,318,329 14.68 176.92 74 3,003,615 37.49 
UW6724 1,232,615 9.91 39.94 38 3,085,224 37.33 
UW7761 2,025,698 12.71 81.94 26 2,939,826 37.53 
UW7777 1,504,959 24.05 45.28 24 2,999,678 37.43 
UW7780 1,108,686 10.91 37.28 38 3,115,640 37.31 
UW7753 1,424,574 11.14 39.48 67 3,119,011 37.09 
UW1833 3,127,985 14.89 100.92 66 3,243,986 37.05 
UW7779 1,412,336 18.92 37.1 45 3,070,536 37.20 
UW7729 972,823 9.01 28.64 75 3,094,285 37.19 
UW7801 1,478,988 10.79 56.72 26 2,933,628 37.52 
UW6727 1,442,566 12.5 45.58 34 3,330,760 36.91 
UW7709 2,403,224 12.98 90.18 36 2,928,951 37.30 
UW7742 3,271,151 18.06 101.23 64 3,054,136 37.17 
  Genomes of 14 selected ST40 isolates were sequenced by using Solexa technology. Reads of 454 
and Solexa sequencing were hybrid assembled by using Mira assembler software (33, 34) and 
resulted in an increase of coverage in combination with reduction of the number of large contigs. 
 
4.1.3 Genomic characteristics of D32 in comparison to the already 
finished and publicly available E. faecalis genomes 
The completed E. faecalis D32 circular chromosome contains of 2,987,450bp with a 
GC content of 37.49%. Finally, annotation of the chromosome created a total of 
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2,890 CDS, 62 tRNA-encoding genes, and four entire rRNA-encoding operons. The 
final annotated sequences were submitted in GenBank under the accession numbers 
CP003726 to CP003728 (300). 
 
4.1.3.1 Chromosome 
First analyses of the core genome of strain D32 did not reveal any specific features. 
Analog to the determination of the antibiotic profile (Table 4.1), high-level resistance 
to streptomycin (129) is chromosomally encoded by an aminoglycoside 6-
adenyltransferase gene aadK. 
 
We also used a Venn diagram, generated by the web application EDGAR (20), to 
illustrate homologies and differences between the finished and publicly available non-
ST40 E. faecalis genomes. 
Genome alignment, illustrated by Venn diagram (20) (Figure 4.5), showed a common 
gene pool of 2173 CDS, present in all of the finished E. faecalis genomes. This 
analysis also revealed that the number of unique CDS of the clinical strain V583 
(184) was approximately two times higher than the counts of the commensal isolates 
62 (28) and D32 (300), as well as, the probiotic Symbioflor 1 strain (71). As a derivate 
of the commensal isolate OG1, OG1RF strain (24) carried the minimal number of 140 
unique CDS. Both commensal strains 62 and D32 shared significantly more CDS 
with the V583 chromosome, while the Symbioflor and OG1RF chromosomes 
overlapped less with the V583 chromosome. 
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Figure 4.5: Comparative analysis of the finished and publicly available E. faecalis genomes. 
EDGAR generated Venn diagram (20) facilitates visualizing core and strain-specific (“unique”) genes. 
This comparative analysis only exploits CDS of the chromosomes without considering of plasmid 
genes, whereby all strains shared 2197 CDS; 1, E. faecalis strain 62 (28); 2, E. faecalis strain OG1RF 
(24); 3, E. faecalis V583 (184); 4, E. faecalis probiotic strain Symbioflor 1 Clone DSM 16431 (71); 5, E. 
faecalis strain D32 (300). 
 
Genomic islands (GI) 
Focusing of virulence-associated markers located on the PAI (location: 414203 – 
449940, EFD32_0408 – EFD32_0443), analysis of genome data in conjunction with 
PCR results revealed that it only contained a bile acid hydrolase (cbh) and lactose 
metabolic pathway genes (lacABCDEFG). Utilization of lactose was also 
demonstrated by Biolog MicroArray™ analysis (part 4.2). In accordance to the 
original PAI in MMH594 (149, 215), the PAI of the D32 genome lacked common 
markers such as enterococcal surface protein gene (esp) and the cytolysin operon, 
which was also demonstrated by PCR and hemolytic activity test in vitro (part 
4.1.1.3). 
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Additionally, a previously novel and uncharacterized GI with a size of 138kb (location: 
1901082 – 2036659, EFD32_1828 – EFD32_1978) is integrated at the attachment 
site of the conjugative vanB transposon in V583 (EF_2282 – EF_2334) (184) and m-
inositol (iol) operon in OG1RF (24), respectively (see parts 4.1.4.1 and 4.2). Genomic 
data of the probiotic strain Symbioflor indicated that neither the iol operon of the 
OG1RF nor the vanB transposon of V583 or the uncharacterized GI of the D32 strain 
are present (24, 53, 71). 
 
We used SwissProt and BLASTP analyses to identify similarities to capulse-like 
genes encoded by the novel GI in D32, also described for Streptococcus 
pneumoniae and Bacillus subtilis (Table 4.5). 
 
Table 4.5: SwissProt and BLASTP analyses of a putative capsule-encoding region within the E. 
faecalis D32 GI. 
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1891 UDP-glucose 6-
dehydrogenase 
UDP-glucose 6-
dehydrogenase 
(0.0, 64%, 100%) 
None UDP-glucose 
dehydrogenase 
(2e-41, 29%, 86%) 
1892 Glycosyl 
transferase, group 
1 family protein 
Glycosyltransferase 
Gtf1 
(2e-07, 26%, 45%) 
Group 1 glycosyl 
transferase 
(2e-08, 26%, 43%) 
UDP-glucose: 
polyglycerol 
phosphate alpha-
glucosyltransferase 
(1e-07, 30%, 36%) 
1895 UDP-glucose 4-
epimerase 
UDP-glucose 4-
epimerase 
(2e-163, 65%, 98%) 
Capsular 
polysaccharide 
biosynthesis protein 
Cps4J 
(1e-169, 65%, 98%) 
EpsC, UDP-sugar 
epimerase 
(1e-42, 35%, 88%) 
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1897 Undecaprenyl-
phosphate  
galactosephosphotr
ansferase 
Undecaprenyl 
phosphate N,N'-
diacetylbacillosamine 
1-phosphate 
transferase 
(3e-77, 58%, 96%)b 
Capsular 
polysaccharide 
biosynthesis protein 
Cps4E 
(4e-38, 47%, 91%) 
Phosphotransferase 
(6e-78, 56%, 96%)c 
1901 Putative tyrosine-
protein 
phosphatase CapC 
Tyrosine-protein 
phosphatase YwqE 
(3e-61, 41%, 100%) 
Capsular 
polysaccharide 
biosynthesis protein 
Cps4B 
(9e-25, 27%, 88%) 
YwqE, protein 
tyrosine-
phosphatase 
(3e-63, 41%, 100%) 
1902 Tyrosine-protein 
kinase YwqD 
Tyrosine-protein 
kinase YwqD 
(2e-69, 50%, 93%) 
Capsular 
polysaccharide 
biosynthesis protein 
Cps4D 
(5e-40, 38%, 88%) 
YwqD, protein 
tyrosine kinase 
(2e-70; 50%, 93%) 
1903 Capsular 
polysaccharide 
synthesis enzyme 
Probable capsular 
polysaccharide 
biosynthesis protein 
YwqC 
(8e-42, 38%, 93%) 
Transcriptional 
regulator 
(1e-70, 41%, 94%) 
YwqC, modulator of 
YwqD protein 
tyrosine kinase 
activity 
(5e-41, 38%, 93%) 
1904 Transcriptional 
regulator lytR 
Transcriptional 
regulator LytR 
(3e-163, 72%, 96%) 
Transcriptional 
regulator 
(1e-70, 41%, 94%) 
Membrane-bound 
transcriptional 
regulator LytR 
(4e-81, 41%, 90%) 
  a Values in parentheses are E value, % identity, % query coverage; b second best hit: 
uncharacterized sugar transferase EpsL (7e-76, 56%, 96%); c second best hit: TuaA, putative 
undecaprenyl-phosphate N-acetylgalactosaminyl 1-phosphate transferase (4e-26, 40%, 69%). 
 
Prophages 
The web server PHAST (PHAge Search Tool) (299) was used to identify and 
graphically display integrated prophage structures in the D32 genome and both 
plasmids. Six prophage regions have been identified in D32 chromosome, of which 
three regions were intact, two regions were incomplete and also one questionable 
region was detected (Figure 4.6). Structures of prophages could not be identified in 
both plasmids. 
 
Results 
65 
 
 
Figure 4.6: Circular D32 genome view with marked prophage regions. 
  By using PHAST (299), six putative prophage sequences (no. 1 – 6) were identified as part of the 
D32 chromosome. Red boxes indicate intact prophages; grey-colored boxes display incomplete 
prophages, while the green box symbolizes a questionable prophage. 
 
Characteristics of the identified prophage regions are listed below (Table 4.6). In 
addition to the integration of E. faecalis temperate bacteriophages philFL4A and 
phiFL1A, comparison of sequence similarities indicated presence of Listeria phage 
B025 and Bacillus phage phBC6A52. The last one was also identified in the 
genomes of E. faecalis strains V583 and Symbioflor 1 by using PHAST (299). 
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Table 4.6: Characteristics of D32 prophages, predicted by PHAST (299). 
Phage 
region 
Length 
[kb] 
Completeness 
No. 
of 
CDS 
Position 
Similarity 
(Accession no.) 
GC 
content 
[%] 
1* 37.5 Intact 50 
257732-
295298 
Enterococcus 
phage phiFL4A 
(NC_013644) 
37.73 
2 22.3 Incomplete 25 
1116761-
1139067 
Enterococcus 
phage phiEf11 
(NC_013696) 
38.58 
3* 60.2 Intact 54 
1699388-
1759670 
Enterococcus 
phage phiFL1A 
(NC_013646) 
34.90 
4 17.1 Incomplete 18 
1904479-
1921631 
Lactobacillus phage 
AQ113 
(NC_019782) 
30.29 
5* 67.7 Intact 64 
2310353-
2378090 
Listeria phage B025 
(NC_009812) 
35.98 
6° 37.3 Questionable 50 
2469609-
2506979 
Bacillus phage 
phBC6A52 
(NC_004821) 
35.06 
  After localization of start and end positions (attL/attR) of the six putative prophages (region no. 1 - 6), 
PHAST predicted whether the region contains an intact (red marked), an incomplete (grey marked) or 
a questionable prophage (green marked). By comparing the phage region with the database, the 
highest similarity to an already described bacteriophage was determined, automatically; * 
bacteriophages also identified by the web application Prophage Finder (23). 
 
According to the results of PHAST search, additional usage of the web tool Prophage 
Finder (23) also revealed four putative prophages, integrated into the chromosome. 
These predicted prophages showed homologies to the prophage regions no. 1, 3, 5 
and 6, also determined by PHAST. 
PHAST analysis did not identify any attachment sites for prophage region no. 2, 
which was also defined as an incomplete phage, but also detected in public available 
and finished genomes of E. faecalis strains V583, OG1RF, 62 and Symbioflor 1, as a 
part of the chromosome. Additionally, integration of the incomplete prophage region 
no. 4 into the uncharacterized genomic island (GI; 138kb) was predicted. Both 
regions only represented fragments of prophage remnants and could be disregarded, 
finally. 
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4.1.3.2 Plasmids 
As previously described, scaffolding also revealed two plasmid scaffolds. Plasmid 
EFD32pA contains of 12,893bp and 14 CDS were predicted. It could be 
characterized as an Inc18 broad-host-range plasmid according to the similarity of its 
putative replicase belonging to rep-family 1 genes (114, 272). Here, resistance to 
macrolide-lincosamide-streptogramin B antibiotics is encoded by an rRNA adenine N-
6-methyltransferase gene (ermB). 
For the larger plasmid EFD32pB, a size of 62,162bp was calculated and annotation 
resulted in 75 CDS. By using RAST server (10) and NCBI database (209), analyses 
revealed only a few sequence similarities, such as the autolysin N-acetylmuramoyl-L-
alanine amidase (family A) or other genes associated with replication, stabilization 
and mobilization. According to the established Rep typing system (114), the plasmid 
family could not been unambiguously determined (see part 4.1.4.1). 
There is a conflict regarding the size of one plasmid of D32. S1 nuclease PFGE 
indicated a size of 75kb (see Figure 4.4 and Table 4.11), while genome sequences 
suggested plasmid EFD32_pA with a size of 12,893bp and EFD32_pB with 62,162bp 
(see part 4.1.3.2). We suppose an assembly error and a combination of both 
scaffolds in to one (exactly 75kb) but could not confirm this by further analyses. 
 
4.1.3.3 Presence of CRISPR loci and characterization of integrated 
spacers 
Described as a bacterial adaptive immune system, CRISPR-cas system prevents 
integration of foreign DNA elements, like plasmids, transposons and viruses (14, 
230). 
By using the web application CRISPRFinder (82), two CRISPRs and one additional 
questionable structure (Table 4.7), lodged in CRISPR database (CRISPRdb) (81), 
were identified in the complete genome sequence of E. faecalis strain D32. Precisely 
formulated, CRISPR1 (NC_018221_1) possesses nine spacers (Figure 4.7), while 
CRISPR2 (NC_018221_2) composed of 13 spacers (Figure 4.8). 
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Table 4.7: CRISPRdb (81) revealed CRISPR loci in E. faecalis D32 genome. 
CRISPR-ID 
Start 
position 
End 
position 
No. of 
spacer 
DR consensus 
CRISPR1 
(NC_018221_1) 
498298 498926 9 
GTTTTAGAGTCATGTTGTTTAGAATGGTACCAA
AAC 
CRISPR2 
(NC_018221_2) 
1772093 1772986 13 
GTTTTGGTACCATTCTAAACAACATGACTCTAA
AAC 
CRISPR4 
(NC_018221_4) 
2098379 2098492 1 ACAACGTTCCCTTTGGTCACCTTGTGCTGTTC 
  Presence of two CRISPR loci (1 and 2) and one questionable structure (grey marked) was lodged in 
CRISPRdb. Database entries correlated to the results of PCR and sequencing, as described in Table 
4.12. 
 
 
Figure 4.7: CRISPR1 locus of D32. 
  CRISPR1 locus (NC_018221_1), lodged in CRISPRdb (81), contained nine spacers. DR, directed 
repeats. 
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Figure 4.8: CRISPR2 locus of D32. 
  CRISPR2 locus (NC_018221_2), lodged in CRISPRdb (81), contained 13 spacers. DR, directed 
repeats. 
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In the reference sequence D32, four annotated CRISPR-associated genes were 
identified in relation to CRISPR1 locus (Table 4.8). 
 
Table 4.8: CRISPR-associated genes near to the CRISPR1 locus. 
Locus_tag Start End Product 
EFD32_0487 492339 496352 CRISPR 
associated protein 
EFD32_0488 496353 497219 CRISPR 
associated protein 
EFD32_0489 
 
497216 497545 CRISPR 
associated protein 
EFD32_0490 497546 498205 CRISPR 
associated protein 
  Presence of CRISPR-associated genes was analyzed by CRISPR-Finder (82) and identified four 
genes in striking distance to the CRISPR1 locus. In contrast, the single CRISPR2 locus lacked 
functional cas genes. 
 
By using publicly available CRISPRdb (81), BLAST comparisons (209) of both 
CRISPR loci only revealed similarities of five integrated spacers of the cas-deficient 
CRISPR2 locus to previously described enterococcal phages, as presented in Table 
4.9. 
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Table 4.9: Similarity of CRISPR spacers to publicly available MGE. 
CRISPR_ 
spacer-no. 
Spacer sequence Seqeunce 
identity*  
Significant alignments 
of blastn 
Area of identity 
CRISPR2_3 GGAGAAATGTAGC
TGCTGTTTTGACAT
TAG 
30/30 gb|HQ426665.1| 
Enterococcus faecalis 
plasmid pLG2 
pLG2-0017 
hypothetical protein 
CRISPR2_5 TTTGATAATCCAGA
ATCAACATCTTCAC
CA 
26/30 gb|GQ452243.1| 
Enterococcus phage 
phiEf11, complete 
genome 
PHIEF11_0019 
putative phage 
tape measure 
protein 
CRISPR2_7 TTAGGATTGCATCA
CGCTCTACTTCAA
CAT 
29/30 gb|GQ478087.1| 
Enterococcus phage 
phiFL3B, complete 
genome 
gp37 
conserved 
hypothetical protein 
 
29/30 gb|GQ478086.1| 
Enterococcus phage 
phiFL3A, complete 
genome  
gp34 
transcriptional 
regulator 
 
CRISPR2_9 TACGAGCTCCCAA
CATACGTTGACGG
TGCA 
28/30 gb|JF731128.1| 
Enterococcus phage 
SAP6, complete 
genome 
LPS 
glycosyltransferase 
 
CRISPR2_13 TCCGTTGTCTAATT
CGATTAATTTCATC
AT 
30/30 dbj|AB712291.1| 
Enterococcus phage 
BC-611 DNA, complete 
genome 
efb53 
hypothetical protein 
 
30/30 gb|JF731128.1| 
Enterococcus phage 
SAP6, complete 
genome 
Intergenic region 
  BLAST comparisons of the spacer of D32 CRISPR loci (209). CRISPR spacers are numbered in 
consecutive order from left to right. Only spacers with sequence identities to mobile genetic elements 
are listed. * Sequence identity is shown as the number of bp with sequence identity in GenBank/total 
number of bp in this spacer. 
 
Results of further investigations regarding the presence of CRISPR loci within the 
collection of the sequenced E. faecalis ST40 strains will be presented in part 4.1.4.4. 
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4.1.4 Comparative analysis of E. faecalis ST40 genomes 
4.1.4.1 Comparative genome alignment 
Comparisons of the 14 ST40 draft genomes against the D32 reference genome 
suggested a high level of genomic similarity regarding the core, irrespective of their 
geographical, temporal or clinical/non-clinical origin (Figure 4.9). 
 
 
Figure 4.9: E. faecalis ST40 genome comparison against the D32 reference genome. 
  Generated by BRIG (4), the circular map illustrates the whole genome comparison of D32 against the 
other 14 sequenced ST40 isolates and the probiotic isolate Symbioflor 1 Clone DSM 16431 (71). The 
outer cycle (dark grey) represents the complete genome of the reference strain D32. The shade of 
color is geared to similarities in origin of the strains. The inner cycle illustrates the GC content of D32. 
Location of the PAI is illustrated by a blue colored box, while the red box indicates the presence of an 
uncharacterized and large genomic island (GI; 138kb). Additionally, black labels highlighted four 
identified prophages of D32; A, animal; B, blood culture; C, colonizer; E, endocarditis; H, human; M, 
bovine mastitis; U, urine. 
 
Results 
73 
 
Of note, genome comparisons also revealed that the probiotic Symbioflor 1 strain 
contains parts of the PAI (see Figure 4.9) (53, 184). 
 
4.1.4.2 Phylogenetic analysis 
Phylogenetic analysis was done by using concatenated nucleotide regions, 
represented in all aligned strains and after elimination of existing gaps. A 
phylogenetic tree resulting from an alignment of concatenated sequences, presented 
in all analyzed strains, is shown in Figure 4.10. It revealed a high level of genomic 
similarity of unrelated ST40 strains, despite their diverse origins and the time interval 
from 1975 to 2008. 
When focusing on the ST40 isolates, the phylogenetic tree also showed an 
exceptional position of D32 in relation to the other sequenced ST40 isolates and 
furthermore, its close relationship to the other Danish porcine isolate UW7742. 
Within the genomic homology, strains of a similar origin were not arranged in the 
same cluster. Especially, animal-associated strains were more diverse than human 
isolates. But, whole genome alignment suggests a minimal phylogenetic distance 
between the fish colonizing strain UW7729 and the isolate UW7801 from bovine 
mastitis. 
When focusing on the human associated isolates, phylogenetic analyses also 
indicated a high genomic similarity between the human colonizing strain UW7779 
and the urine isolate UW1833, as well as, the blood culture isolate UW7753 and the 
isolate UW7709, obtained from a patient with infective endocarditis. 
As expected, the other completed and publicly available E. faecalis genomes branch 
separately, supporting their assessment to different sequence types and clonal 
complexes based on MLST. 
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Figure 4.10: Phylogenetic relationship among selected E. faecalis strains based on whole 
genome alignments. 
The alignment was calculated with Mugsy (5) and only aligned regions present in all analyzed strains 
were extracted. These regions were concatenated and positions with gaps removed (201). The 
resulting core alignment (126.7 kb) was used to infer a Maximum Likelihood tree with RAxML (233). 
The GTRGAMMA model for nucleotide substitution and rate heterogeneity was utilized, bootstrap 
support values of 1000 replicates are shown at the nodes. Melissococcus plutonius was used as an 
outgroup. Names of the ST40 isolates and their origin are indicated at the end of the branches; ST, 
sequence type; AC, animal colonizer; B, blood culture; E, endocarditis; HC, human colonizer; M, 
bovine mastitis; U, urine. 
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4.1.4.3 Analyses of MGE 
Genomic islands 
All isolates featured a modular structured pathogenicity island (PAI), which is flanked 
by phage-related integration and excision genes, as well as, varies independently of 
the core genome. 
By using long template PCR, investigations regarding the structure of the PAI also 
confirmed results of genome analysis (Table 4.10). 
 
Table 4.10: Screening of the E. faecalis PAI (215) by long PCR. 
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1 + - + + + + + + + + + + + + + + + 
2a + - - - - - - - - - - - - - + - - 
2b + - - - - - - - - - - - - - - - - 
2c + - - - - - - - - - - - - - - - - 
3a + - - - + - - + + + + - - - - + - 
3b + - - - - - - - - - - - - - - - - 
4a + - - - - - - - - - - + - - - - - 
4b + - + + + + - + + + + + + + - + + 
5a + - - - - - - - - - - + - - - - - 
5b + - - - + - + - - - - - - - - - - 
6a + - - - - - - - - - - - - - - - - 
6b + - - - - - - - - - - - - - - - - 
7a + - - - - - - - - - - - - - - - + 
7b + - + + + + + + + + + - + + - - - 
8a + - - - - - - - - - - - - - - - - 
8b + - - - - - - - - - - - - - - - - 
9 + - + + + + + + + + + - + + - + - 
PAI* + + + + + + + + + + + + + + + + + 
  Accordingly to (131), structure of the PAI based on the entire E. faecalis PAI of MMH594 (215) was 
analyzed by long template PCR, amplifying overlapping regions (Table 6.7 and Table 6.8). Positive 
results of amplification demonstrated a similar genomic structure compared to the prototype of the 
PAI. Structurally genomic differences, such as the absence of genes and/or the presence of additional 
insertions, were indicated by negative results. Integration of the PAI was additionally investigated by 
regular PCR (*). 
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Results of bidirectional BLAST showed that the uncharacterized GI (138kb; see part 
4.1.3.1) of D32 was only verifiable in UW7729, an isolate originating from fish (Figure 
4.9; data not shown in detail). Up until now, it is still unclear, whether the GI was 
additionally integrated with the inositol operon or instead of this because contig 
border was located at the end of the inositol operon . 
 
Prophages 
Comparison of the ST40 strains with the reference strain D32 indicated strain-specific 
phage patterns because of differences in prophage content independently of the 
strain background (Figure 4.9). 
According to part 4.1.3.1, prophage 1, showing high similarity to the enterococcal 
phage phiFL4A (NC_013644), was also present in UW1833, isolated from urine, and 
in the human colonizing strain UW6727. In relation to D32, strains isolated from blood 
culture and bovine mastitis differed in prophage content, while the other ST40 
isolates showed a relatively homogenous level of phage content. But, here it is noted 
that more detailed work is necessary to investigate the presence and the 
characteristics of other prophages, which differ from D32. 
 
Plasmid content and classification 
In the context of the 15 de novo sequenced strains, investigation of plasmid content 
indicated a certain level of diversity independently of the strain background (Table 
4.11). Plasmids could be classified by the replication initiating gene repA of the 
corresponding replicase (rep) family (114, 272). Presence of repA of the well 
described E. faecalis plasmids pAD1, pCF10 and pRE25 was determined by 
Southern hybridization. Additionally, sequencing was used to review these results 
and to differentiate between the amplified conserved repA areas of the closely 
related pAD1 and pCF10. 
The most dominant rep-family among the sequenced E. faecalis ST40 was rep2 and 
rep9 found in three (20%) and six isolates (40%), respectively. In addition, data also 
indicated the presence of plasmids of other rep-families, which were not investigated 
in detail. 
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Table 4.11: Plasmid content and the definition of the corresponding rep-families. 
Isolate Origin No. Size [kb] pAD1 pCF10 pRE25 Putative rep-family 
UW6149 B 1 65 + (89%) + (94%) - 9 
UW2860 B 1 65 - Undetermined - Unknown 
UW6724 HC 2 70 / <60 + (92%) + (96%) - 9 
UW7761 B Ø      
UW7777 HC Ø      
UW7780 HC 2 75 / 60 + (92%) + (97%) - 9 
UW7753 B 2 70 / 60 + (90%) + (95%) + 9/2 
UW1833 U ? Unknown - - + 2 
UW7779 HC 2 75 / <60 - - + 2 
UW7729 AC 1 <60 + (95%) + (95%) - 9 
UW7801 M Ø      
UW6727 HC 2 60 / <60 + (88%) + (<90%) - 9 
D32 AC 2 75 / unknown - - - 1/Unknown* 
UW7709 E Ø      
UW7742 AC Ø      
  Plasmid content was determined by plasmid profiling using (i) phenol-chloroform-based extraction 
(290) with subsequent agarose gel analysis and (ii) S1 nuclease PFGE. Approximate plasmid size was 
estimated from the S1 nuclease gel in accordance to the HARMONY protocol (164). Presence of the 
replication initiating gene (repA) of the corresponding plasmids pAD1, pCF10 and pRE25 was 
detected by Southern hybridization and checked by sequencing. Values in brackets indicated 
sequence identities in comparison to NCBI database. Based on PCR amplification and sequencing of 
conserved areas of the rep gene, plasmid rep-families were defined (114, 272). * Genomic 
characteristics of the plasmids EFD32pA and EFD32pB were described in part 4.1.3.2; A, animal; B, 
blood culture; C, colonizer; E, endocarditis; H, human; M, bovine mastitis; U, urine. 
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4.1.4.4 CRISPRs within the subset of sequenced E. faecalis ST40 
strains 
Within the subset of sequenced E. faecalis ST40 strains, presence of CRISPR1-cas 
and CRISPR2 was checked by PCR. CRISPR2 locus was also sequenced to 
characterize the integrated spacer (Table 4.12). Regarding to the two CRISPR loci 
identified in OG1RF (24, 102), our PCR results indicated that all of the selected ST40 
genomes possess the CRISPR1-cas and CRISPR2 loci, lacking the functional cas 
genes. An exception represents the genome of UW7729, where only the CRISPR2 
locus was present. 
 
Table 4.12: Identification of CRISPR loci in selected E. faecalis ST40 strains by PCR. 
Isolate cas_csn1 CRISPR1-cas Size [bp] CRISPR2 No. of spacer 
V583 - - 773 - 0 
OG1RF + + 1031 + 7 
UW1833 + + 870 + 4 
UW6724 + + 886 + 4 
UW6727 + + 857 + 4 
UW7777 + + 864 + 4 
UW7779 + + 892 + 4 
UW2860 + + 891 + 4 
UW6149 + + 892 + 4 
UW7801 + + 861 + 4 
UW7729 - - 927 + 5 
UW7709 + + 834 + 4 
UW7742 + + 988 + 6 
D32 + + 1432 + 13 
UW7761 + + 915 + 5 
UW7753 + + 860 + 4 
UW7780 + + 831 + 4 
  Analog to (180), presence of CRISPR loci corresponding to OG1RF CRISPR1-cas and CRISPR2 loci 
(24, 102) was checked by PCR. CRISPR2 locus was also sequenced to identify the integrated spacer. 
Analog to (102), existence of an empty CRISPR2 locus of the hospital-adapted V583 strain, also 
lacking the functional cas genes (102, 180) was demonstrated. 
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Our detailed analyses of CRISPR2 locus showed that all strains of the selected ST40 
subgroup possessed three identical spacers, whereby two of those are also present 
in OG1RF (24) (data not shown). 
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4.2 Utilization of various carbon sources 
We postulated that the different origins and habitats of the isolates may be reflected 
by minor, host-specific differences in their metabolic properties as described for 
isolates of E. faecium (298). To determine supposed differences in their metabolic 
profiles, Biolog MicroArray™ analyses were performed. Utilization of various carbon 
sources at aerobic conditions did not show significant differences between the 15 
sequenced E. faecalis ST40 isolates. Additionally, this approach did not reveal any 
obvious association between origin or host and utilization of different carbon sources. 
For reasons of simplification, data values in Table 4.13 and Table 4.14 have been 
replaced by color codes. Tables with the complete, quantitative data sets and 
standard derivations are shown in Table 6.13 to Table 6.32. 
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Table 4.13: Aerobic utilization of carbon sources of Biolog MicroArray™ PM01. 
 
  Mean area values were calculated of three independent experiments performed at 37°C for a 72h 
incubation time. For reasons of simplification, mean area values have been replaced by a color code. 
Grey color indicated no or only weak substrate utilization (mean area value below 10,000) and pink 
symbolized middle values (mean area value between 10,000 and 19,999). The green color 
represented strains with a high capability of utilization of the respective carbon source (mean area 
value greater or equal to 20,000). The red box highlighted m-Inositol as the carbon source of main 
interest. 
  
C-source V583 OG1RF UW6149 UW2860 UW6724 UW7761 UW7777 UW7780 UW7753 UW1833 UW7779 UW7729 UW7801 UW6727 D32 UW7709 UW7742
Negative Control
L-Arabinose
N-Acetyl-D-Glucosamine
D-Saccharic Acid
Succinic Acid
D-Galactose
L-Aspartic Acid
L-Proline
D-Alanine
D-Trehalose
D-Mannose
Dulcitol
D-Serine
D-Sorbitol
Glycerol
L-Fucose
D-Glucuronic Acid
D-Gluconic Acid
D,L-a-Glycerol- Phosphate
D-Xylose
L-Lactic Acid
Formic Acid
D-Mannitol
L-Glutamic Acid
D-Glucose-6-Phosphate
D-Galactonic Acid-g-Lactone
D,L-Malic Acid
D-Ribose
Tween 20
L-Rhamnose
D-Fructose
Acetic Acid
a-D-Glucose
Maltose
D-Melibiose
Thymidine
L-Asparagine
D-Aspartic Acid
D-Glucosaminic Acid
1,2-Propanediol
Tween 40
a-Keto-Glutaric Acid
a-Keto-Butyric Acid
a-Methyl-D-Galactoside
a-D-Lactose
Lactulose
Sucrose
Uridine
L-Glutamine
m-Tartaric Acid
D-Glucose-1-Phosphate
D-Fructose-6-Phosphate
Tween 80
a-Hydroxy Glutaric Acid-g-Lactone
a-Hydroxy-Butyric Acid
b-Methyl-D-Glucoside
Adonitol
Maltotriose
2`-Deoxy-Adenosine
Adenosine
Glycyl-L-Aspartic Acid
Citric Acid
m-Inositol
D-Threonine
Fumaric Acid
Bromo-Succinic Acid
Propionic Acid
Mucic Acid
Glycolic Acid
Glyoxylic Acid
D-Cellobiose
Inosine
Glycyl-L-Glutamic Acid
Tricarballylic Acid
L-Serine
L-Threonine
L-Alanine
L-Alanyl-Glycine
Acetoacetic Acid
N-Acetyl-b-D-Mannosamine
Mono Methyl Succinate
Methyl Pyruvate
D-Malic Acid
L-Malic Acid
Glycyl-L-Proline
p-Hydroxy-Phenylacetic Acid
m-Hydroxy-Phenylacetic Acid
Tyramine
D-Psicose
L-Lyxose
Glucuronamide
Pyruvic Acid
L-Galactonic Acid-g-Lactone
D-Galacturonic Acid
b-Phenylethylamine
Ethanolamine
Results 
82 
 
Table 4.14: Aerobic utilization of carbon sources of Biolog MicroArray™ PM02. 
 
  Mean area values were calculated of three independent experiments performed at 37°C for a 72h 
incubation time. For reasons of simplification, mean area values have been replaced by a color code. 
Grey color indicated no or only weak substrate utilization (mean area value below 10,000) and pink 
symbolized middle values (mean area value between 10,000 and 19,999). The green color 
represented strains with a high capability of utilization of the respective carbon source (mean area 
value greater or equal to 20,000). 
 
In the following, the role of myo-inositol (m-inositol) will be reconsidered in more 
detail. Belonging to one of nine isomers of the inositol group, m-inositol is used as a 
sole carbon source by many soil and plant microorganisms by degradation into 
glyceraldehyde-3P (24). 
C-source V583 OG1RF UW6149 UW2860 UW6724 UW7761 UW7777 UW7780 UW7753 UW1833 UW7779 UW7729 UW7801 UW6727 D32 UW7709 UW7742
Negative Control
Chondroitin Sulfate C
a-Cyclodextrin
b-Cyclodextrin
g-Cyclodextrin
Dextrin
Gelatin
Glycogen
Inulin
Laminarin
Mannan
Pectin
N-Acetyl-D-Galactosamine
N-Acetyl-Neuraminic Acid
b-D-Allose
Amygdalin
D-Arabinose
D-Arabitol
L-Arabitol
Arbutin
2-Deoxy-D-Ribose
i-Erythritol
D-Fucose
3-0-b-D-Galactopyranosyl-D-Arabinose
Gentiobiose
L-Glucose
D-Lactitol
D-Melezitose
Maltitol
a-Methyl-D-Glucoside
b-Methyl-D-Galactoside
3-O-Methyl-Glucose
b-Methyl-D-Glucuronic Acid
a-Methyl-D-Mannoside
b-Methyl-D-Xyloside
Palatinose
D-Raffinose
Salicin
Sedoheptulosan
L-Sorbose
Stachyose
D-Tagatose
Turanose
Xylitol
N-Acetyl-D-Glucosaminitol
g-Amino-Butyric Acid
d-Amino-Valeric Acid
Butyric Acid
Capric Acid
Caproic Acid
Citraconic Acid
D,L-Citramalic Acid
D-Glucosamine
2-Hydroxy-Benzoic Acid
4-Hydroxy-Benzoic Acid
b-Hydroxy-Butyric Acid
g-Hydroxy-Butyric Acid
a-Keto-Valeric Acid
Itaconic Acid
5-Keto-D-Gluconic Acid
D-Lactic Acid Methyl Ester
Malonic Acid
Melibionic Acid
Oxalic Acid
Oxalomalic Acid
Quinic Acid
D-Ribono-1,4-Lactone
Sebacic Acid
Sorbic Acid
Succinamic Acid
D-Tartaric Acid
L-Tartaric Acid
Acetamide
L-Alaninamide
N-Acetyl-L-Glutamic Acid
L-Arginine
Glycine
L-Histidine
L-Homoserine
4-Hydroxy-L-Proline (trans)
L-Isoleucine
L-Leucine
L-Lysine
L-Methionine
L-Ornithine
L-Phenylalanine
L-Pyroglutamic Acid
L-Valine
D,L-Carnitine
Butylamine (sec)
D,L-Octopamine
Putrescine
Dihydroxy-Acetone
2,3-Butanediol
2,3-Butanone
3-Hydroxy-2-Butanone
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As already described before, the novel and uncharacterized GI (138kb) of D32 was 
integrated at the attachment site of the conjugative vanB transposon in V583 (184). 
The genome sequence of OG1RF harbored the inositol operon at exactly this 
integration site, which consists of 10 genes (24). Presence of the inositol operon was 
also checked by PCR. In contrast to OG1RF, neither in the D32 nor the V583 
genome the inositol operon was detected (Table 4.15). Accordingly, Biolog 
MicroArray™ analyses showed that only OG1RF, but not V583 and D32, was able to 
utilize m-inositol (Table 4.13). 
 
Table 4.15: Evidence of the presence of the iol operon in combination of inositol utilization. 
Strain iolR iolB iolG2 iolE Inositol utilization 
V583 - - - - - 
OG1RF + + + + + 
D32 - - - - - 
  Presence of selected genes of the inositol (iol) operon was tested by PCR and inositol utilization was 
further checked by Biolog MicroArray™ analysis. iolR, annotated as OG1_0175, the probable inositol 
regulator; iolB, myo-inositol catabolism protein; iolG2, inositol 2-dehydrogenase; iolE, myo-inositol 
catabolism protein. 
 
For all the other sequenced strains, presence (but not the genomic localization) of the 
iol operon could be confirmed by PCR (data not shown) in combination with a 
positive result of inositol utilization in the Biolog MicroArray™ assay (Table 4.13). 
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4.3 Comparative assessment of the pathogenic potential of closely 
related E. faecalis isolates 
Genomic comparisons revealed a high level of similarity between the porcine, 
commensal D32 and a human clinical endocarditis isolate UW7709, both from 
Denmark. Ability to adhere to human epithelial cells and to cause pathogenic effects 
in selected animal models was analyzed for these two related ST40 strains. 
 
4.3.1 In vitro growth kinetics 
Over a course of 24 hours, optical density and the corresponding bacterial counts 
were determined (Figure 4.11). Measurement of optical density suggested that D32 
showed faster growth when compared to UW7709. But bacteria of D32 also showed 
an increased tendency to clump. We also determined the corresponding bacterial 
counts, showing comparatively similar growth rates of both E. faecalis strains D32 
and UW7709. 
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Figure 4.11: Comparative in vitro growth of E. faecalis strains D32 and UW7709. 
   Bacterial growth of both E. faecalis strains was analyzed by measuring the optical density (A) and 
determining the corresponding bacterial counts (B). Data are representative of at least three 
independent experiments with similar outcome. 
 
4.3.2 In vitro biofilm formation 
E. faecalis strain UW7709 showed a significantly enhanced biofilm production when 
compared with the strain D32 (Figure 4.12). 
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Figure 4.12: In vitro biofilm formation. 
  Biofilm formation of E. faecalis strains D32, UW7709 and the internal controls V583, OG1RF and E. 
faecium strain 64/3 on a synthetic surface was investigated by using polystyrene plates. After 
incubation in TSB for 24 hours, produced biofilms of adherent bacteria were stained with crystal violet. 
Bars represent the mean values of six or three (D32) replicates ± SEM. *** significant P-value < 
0.0005, unpaired two-tailed t-test. 
 
Results of biofilm formation were also compared to the corresponding genotype. 
Genomes of both strains harbored fsrB and gelE genes in combination with 
expression of an active metalloprotease GelE. No correlation between the presence 
of esp or other biofilm-enhancing factors (see Table 2.1), such as the ebpABC or epa 
locus, and the increase of biofilm formation was detected, because esp was absent in 
both genomes, while both genomes harbor the ebp and epa locus. 
 
4.3.3 Adherence to Caco-2 cells 
A monolayer of colonic epithelial cells (Caco-2) was incubated with E. faecalis strains 
D32 and UW7709 to test the potential of adhesion to human intestinal cells in vitro. 
In summary, adherence of D32 to Caco-2 cells was approximately 1.5 times higher 
than adhesion of UW7709 (Figure 4.13). 
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Figure 4.13: Adhesion ability to Caco-2 cells. 
  To analyze the potential of adhesion, a monolayer of Caco-2 cells was incubated with a bacterial cell 
to epithelial cell ratio of (A) 100:1 and (B) 1000:1 for two hours with the respective strain. Data 
represent the mean values ± SEM. * significant P-value < 0.05, unpaired two-tailed t-test. 
 
4.3.4 Analysis of pathogenicity by using the model organism G. 
mellonella 
The insect larvae G. mellonella is an alternative model to study bacteria-host 
interactions, also showing a complex immune reaction, consisting of both cellular and 
humoral responses (74, 163, 261). 
In this assay, D32 was more rapidly lethal for G. mellonella and pathogenicity of D32 
was generally increased in comparison to UW7709 (Figure 4.14). 
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Figure 4.14: Pathogenicity of E. faecalis D32 and UW7709 in a G. mellonella model. 
  Death rates of G. mellonella larvae after injection with E. faecalis strains D32 (real infectious dose: 
1.7 x 105 CFU per larvae) and UW7709 (real infectious dose: 2.8 x 105 CFU per larvae), respectively. 
PBS served as a negative control. One representative experiment of three independent experiments is 
shown. Data were analyzed by using Kaplan-Meier plot method. 
 
4.3.5 Analysis of pathogenicity by using chicken embryos as model 
organisms 
Two different infection methods were tested. The bacterial inoculum was injected into 
the: 
a) Yolk sac at day five after fertilization (103 CFU per egg) 
b) Allantois cavity at day 10 to 12 after fertilization (105 CFU per egg). 
 
Independently of the strain background, infection of the yolk sac induced death of all 
embryos until the fifth day post infection. Embryos, infected with the enterococcal 
strain UW7709, died significantly later (Figure 4.15 (A)). After infection of the allantoic 
cavity, both strains were highly virulent, but only infection with D32 resulted in killing 
of all of the chicken embryos (Figure 4.15 (B)). 
Additionally, Enterococcus spp. was identified in all screened death embryos with the 
exception of the negative control group. 
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Figure 4.15: Killing of chicken embryos by E. faecalis strains D32 and UW7709. 
  Death rates of chicken embryos were tested after injection of an infectious dose of (A) 103 CFU per 
0.2mL into the yolk sac and (B) 105 CFU per 0.2mL into the allantoic cavity. Survival of embryos was 
checked using the mercury vapor lamp over a period of four days. PBS served as a negative control. 
Data were analyzed by using Kaplan-Meier plot method. 
 
4.3.6 Murine bacteremia model 
Mice were infected with 5 x 108 CFU via the tail vein 48 hours before sacrifying. 
Bacterial counts were recovered from liver, kidneys, spleen and blood. D32 showed 
significantly enhanced growth rates in comparison to UW7709 (Figure 4.16 (A) and 
(B)). 
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Figure 4.16: Growth rates of E. faecalis UW7709 and D32 in a mouse bacteremia model. 
  Eight female BALB/c mice were infected via the tail vein with E. faecalis strains UW7709 or D32 (5 x 
108 CFU). After 48 hours, mice were sacrificed and bacterial counts in (A) liver, kidneys and spleen, as 
well as, in (B) blood were determined. Data represent the individual bacterial burdens and the 
geometric mean value. Asterisks indicate significant P values calculated by using Mann-Whitney test 
(* P < 0.05, *** P < 0.0005). 
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5 Discussion 
5.1 Comparative genomic studies of E. faecalis ST40 strain 
collection 
The “two-faced” E. faecalis is not only of relevance as part of the human and animal 
intestinal microbiota or as a probiotic in health care, but also as a leading cause of 
nosocomial infections, especially of the urinary tract, bacteremia and/or endocarditis. 
Based on multilocus sequence typing (MLST) in combination with phylogenetic 
analyses (eBURST), strains from distinct ecological backgrounds can be allocated to 
defined clonal complexes (CC) (199). Special clonal groups, such as CC2, CC9, and 
CC87, are also designed as high-risk enterococcal clonal complexes (HiRECCs) 
because they are preferentially associated with hospital infections and outbreaks, 
and are quite often multi-resistant (125, 133, 199, 262, 286). Epidemiological 
investigations of a diverse E. faecalis strain collection revealed that CC40/ST40 is the 
most common sequence type (ST), not showing a preferred host-specificity or any 
other characteristic (150). 
 
In this study, a heterogeneous E. faecalis MLST ST40 strain collection, comprising 
randomly collected isolates of environmental and commensal/pathogenic sources 
(humans/animals) also originating from different countries and years, was examined 
for genomic and phenotypic characteristics. In enterococci, recombination and 
horizontal gene transfer (HGT) are suggested to be more relevant for genomic 
variability than single nucleotide polymorphism (SNP) mutations (278, 287)). 
Consequently, we supposed that additional to lineage-specific genes also genomic 
and phenotypic differences are present as a result of adaptation to the corresponding 
environments. 
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5.1.1 Genomic pre-characterization of the E. faecalis ST40 strain 
collection 
SmaI macrorestriction patterns in combination with analyses of the presence and 
expression of so far described virulence-associated genes revealed a high level of 
similarity among the rather diverse collection of ST40 isolates. Thereby, strains of 
this clonal group did not show specific genomic characteristics or differences in 
relation to their origin in terms of host, context (commensal/clinical), time, and 
geography. As an example, I would like to point out the close, but also unclear 
relationship between the strain UW6724, isolated from the neonatology unit in 
Germany (Wernigerode), and the blood culture isolate UW7761, isolated from a 
patient in Cuba (Havanna) (see Figure 4.1). This suggests that genomic variability 
also might be limited as well among bacteria, showing a high level of recombination 
in general. 
 
Corresponding to previous PCR-based screenings (214) and microarray-based 
comparative genomic hybridization (CGH) studies (1, 150, 227), our results further 
showed that previously described virulence-associated genes, including fsrABDC-
regulated gelE (190), cylM (115), and esp (219), as well as, clinically relevant 
antibiotic resistance traits are also present in non-clinical strains (129). Formation of 
biofilm could not be correlated with the presence of already described and putative 
biofilm-associated genes, such as esp and asc-10 (see Table 2.1). 
According to McBride et al., all isolates of this most common sequence type ST40 
are non-encapsulated and are characterized as cps type 1, consequently (150). 
 
Moreover, I would like to point out another study, where a diverse E. faecalis strain 
collection of unrelated isolates isolated from bovine mastitis was molecularly 
characterized. Thereby, strains of ST40 predominated, which emphasizes its 
prevalence as a common and frequent sequence type without showing any preferred 
host-association (150, 280). 
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5.1.2 De novo sequencing strategy and generation of a ST40 
reference genome 
On the basis of these previous characterizations, a subset of 15 strains, representing 
the diversity of the collection, was chosen for de novo pyrosequencing by standard 
Roche 454 GS-FLX technology. But this strategy was limited due to a low coverage 
in combination with a high number of contigs (see Table 4.3) due to technological 
inconsistencies, which was still frequent at that time. Because no complete ST40 
genome sequence had been publicly available, we decided to resolve the complete 
genome sequence of the pig commensal strain D32 (300) to use it as a ST40 
template for detailed genome comparisons. After scaffolding by using an 8kb long-
paired end (LPE) library, the remaining gaps and assembly ambiguities (“InDel” 
errors) were corrected by a Sanger-based process (300). We also gained 
experiences with the usage of the two different assembly software tools Newbler and 
Celera, generated two and one chromosomal scaffold, respectively. Usage of Celera 
resulted in a lesser extent of misassembled regions, while especially the assembly of 
repetitive sequences was more difficult for Newbler software (Eurofins MWG-Operon, 
personal communication). 
 
For comparative genomics, including SNP-based phylogenies, we decided to 
additionally use Illumina sequencing technology, providing more accuracy and 
avoiding “InDel” errors. After Illumina sequencing of the remaining 14 E. faecalis 
ST40 strains and a subsequent hybrid assembly of both sequencing data sets (454 
and Illumina), genomes of these strains could be mapped against the D32 reference 
genome. This strategy allowed a more detailed molecular analysis with respect to the 
structure of the pathogenicity island (PAI) and other mobile genetic elements (MGE), 
including plasmids and phages. This approach further reveals possible minor 
genomic differences between isolates of commensal and pathogenic origin and 
allows generation of the SNP-based phylogeny of the core and entire genome. Of 
note, detailed analysis of the genomic mapping against the D32 reference sequence 
was partially limited by the existence of intra-chromosomal gaps within the 14 E. 
faecalis genomes. 
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Sequencing technology platforms of the third generation are now available and could 
replace time-consuming gap closing approaches for “sequence polishing”. Especially, 
Pacific Biosciences´ single molecule real time technology (SMRT) is an ambitious 
tool, allowing cost- and time-efficiently sequencing with extra-long reads (up to 
10,000bp) of high accuracy (>99.999%) ((151) and general information are presented 
on the website of Eurofins MWG (http://www.eurofinsgenomics.eu/en/home.aspx)). 
Thereby, quality of the draft genomes could be upgraded by using the software tool 
PBJelly, automated filling the existing gaps by using the generated long-reads in a 
reference-guided assembly process. But simultaneously, this emphasizes the 
importance regarding the excellent quality of the reference sequence (61). Other 
experiments in our group, when using PacBio for resolving the entire genome 
sequence of an E. faecium isolate, verified these predictions (Werner, G., 
unpublished data). 
 
5.1.3 Comparative genomic studies 
5.1.3.1 Conserved genomic backbone 
Analog to the results of the pre-characterization, genome data also revealed a high 
degree of similarity. Regarding the presence of putative and described virulence-
associated genes, genome data were in congruence to results of previous molecular 
typing. Furthermore, the close genomic relationship of the ST40 isolates was also 
reflected by phylogenetic analyses of the core genome DNA, suggesting a correlation 
between lineage-specific genes and MLST (52, 227). When comparing the 
phylogenetic tree and SmaI macrorestriction analysis, we have partially found 
overlapping results of clustered strains. For example, one cluster was composed of 
the human colonizing strain UW7779 and the urine isolate UW1833 (Figure 4.1 and 
Figure 4.10). In general, this genetic homogeneity was also reflected by similar 
patterns in the utilization of various carbon sources, tested by Biolog MicroArray™ 
analyses (see part 4.2). 
 
Illustrated by Venn diagram (Figure 4.5), a genomic alignment of the five publicy 
available and completely closed E. faecalis genomes (24, 28, 71, 184, 300), revealed 
the presence of unique chromosomal genes, which might be acquired during niche 
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adaptation (181, 262). Notably, the number of unique CDS of the clinical strain V583 
(184) was approximately two times higher than the counts of the commensal isolates 
62 (28) and D32 (300), as well as, the probiotic Symbioflor 1 strain (71). As a derivate 
of the commensal isolate OG1, OG1RF strain carried the minimal number of 140 
unique CDS compared to the other completed genomes, which are possibly 
explainable due to the lack of chromosomal integrated MGE, like the PAI or several 
prophages (24). Moreover, it might be interesting to analyze genes, which are only 
shared between V583 (184) and the commensal strains 62 (28) and D32 (300). But 
nevertheless, our comparisons of the chromosomes did not reveal a specific portfolio 
of hospital-associated E. faecalis V583 strain (184), which would explain its preferred 
hospital association in comparison to the commensal enterococcal strains. 
Relevance of transferred and integrated genetic elements must be considered and 
needs more attention (see 5.1.3.2). 
A detailed analysis of the genome data of Symbioflor 1 strain showed the absence of 
putative virulence genes, like cytolysin and esp (53, 71). The relevance of present 
auxiliary traits, such as capsule formation or expression of aggregation substance, 
was associated with an advantage for colonization (53). Other studies demonstrated 
that adherence-promoted surface structures, especially enriched in strains of CC2, 
are supposed to play a crucial role in fitness and virulence, and especially in biofilm 
formation (178, 194, 229), which will be further discussed in the following section 
5.1.3.2. 
 
5.1.3.2 Genomic variability induced due to the acquisition of MGEs 
Genomic “flexibility” plays a crucial role in adaption to and colonization of diverse 
ecological niches (49, 52). In this context, genomic variability is mainly realized by 
acquisition and loss of mobile elements, composing more than one quarter of the 
genome of E. faecalis V583 (184). 
 
PAI and its genomic content 
Comparable to the findings of McBride and co-workers (149), we could also 
demonstrate that all of the isolates featured a modular structured pathogenicity 
island, varying independently of the strain background and being flanked by putative 
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phage-related integrase and excisionase genes (215). Additionally, differences in 
GC-content and the presence of a characteristically large subset of mobility genes 
are associated with its foreign character, as well as, horizontal acquisition and gene 
loss (52, 144, 215, 216, 262)). Within several studies, transfer of virulence-associated 
determinants of the PAI, as well as, of the PAI itself were demonstrated and probably 
occurred via conjugative elements (40, 52, 131, 145, 175, 216, 262). Corresponding 
to the results of previous studies, the D32 PAI contains a bile acid hydrolase (cbh) 
and lactose metabolic pathway genes (lacABCDEFG), but lacks common markers 
present in the original prototype of MMH594, associated with virulence, like esp and 
cytolysin operon (129, 215, 216, 300). Taken together, these results revealed that the 
PAI evolves by HGT and recombination in a much faster way than the relatively 
conserved core genome (149, 199, 262, 286). In case of D32, composition of the PAI 
suggested a putative niche adaptation to the pig´s intestine, may be indicated by 
selective pressure, like due the host immune response or, in some cases, antibiotics. 
Concrete examples are the presence of bile acid hydrolase (cbh) and lactose 
metabolic pathway genes (lacABCDEFG) (49, 52, 129, 144, 194, 216, 300). 
Detailed analyses of the genetic components of the PAIs of the 14 E. faecalis ST40 
draft genomes were limited by the existence of intra-chromosomal gaps. But, 
comparisons of PCR analyses with in vitro biofilm assays revealed that esp might be 
only one of the beneficial factors, involved in enhanced adhesion (60, 158). 
 
Genomic islands (GI) – probably encoding for enterococcal exopolysaccharides 
A so far unknown GI was identified to be integrated within the genome of the porcine 
commensal strain D32. Among several genes with unknown identity, a genomic 
cluster is encoded, probably associated with exopolysaccharid synthesis. Consisting 
of different sugars, the extracellular polysaccharides (EPS) are polymeric complex 
structures covalently bound to cell surface or released in its environment (44, 157). 
Generally, important conserved E. faecalis cell wall polysaccharides are the 
rhamnopolysaccharide Epa, encoded by the enterococcal polysaccharide 
biosynthesis locus epa, and the capsular polysaccharide Cps (cps cluster), consisting 
of galactose, glucose and phosphate (87, 89, 103, 181, 245, 292, 293). As already 
described before, we could demonstrate that all of the ST40 strains are non-
encapsulated and are grouped as CPS type 1, representing the common CPS type 
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(150). Although presence of cps genes did not result in the expression of the 
corresponding capsule phenotype (75), genes related to cell surface structures are 
enriched in strains of CC2 (150, 227, 229, 267). In the context of fitness and host 
adaption, surface structures are thought to promote adhesion to human tissue cells 
(95, 194, 207, 239), enriched in strains of CC2 (184, 194, 229). First results of 
secretome analyses at the working group of Katharina Riedel at Greifswald University 
suggested differences in the extracellular proteome of both strains, D32 and UW7709 
(Zühlke, D., personal communication). Eventually, differences within the secretome 
could explain why D32 showed significantly enhanced (i) adherence to human Caco-
2 epithelial cells, as well as, (ii) growth rates in murine organs and blood, when 
compared to UW7709 (see part 5.2) (16, 22). In the working group of Prof. Johannes 
Hübner at Freiburg University, a rat endocarditis model was additionally established 
and here, D32 again showed enhanced growth rates at aortic values, comparable to 
murine bacteremia model (Hübner, J., personal communication). 
 
The gastrointestinal tract (GIT) could be the starting point for a systemic infection 
when bacteria enter the blood stream and are dispersed inside the whole body, 
enabling the establishment of new sites of infection (7)). Intestinal overgrowth under 
specific conditions, such as antibiotic treatment, precedes systemic infections, 
especially involving members of Enterococcus (258, 259). For E. faecalis, relevant 
mechanisms for crossing the endothelial barrier of the GIT are not really understood, 
but capacity to invade depends on cell surface structures (32, 55). For example, S. 
aureus is suggested to use various strategies, such as transcytosis, paracytosis, 
phagocytic transport, and cytolytic toxin induced damage of the endothelium. 
However, attachment to the tissue cells plays a key role for bacterial entry into the 
blood stream (59, 207). Therefore, is might be interesting whether increased capacity 
of porcine commensal strain D32 to adhere to various endothelial cells, such as 
aortic values, is potentially associated with an increased capacity to infect the 
endocard, underlining the relevance of the normal intestinal microbial flora of humans 
and pigs as community reservoirs of clinical E. faecalis strains (129). 
Deficiencies of the immune system and/or disturbance of the microbial flora of the 
gastrointestinal tract, especially by antibiotic long-term therapy, could increase the 
selective pressure for the colonization with enterococcal strains. A special feature is 
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that these strains acquired new traits by HGT, like antibiotic resistance traits or 
virulence genes, constituting an advantage for niche adaption (7, 77, 78, 120, 287). 
Especially acquisition of surface proteins, such as capsule formation, may also be an 
efficient strategy to evade the host immune system, by mediating resistance to 
phagocytosis (52, 87, 194, 244, 253, 267) and masking of lipoteichoic acids (LTA), 
which are targets of opsonic antibodies (17, 150, 208, 248, 253). This might result in 
an increased pathogenicity (163, 194), as it was described for D32 in the tested 
Galleria mellonella (G. mellonella) and the chicken embryo models. 
 
Mass spectrometric analyzes of the secretome could be an useful approach to 
analyze the surface proteome in more detail, while a reference map of the membrane 
proteome of E. faecalis OG1X was previously provided by Maddalo and colleagues 
(139). Especially surface proteins, like LTA, peptidoglycan-attached wall teichoic 
acids (WTA), choline-binding proteins (CBP), putative microbial surface component 
recognizing adhesive matrix molecule proteins (MSCRAMMs), mucins and variation 
of glycosylation, have to be focused to get knowledge about their relevance in 
colonization and virulence (22, 95, 194, 208, 229, 239, 248, 249). 
 
Because of the relatively conserved core genome of the ST40 strain collection, 
further investigations, concerning variations of the expression level of surface 
proteins dependent on host cell contact, could also be an interesting approach (177, 
265). While cps and epa are down-regulated when growing in blood (266), the fsr 
quorum sensing system of E. faecalis directly mediates adherence to collagen (187). 
It is thought to control cell functions relevant for virulence (74), for example it 
regulates expression of the metalloprotease gelatinase GelE (190), while its activity 
correlates with reduced adhesion because of the cleavage of MSCRAMM Ace at the 
cell surface (169, 170, 187, 193). Expression of other surface proteins might also be 
regulated by cell-cell communication (289). Differential gene expression could also 
be controlled by environmental factors (96), such as the presence of bile (21, 228), 
blood (266), urine (267), metals (2, 138, 192), or bicarbonate (27, 140). 
This complexity is also demonstrated by our results of in vivo biofilm formation (see 
part 5.2), where adhesion plays an important role (248, 249). In this study, increase 
of adherence of D32 could not be associated with enhanced biofilm formation in vitro, 
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corresponding to Larsen et al. (129). So far described regulators, such as Fsr (88), 
EbpR (26), EbrA (12), and PerA (140), suggested to have an influence to biofilm 
accumulation. But, Ballering and colleagues further concluded that other genes of the 
conserved core genome could also be involved in biofilm gene regulation (12). 
 
More investigations, regarding the integration site of this novel GI, also showed that it 
is integrated within a conserved attL/attR attachment site, previously described as a 
“hot spot” for rearrangements or new integrations (24). It is suggested that two 
different integration events resulted in the presence of an iol operon in OG1RF and a 
conjugative vanB transposon in V583 (24, 184). This region is missing in the 
Symbioflor 1 strain (24, 53, 71). Our sequencing results demonstrated that all of the 
ST40 strains, with the exception of D32, harbor an iol operon comparable to OG1RF 
(24), coupled with identical phenotypes of myo-inositol utilization (seeTable 4.13). In 
general, metabolism of myo-inositol, abundant in nature, is suggested to be an 
auxiliary trait promoting fitness, also generally described for Lactobacilli (24, 294). 
Furthermore, genome data in combination with results of Biolog MicroArray™ 
analyses of the strain UW7729, isolated from fish, suggested that the iol operon was 
co-integrated next to the novel GI. But the presence of intra-chromosomal gaps 
within this genomic region limited our possibilities to display the co-existence in more 
detail. 
 
Other MGEs 
Currently, there are no suitable software tools to filter out plasmid sequences, 
generated by 454 or the Illumina´s Solexa sequencing technology. Thus, “classical” 
molecular methods, such as plasmid isolation, analysis of the plasmid size by S1 
nuclease PFGE in combination with PCR- and hybridization-based rep-typing, were 
used as meaningful approaches to improve data analysis. In combination with 
genomic mapping of the ST40 draft genomes against the D32 template, results 
revealed a high level of genomic diversity (270) and strain-specific phage patterns 
(see Figure 4.9 and Table 4.11). We propose that integration of bacteriophages 
might have a significant impact on niche adaptation. In this context, Duerkop et al. 
hypothesized that bacteriophages, especially a composition of different 
bacteriophages, cause bacterial dominance within the bacterial ecosystem, where 
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especially competition for nutrients plays a crucial role (57). Furthermore, the 
examination of the genomic integration sites would be an interesting approach. Here, 
integration of the bacteriophage into a promoter region might result in an increase of 
expression of putative virulence-associated genes (269). Additionally, surface-
exposed WTA structures might be used as specific identification markers for 
bacteriophages, enabling HGT of virulence and resistance genes across genus–
specific barriers of Gram-positive pathogens (288). 
 
Using the rep-typing scheme, demonstrated that rep-types 2 and 9 were dominant 
and also offered some new plasmids (114, 272, 300). These results indicated that 
recombination and rearrangements of chromosomal and other plasmid DNA might 
contribute to mosaic-related structures, whereby an adaptation to changing 
environmental conditions is mediated (278). 
 
Finally, there are several unanswered questions, regarding the presence and 
detailed analysis of additionally acquired genes or MGEs of the other ST40 strains, 
as well as, investigations regarding presence of plasmid stabilization systems (270). 
 
5.1.3.3 CRISPR-cas – conferring bacterial adaptive immunity 
Our studies highlighted the MGE-dependent genomic diversity of the E. faecalis 
ST40 strain collection. In this context, it is substantial to discuss the relevance of the 
CRISPR-cas system, mediating adaptive immunity against integration of 
bacteriophages and plasmids by taking up genetic material (101). 
During this thesis, we mainly focused on CRISPR loci within the finished genome of 
E. faecalis strain D32. Detailed sequence analyses showed that only CRISPR1 locus 
is associated with four related cas genes, which are supposed to be responsible for 
recognition of foreign DNA and/or integration of new repeat-spacer units. 
Consequently, only CRISPR1 locus might be functional (101). Because of non-
identical repeat sequences of CRISPR1-cas and CRISPR2 (see Table 4.7), 
interacting with Cas proteins, it is rather unlikely that both CRISPR loci are 
functionally linked (101, 180). Interestingly, the CRISPR2 locus occurred not only in 
the finished E. faecalis strains OG1RF and D32 but also in all of the sequenced E. 
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faecalis ST40 strains. As already described in (180), it is still unclear, whether 
CRISPR2-related cas genes have existed and have been lost over the time. In 
general, a functional analysis of the CRISPR2 locus might be an important approach. 
But nevertheless, a kind of dynamics in terms of the integrated spacers was also 
shown, when analyzing the CRISPR2 locus within the subset of sequenced ST40 
strains.  Conserved spacer sequences within this locus indicated their inheritance 
over time (101, 275), but minor variations also revealed a replacement of spacers as 
a consequence of niche adaptation and changing environmental conditions, probably 
acquired from the microbial ecosystem by HGT (136, 274, 275). Within a CRISPR-
cas system, spacer acquisition needs to be regulated because integration is not only 
limited to new beneficial traits. Furthermore, it is more a balance of spacer addition 
and loss to guarantee fitness within the microbial ecosystem and to respond quickly 
to changing conditions (18, 135, 276). As a consequence of this obvious diversity 
within the ST40 strain collection, typing based on CRISPR locus would be 
complicated (180, 181). 
Interestingly, we also noticed that the number of CRISPR2 spacers of the porcine 
commensal strain D32 sets apart from the other ST40 strains, raising further 
questions. Further analyzes, regarding homologies of the D32 CRISPR spacers, 
revealed that only one spacer, also belonging to CRISPR2 locus (CRISPR2_5; see 
Table 4.9), showed homologies to the E. faecalis phage phiEF11 (235). 38.5% of the 
phiEf11 phage components are detectable as remnants in the core genome of D32, 
as well as, other finished E. faecalis strains V583 (184), OG1RF (24), 62 (28) and 
Symbioflor 1 (71). But in contrast to D32, general analyses of the CRISPR-cas 
elements of these also finished genomes showed a lack of the corresponding, 
matching protospacer (see CRISPRdb; http://crispr.u-psud.fr/CRISPR-). Here, it 
could be hypothesized that these E. faecalis strains may have lost this spacer during 
the process of niche adaptation, which could ensure and optimize their fitness (136, 
275). 
 
Finally, genome data have a great potential for further more in-depth analyzes, 
especially with respect to the CRISPR1-cas integrated spacers of these closely-
related E. faecalis ST40 strains. Further investigations, regarding the impact of the 
CRISPR-cas system on the regulation of surface genes, thought to be one way of 
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possible interaction between bacteria and eukaryotes, are possible (204). Moreover, 
it would be interesting to analyze whether individual phages or plasmids have already 
possessed strategies to circumvent this defense mechanism, like acquisition of 
mutations within the nucleic acid that matches to one of the CRISPR spacer (“proto-
spacer”) (136). 
 
5.1.4 Aspects of “Functional Genomics“ 
Palmer and colleagues used Biolog MicroArray™ technology to identify species-
specific biochemical traits of a diverse enterococcal strain collection, also including E. 
faecalis strains of various sequence types (181). 
In the context of a relatively conserved core genome, we wanted to analyze possible 
differences within the ST40 strain collection, concerning the utilization of various 
carbon sources, which had never been tested in such a scope. But under aerobic 
conditions, Biolog MicroArray™ technology showed homogenous results of metabolic 
activity, not allowing a conclusion regarding to host- or environmental adaptation of 
metabolic characteristics. 
 
By adaptation of the experimental conditions to the milieu of the gastrointestinal tract, 
we already tested changes within the metabolic profile, when using a microaerophilic 
atmosphere (80). First analyses revealed oxygen-dependence of some of the 
metabolic pathways, but also showed homogenous changes of carbon utilization 
patterns, when comparing the three tested ST40 isolates (D32, UW1833 and 
UW7709). However, this approach will need further tests and more intensive 
analyses. 
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5.2 Comparative assessment of the pathogenic potential of two 
highly related E. faecalis ST40 isolates 
After analysis of the genome data sets, we compared microbiological, cell-biological 
and pathogenic properties of the porcine colonizing strain D32 (300), isolated in 
Denmark in 2001, and the clinical isolate UW7709, obtained from a patient with 
infective endocarditis in Denmark in 1997 (129). Results showed no obvious genomic 
differences between both strains, as well as, comparable in vitro aerobic metabolic 
profiles of carbon utilization, indicating the relevance of in vivo gene regulation. 
In general, comparable in vitro growth rates exclude the possibility that differences in 
bacterial counts have an effect on the experimental design. When using a Caco-2 cell 
adherence assay, the commensal strain D32 showed a greater capacity to adhere to 
GIT-related epithelial cells. Comparable results were also achieved when testing 
adherence to uroepithelial cells (Hübner, J., personal communication). Despite the 
lowered host cell-dependent adherence, the clinical isolate UW7709 was able to form 
an increased biofilm at abiotic surfaces. Thereby, genome data of these both strains 
did not reveal any correlation between the presence of esp und the increase of 
biofilm formation, because esp was absent in both genomes (60, 105, 124, 129, 
159). But in general, a supporting role during the process of infection cannot be 
clearly determined (51, 158). Furthermore, the role of differentially expression of 
LPxTG surface structures in combination with the relevance of other putative biofilm-
associated genes might be causative but have not been investigated in greater 
details (178). 
 
For studying bacteria-host interactions, we used different animal experiments: 
(i) Galleria mellonella model organism 
The use of larvae of the greater wax moth G. mellonella constitutes an attractive 
model because their immune system, showing both cellular and humoral responses, 
is comparable to those of vertebrates (42). Our results indicated that the D32 strain 
showed enhanced characteristics to evade the insect defense strategies (194, 261). 
According to this, G. mellonella might be used as a simple, cost- and time-efficient 
model for pre-tests, before using vertebrate model organisms (42), because of similar 
results when testing other model organisms, like chicken and mice (see below).  
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(ii) Chicken embryo model organism 
We also tested death rates in a chicken embryo infectious model (198), by using 
different time points of infection. By infecting the yolk sac at an early time point of 
embryonic development, the embryo seemed to be more fragile because of the lower 
development status of defense mechanisms. These preliminary results showed that 
both infection models were suitable to assess differences in the pathogenic potential 
of nosocomial pathogens (for which it has not been used until now). To draw more 
general conclusions, further tests with various infectious doses in combination with a 
higher number of eggs would be necessary. 
 
(iii) Murine bacteremia model 
We demonstrated enhanced growth rates of the strain D32 in murine organs, liver, 
kidney, and spleen, by using the murine bacteremia model (105, 248). Of note, one 
important characteristic of colonization of organ-specific tissue cells is influenced by 
the ability for adhesion (95, 194). Consequently, we speculated that the D32 isolate 
should possess increased adherence properties, which should allow it to grow more 
rapidly in the tested organs. Curiously, it also showed enhanced growth at heart 
valves, which was expected to be characteristic of the strain UW7709, which was 
originally isolated from an endocarditis in humans (Hübner, J., personal 
communication). 
 
Taken together, results of the tested animal models and cell culture assays (with the 
exception of the biofilm experiments) point into the same direction: The porcine 
commensal strain D32 generally showed a greater capacity to adhere, which might 
explain its increased pathogenic potential in the tested models in combination with an 
even faster growth in vivo (not in vitro). 
Our detailed genomic comparisons emphasized the presence of a novel GI, only 
integrated into the genome of D32, as one distinctive feature, which might be one 
possibility to explain the different phenotypes. We speculate that the GI-encoded 
exopolysaccharides might increase adherence to host tissue cells and could provide 
one of the opportunities to evade the host immune response (181, 194). 
Consequently, it might be worth considering whether the excision of this GI or its 
integration into the genome of the clinical strain UW7709 would lead to different 
Discussion 
105 
 
results. Within the collection of the 15 sequenced ST40 strains, this GI is only present 
within the genome of the ST40 strain UW7729, isolated from fish. It would be 
worthwhile to include this strain in further analyses, such as the chicken embryo 
lethality assays. 
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5.3 Conclusions and further perspectives 
The close evolutionary relationship is illustrated by the high level of similarity of the 
unrelated strains from the rather diverse E. faecalis ST40 strain collection. This 
implicates that the distribution of known and putative virulence-associated genes 
does not allow any differentiation between ST40 strains from a commensal and 
clinical background (animal/human). Results of comparative genomics also revealed 
differences, concerning probably horizontally acquired MGEs, which might have 
resulted in niche adaptation associated with dominance within the microbial habitat 
(49, 129, 181, 262, 286, 287). 
 
Recombination-based in vivo expression technology (R-IVET) would be an useful 
approach to screen for genes in vivo activated during infection, such as genes 
encoded for cell surface structures, for example located within the novel GI (16, 22, 
90). Knock–out of the novel GI and comparisons of the mutated and original strains 
under various test conditions (in vitro / in vivo models) could further allow a better 
understanding of the role of this supposed new GI. 
A more detailed analysis of the proteome with the focus on secreted proteins might 
be a further objective to reveal differences not visible through genomic comparisons 
at the DNA level. 
 
In the end, further work is warranted to analyze the structures of bacteriophages and 
plasmids in more detail. Studying of minor differences of the accessory genome 
could give insights in microevolution from commensal to pathogenic lifestyle in 
various animals and humans, and might help to trace possible transmission routes. 
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6 Appendix 
Table 6.1: Primers used for Multilocus Sequence Typing (MLST). 
Locus 
name 
Genbank 
Accession no. 
Primer 
name 
Primer sequence 
(5' → 3') 
Reference 
aroE EF_1561 aroE-1 TGGAAAACTTTACGGAGACAGC (199), 
efaecalis.mlst.net 
aroE-2 GTCCTGTCCATTGTTCAAAAGC 
gdh EF_1004 gdh-1 GGCGCACTAAAAGATATGGT (199), 
efaecalis.mlst.net 
gdh-2 CCAAGATTGGGCAACTTCGTCCCA 
gki EF_2788 gki-1 GATTTTGTGGGAATTGGTATGG (199), 
efaecalis.mlst.net 
gki-2 ACCATTAAAGCAAAATGATCGC 
gyd EF_1964 gyd-1 CAAACTGCTTAGCTCCAATGGC (199), 
efaecalis.mlst.net 
gyd-2 CATTTCGTTGTCATACCAAGC 
pstS EF_1705 pstS-1 CGGAACAGGACTTTCGC (199), 
efaecalis.mlst.net 
pstS-2 ATTTACATCACGTTCTACTTGC 
xpt EF_2365 xpt-1 AAAATGATGGCCGTGTATTAGG (199), 
efaecalis.mlst.net 
xpt-2 AACGTCACCGTTCCTTCACTTA 
yqiL EF_1364 yqiL-1 CAGCTTAAGTCAAGTAAGTGCCG (199), 
efaecalis.mlst.net 
yqiL-2 GAATATCCCTTCTGCTTGTGCT 
  Legend: aroE, shikimate-5-dehydrogenase; gdh, glucose-6-phosphate-dehydrogenase; gki, 
glucokinase; gyd, glyceraldehyde-3-phosphate dehydrogenase; pstS, phosphate ATP binding cassette 
transporter; purK, phosphoribosylaminoimidazol carboxylase ATPase subunit; xpt, xanthine 
phosphoribosyltransferase; yqiL, acetyl-coenzyme A acetyltransferase. 
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Table 6.2: Primers used for the analysis of the distribution of antibiotic resistances. 
Locus name Antibitotic Primer name Primer sequence (5' → 3') Amplicon [bp] Reference 
vanA vancomycin (vanA-type) vanA I-1 TCTGCAATAGAGATAGCCGC 377 (119) 
vanA II-2 GGAGTAGCTATCCCAGCATT 
ermB erythromycin ermB-F AGCCATGCGTCTGACATCTAT 341 (282) 
ermB-R TGCTCATAAGTAACGGTACT 
tetM tetracycline tetM-F GGTGAACATCATAGACACGC 401 (285) 
tetM-R CTTGTTCGAGTTCCAATGC 
aacA-aphD gentamicin gen-F TAATCCAAGAGCAATAAGGGC 227 (237) 
gen-R GCCACACTATCATAACCACTA 
aadE streptomycin aadE-1 GCAGAACAGGATGAACGTATTCG 369 (50) 
aadE-2 ATCAGTCGGAACTATGTCCC 
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Table 6.3: Primers used for screening of virulence-associated markers. 
Locus name Genbank  
accession no. 
Primer 
name 
Primer sequence (5' → 3') Amplicon [bp] Reference 
asc10 EF0005 PAIasc10-1 GCCAAAGTGGAACGTTAAATG 345 (215), (Werner, G., unpublished data) 
PAIasc10-2 TCAATCCAGAAGGTCCTGTG 
cylM EF0046 cylM-TQ1 GATGCGTATTACTGTTGTTAGAATGAGAT 150 (215), (Werner, G., unpublished data) 
cylM-TQ2 GAGTCTCCCTGTGATTCTGATATAGAGTT 
esp EF0056 esp-TIM1 CTTTGATTCTTGGTTGTCGGATAC  475 (264) 
esp-TIM2 TCCAACTACCACGGTTTGTTTATC  
xyl kinase EF0083 PAIefc-83F GGAGCTGATAATGCTTGTGC 202 (131) 
PAIefc-83R AAGAATTACCTGCTGCCAAC 
gls24-like EF0117 gls24-F TGAAGCAAATTCTCCAGTAGC 262 (215), (Werner, G., unpublished data) 
gls24-R TGGAGTGGATGTTGAAGTAGG 
 AE016830.1 PAI164 ATGCCATGTTCAGCGAAGTTGCCAATTATC  *  (130, 131) 
PAI167 ATGTTGGTTGAAAGTTGCTTTTTGGCAAAC 
gelE M37185.1 gelE-F TATGACAATGCTTTTTGGGAT 213 (264) 
gelE-R AGATGCACCCGAAATAATATA 
fsrB EF_1821* fsrB-1 GCATTGTTATCTATGTCGCCATACC 397 (150) 
fsrB-2 GGCTTAGTTCCCACACCATC 
 
 
Table 6.4: Primers used in this study for analysis of the capsule locus type. 
Locus name Genbank accession no. Primer name Primer sequence (5' → 3') Amplicon [bp] Reference 
cpsA EF_0095 cpsA-F GTGTCTCCTGAAAAATCAGGCC 383 (87) 
cpsA-R GTTAAAGTCAATGTAATGGGCTACC 
cpsB EF_0094 cpsB-F CTATCAAAACGATCTAAAATACCACC 619 (87) 
cpsB-R GATTAACGTTATTAAGTTTTGAAGGCG 
cpsC EF_0093 cpsC-F CCAACGCTTTGCTTCTTGAATGAC 300 (150) 
cpsC-R CCTGAATATCAATGTATTTGGGCAGTC 
cpsF EF_0090 cpsF-F GGCGATCTATTCTACCATCCGCGC 324 (87) 
cpsF-R CCAAAGAAAGATATTTTGGATTGAG 
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Table 6.5: Primers used for identification of CRISPR loci and characterization of the spacers, integrated in CRISPR2 locus. 
Locus name Reference Sequence Primer name Primer sequence (5' → 3') Amplicon [bp] Reference 
CRISPR1-cas AE016830.1 
CRISPR1-cas-F GCGATGTTAGCTGATACAAC 
316 (180) 
CRISPR1-cas-R CGAATATGCCTGTGGTGAAA 
CRISPR1 cas_csn NC_017316.1 
CRISPR1-cas_csn1-F CAGAAGACTATCAGTTGGTG 
783 (180) 
CRISPR1-cas_csn1-R CCTTCTAAATCTTCTTCATAG 
CRISPR2 AE016830.1 
CRISPR2-F CTGGCTCGCTGTTACAGCT 
variabel (180) 
CRISPR2-R GCCAATGTTACAATATCAAACA 
CRISPR3-cas AE016830.1 
CRISPR3-cas-F GATCACTAGGTTCAGTTATTTC 
225 (180) 
CRISPR3-cas-R CATCGATTCATTATTCCTCCAA 
 
 
Table 6.6: Primers used for analysis of the presence of the inositol (iol) operon. 
Locus name Reference Sequence Primer name Primer sequence (5' → 3') Amplicon [bp] Reference 
iolB 
  
NC_017316.1 
  
iolB-F CCATCTGGCACGCCGACAGGA 363 This study 
iolB-R GCCAGTGCACGTGATTACCGCTG 
iolG2 
  
NC_017316.1 
  
iolG2-F GCGTTTGCCAGTCGGGCGAAA 465 This study 
iolG2-R TGGTACAGGTGGGCTTCATGCGT 
iolE 
  
NC_017316.1 
  
iolE-F ACGGATTGGCTTTGGCCGGATCT 363 This study 
iolE-R TGGGGACAGGAGTCCAAACGACTG 
iolR 
  
NC_017316.1 
  
iolR-F TCCCTAATCGCCACACTA 379 (24) 
iolR-R TTGCTGAAAAAGCAGGAG  
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Table 6.7: Primers used for the screening of the E. faecalis PAI (215) by long PCR - Part I. 
Primer 
name 
Primer sequence (5' → 3') Amplicon 
[bp]  
Location 
(gbAF454824.1) 
Reference 
PAI164 ATGCCATGTTCAGCGAAGTTGCCAATTATC  1548 C:427 (131) 
1 PAI R GGAAGATGGACGGTTGATGAAGCCTCAATATG 
2a PAI F CAGTTGTCGAATACGATGCATGTCCCAGCC  9674 240:9913 (131) 
2a PAI R AAACCAAAGGAACCGAAACGGAAAAACTTAGCATGG 
2b PAI F TTTAACCAGCCATGCTAAGTTTTTCCGTTTCGGTTC 6066 9869:15934 (131) 
2b PAI R TTTGAAATAATCTCCAACTTTTCCCCCGTTCCACAC 
2c PAI F AACCATAAAAAGGAACGGAGGGAGCACAACAAAAGG 7697 14033:21999 (131) 
2c PAI R ACTTGCAGTGTGACTGTCTGTCGTAACTTCACC 
3a PAI F CTCGTCCGTAACGATCTGTTTTATCGCCCTTATC 11645 21566:32079 (131) 
3a PAI R TCAAGTCCGTACAACAGGCACTTTCTTTATCAAGC 
3b PAI F GAAGGCCGTTGCCAATTTTGCATTAGCTTGC 11411 31320:42730 (131) 
3b PAI R TCCTAAGCCTATGGTAAAACATGCTGGAGTTGTCTC 
4a PAI F CAAGGTAGTGGAGATGTTCAGGCTGAGACAACAC 11079 42395:53473 (131) 
4a PAI R CGGATGTTACTTCTGCTGGACTTAAAACAATCCC 
4b PAI F GGGATTGTTTTAAGTCCAGCAGAAGTAACATCCG 11561 53440:65000 (131) 
4b PAI R ACGCCAAGCACAAGGGATAAAGATTGCGAAAG 
5a PAI F GGACGACCTTTATAGACGCCGTTTGCTTTCG 10629 64944:75572 (131) 
5a PAI R AGTCCCCTTTTTCTGCCATGACACCAGTTAAAATC 
5b PAI F GCTGTGGTCAAGATAGATGGGAAAGAGATTGAGCG 11431 74158:85588 (131) 
5b PAI R GGATCTGAACCGTCTTGTGTCATAGTGTGCCAG 
6a PAI F TGTAGCATACTGGCACACTATGACACAAGACGG 9115 85547:94661 (131) 
6a PAI R CGTGCCCCTAATTACCATAGAGATAGTCGCGTTG 
6b PAI F TGGTAAACGCTGCTCCTGAAATGAAGAGTTTGAC 8432 93984:102421 (131) 
6b PAI R AGGTTTGATACGCAACTACCTTTCCCAACTGACG 
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Table 6.8: Primers used for the screening of the E. faecalis PAI (215) by long PCR - Part II. 
Primer 
name 
Primer sequence (5' → 3') Amplicon 
[bp] 
Location 
(gbAF454824.1) 
Reference 
7a PAI F  TTTTGGGACAGGAACGCTATCAGTTAACGATTGC 10821 101954:113046 (131) 
7a PAI R CCTGCGGTCAAGCACAGTTGCCTTATCTTAG 
7b PAI F ATTAAAGTCAAAAGAGACTGTTACTTGTGCGCCCTG 13858 113008:126865 (131) 
7b PAI R TCAGCAAACTAAGATAAGGCAACTGTGCTTGACC 
8a PAI F TGCTTTAGTGGGTCGTACTAACGGAACAATAG 11008 125344:136351 (131) 
8a PAI R CAAACAACACGTCGTCGATCTTTACCTTG 
8b PAI F CACCAATGCACATAATCAAACAATTCTAGGCGTAG 11048 135337:146384 (131) 
8b PAI R GTGGACAAGCACAGTCACAATTAGAAGCAATG 
9 PAI F CATCATTTCTTCAGCAAATTGGTTGGCACGC 8298 146272:C (131) 
PAI167R ATGTTGGTTGAAAGTTGCTTTTTGGCAAAC 
 
 
Table 6.9: Primers used for classification of the plasmids by amplification of the corresponding repA gene. 
Primer name Reference sequence Primer sequence (5' → 3') Amplicon [bp] Reference 
repCF10-1 rep of pCF10/pAD1 GCTCGATCARTTTTCAGAAG 201 (72) 
repCF10-2 CGCAAACATTTGTCWATTTCTT 
repRE25-1 rep of pRE25 GAGAACCATCAAGGCGAAAT 630 (72) 
repRE25-2 ACCAGAATAAGCACTACGTACAATCT 
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Table 6.10: Primers used for gap closure of chromosomal contigs during E. faecalis D32 sequencing- Part I. 
Primer name Primer sequence (5' → 3') Reference 
Gap closure     
UW7744_01-F TGATTCATTTCCCCGTCGTG This study 
UW7744_01-R AAGGCCATTGAACCAGCAG This study 
UW7744_02-F TTTAATGGAACTGCCCCCC This study 
UW7744_02-R CGCTTTAATCTGTCGGCTTAG This study 
UW7744_04_05-F TCCCCATTTTCAACATTGACTG This study 
UW7744_04_05-R TGTGCAAACCCAGAATGTAATC This study 
UW7744_06-F CAAATTATTGGCACCACATGG This study 
UW7744_06-R TCAGAAGCAAAGGAAATCCTG This study 
UW7744_07_08-F CATGATGGCGAACATGTCC This study 
UW7744_07_08-R GTAGAAAGCTTGTGAGAAGTCC This study 
UW7744_09-F ACCATTCCTAAAACTGACGC This study 
UW7744_09-R GTTTATCCAATGGTGGAAACAC This study 
UW7744_10-F CTAGCATTGGTGAACTAGCG This study 
UW7744_10-R CAAGAGCTAGAATTGGTGACAG This study 
UW7744_12-F TGTTCTATTTTCTATCGCGGG This study 
UW7744_12-R TCACTCCTAACTACGCAGG This study 
UW7744_13-F ATTGAAGGAGGACAATACGATG This study 
UW7744_13-R TTCCATTCTTTGACACCGC This study 
UW7744_14-F CTTGGAAAAACAGTGATTGTGG This study 
UW7744_14-R CTGTATCAGTGGTCTCTGTTTG This study 
UW7744_15-F GCAGGAATTGGTGTTTTAACC This study 
UW7744_15-R ATTGAAGACGTAATGGCTGAG This study 
UW7744_16-F CAGGATACATGCAACAGATGG This study 
UW7744_16-R GTACGACATACACACCTTTCG This study 
UW7744_17-F AGTATGACGAAGATGTTCTGC This study 
UW7744_17-R ATACTGGAACAAGCTGTCAAG This study 
UW7744_18_F AATCCAACTATTTGCATCCTCC This study 
UW7744_18_R CATTACCTGCGACTCCAAAG This study 
UW7744_19-F AGTTGATATTATCGGTTCCGC This study 
UW7744_19-R TGTCCAATTAGTTCTGGATGTG This study 
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Table 6.11: Primers used for gap closure of chromosomal contigs during E. faecalis D32 sequencing - Part II. 
Primer name Primer sequence (5' → 3') Reference 
UW7744_20-F TGGTGATGTCCGTGAAAAAAC This study 
UW7744_20-R ATGGTATGGCAATCCCTGC This study 
UW7744_21-F TTTTCCTATGCCACAACTAGC This study 
UW7744_21-R GCACAATCTTAACCATGATTGG This study 
UW7744_22-F GTTATACGCAAGTAGCCGC This study 
UW7744_22-R GCCAACGATAAACCAAAAACTG This study 
UW7744_23-F AAGATAATCCGTTTGCGCC This study 
UW7744_23-R GCTTTACTTATGCAAAACCCAG This study 
UW7744_24-F GACGGAAGGCAAAACAATTAC This study 
UW7744_24-R TGGTCTGGTGTTACTTTAACTG This study 
UW7744_25-F TTGCCTTTCACTGTCCCAG This study 
UW7744_25-R GGCCAACTTGCTGAAAAATTTG This study 
UW7744_26-F TCTTTGAACGGTTCTATCGTG This study 
UW7744_26-R AGGTTATTTAGCCATCACAGAC This study 
UW7744_27-F GTTGTACGGACGGATTTAGAC This study 
UW7744_27-R TGACGAAGAGTTAATGATTGCC This study 
UW7744_31b_32b-F GGCATTTACAGCTAGTGATTCATC This study 
UW7744_31b_32b-R GGCCTTAGTTTTTGGAACGATTC This study 
UW7744_33-F CAGCAATTTTGGACAGAAAAGC This study 
UW7744_33-R GGTGGCACTGTTACAATGC This study 
UW7744_4_1_1-F AATGGCCGTTGTAGAACCAG This study 
UW7744_2_1-R TCTTCATCAATGTTCGGACG This study 
UW7744_2_3-F ACATTGTTGCTGCTGGTTTG This study 
UW7744_1_3-R TTGCCACAAAAACACTCACC This study 
UW7744_7_1-F CAACGCACAGAATACATGGG This study 
UW7744_5_1-R ATTTCACCTGTCATTTCGGC This study 
UW7744_5_3-F AAAGTGGCGGTGACAACAG This study 
UW7744_4_2_3-R CCTTTCGCTTTCAACATTCAG This study 
  
Appendix 
XXIII 
 
Table 6.12: Primers used for gap closure of chromosomal contigs during E. faecalis D32 sequencing - Part III. 
Primer name Primer sequence (5' → 3') Reference 
UW7744_c5_1-F AGCAAAGAAAGGTGTAAACTCC This study 
UW7744_c4.2_rc_1-R TGGAAAGCCATTAGTAACCAAC This study 
UW7744_c4.2_rc_6-F AAGTCACTCTTGGTTGGACGCC This study 
UW7744_c4.2_rest_6-R TGAAGAAGGACAGCGCGGTATG This study 
UW7744_c1-7_R01_03-F CAGAAAGCGTATTGCATCAAG This study 
UW7744_c1-7_R01_03-R AAGCGCCTTTCACTCTTATG This study 
UW7744_c1-7_R02_02-F TTAGTTGGGCACTCTAGCG This study 
UW7744_c1-7_R02_02-R ACGAATGTTTTGAGAGTAGACC This study 
GI integration    
UW7744_5-Ende_02-F CAGAACTCACCTCGTCTTTTAC This study 
UW7744_5-Ende_02-R CGGTTGATACCTTTGATTTTGC This study 
UW7744_GI_05_01-F CCCATTTATACTGGCAAATCGG This study 
UW7744_GI_05_01-R GCAAAGGTAGCAGGAGTAAAAC This study 
UW7744_3-Ende_02-F CTTTTCCTTGTGCAGAATCTTC This study 
UW7744_3-Ende_02-R AACAAATTTCGCGCAACAG This study 
UW7744_GI_03_01-F CAGACACATTGAGTAAAACAGC This study 
UW7744_GI_03_01-R ATGGAAAGGATGTGCCTAATAC This study 
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Table 6.13: Aerobic utilization of carbon sources of Biolog MicroArray™ PM01 - Part I. 
C-source 
V
5
8
3
 
O
G
1
R
F
 
U
W
6
1
4
9
 
U
W
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8
6
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U
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6
7
2
4
 
U
W
7
7
6
1
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W
7
7
7
7
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7
7
8
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U
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7
7
5
3
 
U
W
1
8
3
3
 
U
W
7
7
7
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L
M
G
T
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3
3
3
 
A
T
C
C
 2
7
9
5
9
 
U
W
6
7
2
7
 
D
3
2
 
U
W
7
7
0
9
 
D
1
 
Negative Control 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
L-Arabinose 
2,27E+
04 
2,72E+
04 
2,75E+
04 
3,36E+
04 
3,21E+
04 
2,77E+
04 
3,42E+
04 
3,54E+
04 
2,79E+
04 
2,74E+
04 
2,91E+
04 
2,55E+
04 
1,88E+
04 
2,33E+
04 
2,44E+
04 
3,36E+
04 
2,92E+
04 
N-Acetyl-D-
Glucosamine 
3,57E+
04 
4,16E+
04 
3,99E+
04 
4,44E+
04 
4,85E+
04 
4,13E+
04 
4,22E+
04 
4,67E+
04 
4,69E+
04 
4,02E+
04 
3,72E+
04 
4,13E+
04 
4,11E+
04 
4,37E+
04 
4,14E+
04 
5,49E+
04 
4,38E+
04 
D-Saccharic Acid 
7,36E+
02 
1,20E+
01 
2,09E+
02 
3,67E+
00 
1,04E+
02 
8,00E+
00 
9,67E+
00 
7,40E+
01 
4,44E+
02 
6,42E+
02 
1,86E+
02 
3,07E+
01 
7,90E+
01 
1,09E+
02 
1,07E+
01 
4,70E+
01 
6,67E-
01 
Succinic Acid 
5,98E+
02 
2,80E+
01 
9,27E+
01 
0,00E+
00 
1,51E+
02 
0,00E+
00 
0,00E+
00 
3,47E+
01 
2,69E+
02 
2,92E+
02 
3,49E+
02 
0,00E+
00 
9,70E+
01 
3,24E+
02 
4,97E+
01 
2,17E+
01 
0,00E+
00 
D-Galactose 
4,68E+
04 
5,14E+
04 
5,30E+
04 
5,64E+
04 
5,53E+
04 
5,03E+
04 
5,14E+
04 
5,26E+
04 
5,26E+
04 
4,79E+
04 
4,61E+
04 
5,00E+
04 
5,19E+
04 
5,12E+
04 
5,15E+
04 
5,53E+
04 
5,13E+
04 
L-Aspartic Acid 
8,46E+
02 
1,49E+
02 
4,29E+
02 
2,37E+
01 
1,92E+
02 
0,00E+
00 
3,20E+
02 
2,66E+
02 
2,41E+
02 
1,25E+
03 
4,13E+
02 
4,33E+
01 
1,84E+
02 
7,20E+
02 
7,07E+
01 
8,03E+
01 
1,70E+
01 
L-Proline 
5,54E+
02 
4,27E+
01 
5,97E+
01 
1,00E+
00 
6,37E+
01 
0,00E+
00 
8,33E+
00 
3,00E+
01 
1,60E+
02 
5,85E+
02 
3,37E+
02 
5,00E+
00 
6,43E+
01 
3,62E+
02 
5,43E+
01 
1,17E+
01 
3,33E-
01 
D-Alanine 
1,03E+
03 
5,52E+
02 
2,15E+
02 
6,53E+
01 
3,07E+
02 
4,33E+
00 
1,13E+
02 
1,07E+
02 
2,93E+
02 
1,08E+
03 
5,95E+
02 
3,00E+
00 
1,34E+
02 
5,71E+
02 
1,63E+
02 
1,25E+
02 
9,00E+
00 
D-Trehalose 
4,19E+
04 
4,49E+
04 
4,96E+
04 
5,24E+
04 
5,01E+
04 
4,37E+
04 
4,80E+
04 
4,91E+
04 
4,85E+
04 
4,57E+
04 
4,39E+
04 
4,56E+
04 
5,00E+
04 
4,99E+
04 
4,72E+
04 
5,43E+
04 
4,62E+
04 
D-Mannose 
4,47E+
04 
4,84E+
04 
5,03E+
04 
5,49E+
04 
5,57E+
04 
4,82E+
04 
5,08E+
04 
5,18E+
04 
4,89E+
04 
4,90E+
04 
4,60E+
04 
4,78E+
04 
4,81E+
04 
5,29E+
04 
5,44E+
04 
5,87E+
04 
4,91E+
04 
Dulcitol 
9,10E+
03 
7,94E+
03 
1,11E+
04 
6,87E+
03 
8,30E+
03 
6,21E+
03 
6,89E+
03 
5,30E+
03 
6,91E+
03 
1,13E+
04 
1,16E+
04 
6,70E+
03 
7,30E+
03 
9,15E+
03 
5,09E+
03 
1,06E+
04 
5,86E+
03 
D-Serine 
6,55E+
03 
3,87E+
03 
6,39E+
03 
6,06E+
03 
3,46E+
03 
5,78E+
02 
4,39E+
03 
4,45E+
03 
4,76E+
03 
7,12E+
03 
3,65E+
03 
3,60E+
03 
2,71E+
03 
3,41E+
03 
2,44E+
03 
2,84E+
03 
2,51E+
03 
D-Sorbitol 
4,54E+
04 
4,85E+
04 
5,10E+
04 
5,43E+
04 
5,29E+
04 
4,75E+
04 
4,86E+
04 
5,25E+
04 
5,27E+
04 
4,86E+
04 
4,42E+
04 
4,86E+
04 
5,06E+
04 
5,00E+
04 
4,59E+
04 
5,66E+
04 
5,25E+
04 
Glycerol 
4,68E+
04 
5,33E+
04 
5,12E+
04 
5,59E+
04 
5,43E+
04 
5,10E+
04 
5,21E+
04 
5,24E+
04 
5,25E+
04 
4,80E+
04 
4,70E+
04 
4,87E+
04 
5,36E+
04 
5,01E+
04 
4,73E+
04 
4,86E+
04 
4,77E+
04 
L-Fucose 
2,36E+
03 
2,22E+
03 
6,43E+
03 
2,20E+
03 
1,25E+
03 
5,07E+
01 
2,57E+
03 
1,38E+
03 
2,81E+
03 
7,45E+
03 
2,75E+
03 
4,97E+
02 
1,42E+
03 
4,43E+
03 
1,80E+
03 
5,79E+
02 
4,49E+
02 
D-Glucuronic Acid 
1,19E+
03 
9,36E+
02 
7,77E+
02 
4,50E+
01 
5,60E+
02 
0,00E+
00 
1,71E+
02 
6,38E+
02 
8,78E+
02 
1,98E+
03 
1,09E+
03 
4,27E+
01 
4,15E+
02 
9,52E+
02 
1,79E+
02 
1,20E+
02 
5,00E+
01 
D-Gluconic Acid 
4,46E+
04 
4,58E+
04 
5,14E+
04 
5,56E+
04 
5,18E+
04 
4,73E+
04 
4,93E+
04 
5,13E+
04 
5,12E+
04 
4,55E+
04 
4,23E+
04 
4,63E+
04 
4,77E+
04 
1,52E+
03 
4,68E+
04 
5,75E+
04 
5,22E+
04 
D,L-a-Glycerol- 
Phosphate 
1,06E+
04 
4,27E+
03 
5,61E+
03 
5,30E+
03 
5,02E+
03 
4,13E+
03 
6,26E+
03 
6,68E+
03 
7,10E+
03 
1,17E+
04 
1,08E+
04 
7,65E+
03 
3,92E+
03 
1,17E+
04 
3,62E+
03 
2,07E+
03 
5,23E+
03 
D-Xylose 
2,83E+
04 
2,53E+
04 
2,46E+
04 
2,50E+
04 
3,09E+
04 
2,13E+
04 
2,31E+
04 
2,32E+
04 
2,59E+
04 
2,33E+
04 
2,80E+
04 
2,02E+
04 
2,27E+
04 
2,46E+
04 
2,26E+
04 
2,66E+
04 
2,29E+
04 
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Table 6.14: Aerobic utilization of carbon sources of Biolog MicroArray™ PM01 - Part II. 
C-source 
V
5
8
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R
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W
6
1
4
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W
2
8
6
0
 
U
W
6
7
2
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U
W
7
7
6
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U
W
7
7
7
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U
W
7
7
8
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U
W
7
7
5
3
 
U
W
1
8
3
3
 
U
W
7
7
7
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L
M
G
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 2
3
3
3
 
A
T
C
C
 2
7
9
5
9
 
U
W
6
7
2
7
 
D
3
2
 
U
W
7
7
0
9
 
D
1
 
L-Lactic Acid 
8,01E+
02 
6,97E+
01 
9,43E+
01 
0,00E+
00 
5,43E+
01 
0,00E+
00 
2,77E+
01 
5,03E+
01 
7,90E+
01 
3,86E+
02 
8,40E+
01 
4,67E+
00 
5,57E+
01 
6,43E+
01 
1,97E+
01 
9,67E+
00 
1,00E+
00 
Formic Acid 
1,37E+
03 
4,02E+
02 
7,13E+
02 
3,33E-
01 
1,63E+
03 
1,67E+
00 
1,85E+
02 
1,89E+
02 
2,74E+
02 
7,28E+
02 
7,16E+
02 
3,07E+
01 
1,72E+
02 
2,74E+
02 
6,57E+
01 
2,18E+
02 
3,70E+
01 
D-Mannitol 
3,66E+
04 
4,28E+
04 
4,51E+
04 
4,60E+
04 
4,56E+
04 
3,88E+
04 
4,64E+
04 
4,56E+
04 
4,25E+
04 
4,09E+
04 
3,65E+
04 
3,99E+
04 
4,51E+
04 
4,93E+
04 
4,65E+
04 
5,44E+
04 
3,96E+
04 
L-Glutamic Acid 
5,19E+
03 
5,03E+
03 
6,25E+
03 
2,30E+
03 
5,01E+
03 
3,11E+
03 
4,77E+
03 
2,32E+
03 
4,64E+
03 
7,81E+
03 
6,96E+
03 
3,54E+
03 
3,95E+
03 
5,57E+
03 
3,76E+
03 
7,15E+
03 
2,14E+
03 
D-Glucose-6-
Phosphate 
1,27E+
04 
4,52E+
04 
4,96E+
04 
4,60E+
04 
4,98E+
04 
4,81E+
04 
4,70E+
04 
5,03E+
04 
4,95E+
04 
4,73E+
04 
4,57E+
04 
4,78E+
04 
5,35E+
04 
4,76E+
04 
4,54E+
04 
4,78E+
04 
5,00E+
04 
D-Galactonic Acid-g-
Lactone 
6,30E+
02 
0,00E+
00 
4,86E+
04 
5,38E+
04 
5,11E+
04 
4,71E+
04 
2,47E+
02 
3,47E+
01 
4,98E+
04 
4,49E+
04 
4,31E+
04 
0,00E+
00 
5,02E+
04 
4,87E+
04 
0,00E+
00 
1,33E+
00 
0,00E+
00 
D,L-Malic Acid 
5,58E+
04 
5,92E+
04 
5,82E+
04 
6,03E+
04 
5,84E+
04 
5,56E+
04 
5,78E+
04 
5,85E+
04 
5,82E+
04 
5,51E+
04 
5,31E+
04 
5,67E+
04 
5,84E+
04 
5,68E+
04 
5,67E+
04 
5,64E+
04 
5,80E+
04 
D-Ribose 
5,22E+
04 
5,46E+
04 
5,53E+
04 
5,76E+
04 
5,71E+
04 
5,18E+
04 
5,31E+
04 
5,35E+
04 
5,58E+
04 
5,08E+
04 
5,21E+
04 
5,24E+
04 
5,50E+
04 
5,27E+
04 
5,20E+
04 
5,25E+
04 
5,35E+
04 
Tween 20 
1,46E+
04 
7,23E+
03 
6,29E+
03 
1,21E+
04 
8,59E+
03 
7,83E+
03 
1,33E+
04 
1,36E+
04 
1,04E+
04 
1,70E+
04 
1,48E+
04 
1,08E+
04 
8,22E+
03 
2,16E+
04 
7,27E+
03 
5,94E+
03 
8,85E+
03 
L-Rhamnose 
2,72E+
03 
6,56E+
03 
1,27E+
04 
1,08E+
04 
1,05E+
04 
7,71E+
03 
1,58E+
04 
1,46E+
04 
1,25E+
04 
2,75E+
04 
2,17E+
04 
1,17E+
04 
8,41E+
03 
1,31E+
04 
3,69E+
03 
2,23E+
03 
1,23E+
03 
D-Fructose 
4,15E+
04 
3,64E+
04 
4,65E+
04 
5,21E+
04 
4,86E+
04 
4,34E+
04 
4,70E+
04 
5,00E+
04 
4,83E+
04 
4,35E+
04 
4,03E+
04 
4,50E+
04 
4,69E+
04 
5,02E+
04 
4,40E+
04 
5,76E+
04 
4,48E+
04 
Acetic Acid 
1,18E+
04 
5,38E+
03 
8,44E+
03 
5,36E+
03 
1,01E+
04 
5,08E+
03 
7,18E+
03 
5,34E+
03 
7,63E+
03 
1,13E+
04 
7,21E+
03 
7,99E+
03 
6,44E+
03 
7,03E+
03 
5,64E+
03 
8,30E+
03 
1,02E+
04 
a-D-Glucose 
3,62E+
04 
3,81E+
04 
3,94E+
04 
4,44E+
04 
4,90E+
04 
3,99E+
04 
4,16E+
04 
4,60E+
04 
4,06E+
04 
3,55E+
04 
3,66E+
04 
4,12E+
04 
4,04E+
04 
4,45E+
04 
4,11E+
04 
5,43E+
04 
4,08E+
04 
Maltose 
3,72E+
04 
3,73E+
04 
4,36E+
04 
4,82E+
04 
4,80E+
04 
3,96E+
04 
4,38E+
04 
4,60E+
04 
4,41E+
04 
4,02E+
04 
3,78E+
04 
4,05E+
04 
4,43E+
04 
4,48E+
04 
4,25E+
04 
5,18E+
04 
4,23E+
04 
D-Melibiose 
2,48E+
03 
2,25E+
03 
3,50E+
03 
2,15E+
03 
2,74E+
03 
7,34E+
02 
2,66E+
03 
1,93E+
03 
3,23E+
03 
7,45E+
03 
5,02E+
03 
1,77E+
03 
1,46E+
03 
5,63E+
03 
1,12E+
03 
2,62E+
03 
1,56E+
03 
Thymidine 
4,21E+
04 
4,24E+
04 
4,75E+
04 
4,35E+
04 
4,60E+
04 
4,22E+
04 
4,40E+
04 
4,28E+
04 
4,56E+
04 
4,52E+
04 
4,29E+
04 
4,44E+
04 
4,66E+
04 
4,29E+
04 
4,18E+
04 
3,97E+
04 
4,16E+
04 
L-Asparagine 
4,45E+
03 
5,66E+
03 
4,71E+
03 
4,44E+
03 
4,70E+
03 
1,60E+
03 
4,32E+
03 
4,32E+
03 
5,22E+
03 
5,36E+
03 
4,21E+
03 
3,11E+
03 
4,76E+
03 
6,97E+
03 
3,77E+
03 
2,15E+
03 
3,49E+
03 
D-Aspartic Acid 
1,59E+
03 
9,96E+
02 
3,49E+
02 
2,15E+
02 
7,45E+
02 
2,37E+
01 
4,68E+
02 
7,24E+
02 
1,49E+
03 
8,43E+
02 
9,44E+
02 
7,60E+
01 
8,26E+
02 
1,17E+
03 
3,08E+
02 
4,16E+
02 
8,50E+
01 
D-Glucosaminic Acid 
4,70E+
04 
5,32E+
04 
5,54E+
04 
5,77E+
04 
5,74E+
04 
5,22E+
04 
5,43E+
04 
5,64E+
04 
5,64E+
04 
5,14E+
04 
4,85E+
04 
5,43E+
04 
5,63E+
04 
5,39E+
04 
5,46E+
03 
4,97E+
04 
4,36E+
03 
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Table 6.15: Aerobic utilization of carbon sources of Biolog MicroArray™ PM01 - Part III. 
C-source 
V
5
8
3
 
O
G
1
R
F
 
U
W
6
1
4
9
 
U
W
2
8
6
0
 
U
W
6
7
2
4
 
U
W
7
7
6
1
 
U
W
7
7
7
7
 
U
W
7
7
8
0
 
U
W
7
7
5
3
 
U
W
1
8
3
3
 
U
W
7
7
7
9
 
L
M
G
T
 2
3
3
3
 
A
T
C
C
 2
7
9
5
9
 
U
W
6
7
2
7
 
D
3
2
 
U
W
7
7
0
9
 
D
1
 
1,2-Propanediol 
7,45E+
02 
4,73E+
01 
1,41E+
02 
5,33E+
00 
8,87E+
01 
0,00E+
00 
8,33E+
00 
1,05E+
02 
1,25E+
02 
5,02E+
02 
4,22E+
02 
3,33E+
00 
2,99E+
02 
1,21E+
03 
2,03E+
01 
3,67E+
00 
0,00E+
00 
Tween 40 
5,01E+
03 
6,82E+
02 
1,54E+
02 
4,43E+
02 
6,45E+
02 
0,00E+
00 
7,22E+
02 
6,17E+
02 
6,83E+
02 
2,88E+
03 
2,92E+
03 
3,20E+
01 
3,62E+
02 
4,35E+
03 
1,18E+
02 
1,83E+
03 
2,30E+
01 
a-Keto-Glutaric Acid 
1,62E+
03 
2,76E+
02 
8,60E+
02 
4,60E+
01 
8,95E+
02 
2,00E+
00 
1,14E+
02 
4,18E+
02 
6,08E+
02 
1,32E+
03 
1,91E+
03 
7,77E+
01 
2,28E+
02 
1,01E+
03 
1,51E+
02 
1,65E+
02 
7,33E+
00 
a-Keto-Butyric Acid 
4,33E+
04 
4,65E+
04 
4,50E+
04 
4,39E+
04 
4,27E+
04 
4,29E+
04 
4,32E+
04 
4,31E+
04 
4,41E+
04 
4,25E+
04 
4,24E+
04 
1,05E+
04 
4,50E+
04 
4,57E+
04 
4,24E+
04 
4,39E+
04 
4,44E+
04 
a-Methyl-D-Galactoside 
8,72E+
02 
2,79E+
02 
3,93E+
02 
2,73E+
02 
5,30E+
02 
0,00E+
00 
8,30E+
02 
5,30E+
02 
5,04E+
02 
1,78E+
03 
1,69E+
03 
6,90E+
01 
4,11E+
02 
8,77E+
02 
1,16E+
02 
1,62E+
02 
2,61E+
02 
a-D-Lactose 
4,04E+
04 
4,58E+
04 
4,13E+
04 
4,81E+
04 
4,65E+
04 
3,97E+
04 
4,36E+
04 
4,71E+
04 
4,36E+
04 
3,95E+
04 
3,86E+
04 
4,06E+
04 
4,33E+
04 
4,54E+
04 
4,31E+
04 
5,23E+
04 
4,16E+
04 
Lactulose 
9,91E+
03 
1,71E+
04 
5,25E+
04 
5,49E+
04 
5,34E+
04 
4,76E+
04 
5,07E+
04 
5,20E+
04 
5,03E+
04 
4,80E+
04 
4,72E+
04 
5,12E+
04 
5,29E+
04 
5,18E+
04 
4,74E+
04 
5,63E+
04 
4,97E+
04 
Sucrose 
4,57E+
04 
5,41E+
04 
5,68E+
04 
5,75E+
04 
5,62E+
04 
5,26E+
04 
5,36E+
04 
5,28E+
04 
5,44E+
04 
5,17E+
04 
4,87E+
04 
5,22E+
04 
5,67E+
04 
5,42E+
04 
5,45E+
04 
5,88E+
04 
5,48E+
04 
Uridine 
4,39E+
04 
4,78E+
04 
5,05E+
04 
4,75E+
04 
4,78E+
04 
4,48E+
04 
4,69E+
04 
4,50E+
04 
4,83E+
04 
4,57E+
04 
4,59E+
04 
4,19E+
04 
5,02E+
04 
4,61E+
04 
4,49E+
04 
4,35E+
04 
4,63E+
04 
L-Glutamine 
4,91E+
03 
3,46E+
03 
2,56E+
03 
2,75E+
03 
4,36E+
03 
1,83E+
03 
3,82E+
03 
3,49E+
03 
3,79E+
03 
4,77E+
03 
3,92E+
03 
2,57E+
03 
4,33E+
03 
4,21E+
03 
2,22E+
03 
2,80E+
03 
3,56E+
03 
m-Tartaric Acid 
2,12E+
03 
2,55E+
02 
3,07E+
02 
5,10E+
01 
7,45E+
02 
5,67E+
00 
1,85E+
02 
5,49E+
02 
7,75E+
02 
1,21E+
03 
6,85E+
02 
1,80E+
02 
4,80E+
02 
4,29E+
02 
4,13E+
01 
1,06E+
02 
2,46E+
02 
D-Glucose-1-Phosphate 
3,43E+
03 
1,79E+
03 
1,54E+
03 
7,25E+
02 
1,19E+
03 
3,33E+
02 
1,59E+
03 
2,42E+
03 
1,89E+
03 
3,24E+
03 
2,43E+
03 
2,80E+
02 
8,34E+
02 
2,54E+
03 
6,83E+
02 
3,99E+
02 
1,11E+
03 
D-Fructose-6-Phosphate 
1,27E+
04 
5,24E+
04 
5,24E+
04 
5,36E+
04 
5,28E+
04 
5,01E+
04 
5,13E+
04 
5,18E+
04 
5,18E+
04 
4,93E+
04 
4,75E+
04 
5,09E+
04 
5,40E+
04 
5,00E+
04 
5,03E+
04 
4,98E+
04 
5,18E+
04 
Tween 80 
5,84E+
03 
3,34E+
03 
6,11E+
03 
1,02E+
04 
4,96E+
03 
5,27E+
03 
9,37E+
03 
8,99E+
03 
7,33E+
03 
1,17E+
04 
9,52E+
03 
6,61E+
03 
5,57E+
03 
1,61E+
04 
3,31E+
03 
2,40E+
03 
6,70E+
03 
a-Hydroxy Glutaric Acid-
g-Lactone 
8,27E+
02 
4,33E+
00 
6,67E+
01 
1,07E+
01 
1,51E+
02 
6,67E+
00 
1,00E+
01 
8,87E+
01 
5,57E+
01 
7,42E+
02 
1,86E+
02 
6,00E+
00 
8,97E+
01 
9,87E+
01 
1,67E+
00 
3,83E+
01 
7,67E+
00 
a-Hydroxy-Butyric Acid 
8,70E+
02 
4,82E+
02 
2,39E+
02 
6,30E+
01 
4,94E+
02 
5,00E+
00 
2,52E+
02 
5,41E+
02 
3,40E+
02 
5,78E+
02 
9,36E+
02 
7,47E+
01 
2,36E+
02 
5,75E+
02 
3,73E+
01 
2,97E+
01 
1,56E+
02 
b-Methyl-D-Glucoside 
4,62E+
04 
3,97E+
04 
4,49E+
04 
4,61E+
04 
4,77E+
04 
3,96E+
04 
4,33E+
04 
5,19E+
04 
4,29E+
04 
4,13E+
04 
4,07E+
04 
4,00E+
04 
4,32E+
04 
4,72E+
04 
4,15E+
04 
5,00E+
04 
4,25E+
04 
Adonitol 
1,34E+
03 
1,51E+
03 
1,12E+
03 
4,73E+
02 
1,69E+
03 
1,03E+
01 
4,11E+
02 
4,11E+
02 
1,01E+
03 
1,19E+
03 
2,43E+
03 
1,55E+
02 
1,69E+
03 
1,84E+
03 
2,55E+
02 
5,24E+
02 
9,11E+
02 
Maltotriose 
4,09E+
04 
4,12E+
04 
4,77E+
04 
5,11E+
04 
5,10E+
04 
4,26E+
04 
4,76E+
04 
4,99E+
04 
4,60E+
04 
4,47E+
04 
4,15E+
04 
4,44E+
04 
4,78E+
04 
4,91E+
04 
4,66E+
04 
5,35E+
04 
4,55E+
04 
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Table 6.16: Aerobic utilization of carbon sources of Biolog MicroArray™ PM01 - Part IV. 
C-source 
V
5
8
3
 
O
G
1
R
F
 
U
W
6
1
4
9
 
U
W
2
8
6
0
 
U
W
6
7
2
4
 
U
W
7
7
6
1
 
U
W
7
7
7
7
 
U
W
7
7
8
0
 
U
W
7
7
5
3
 
U
W
1
8
3
3
 
U
W
7
7
7
9
 
L
M
G
T
 2
3
3
3
 
A
T
C
C
 2
7
9
5
9
 
U
W
6
7
2
7
 
D
3
2
 
U
W
7
7
0
9
 
D
1
 
2`-Deoxy-
Adenosine 
4,35E+
04 
4,10E+
04 
4,75E+
04 
4,52E+
04 
4,93E+
04 
4,58E+
04 
4,66E+
04 
4,46E+
04 
4,64E+
04 
4,59E+
04 
4,49E+
04 
4,60E+
04 
4,99E+
04 
4,59E+
04 
4,35E+
04 
3,97E+
04 
4,60E+
04 
Adenosine 
3,58E+
04 
3,61E+
04 
3,90E+
04 
3,78E+
04 
4,35E+
04 
3,85E+
04 
3,93E+
04 
3,64E+
04 
4,28E+
04 
4,21E+
04 
3,96E+
04 
3,92E+
04 
4,34E+
04 
3,62E+
04 
3,62E+
04 
4,22E+
04 
3,99E+
04 
Glycyl-L-Aspartic 
Acid 
9,10E+
03 
6,75E+
03 
7,09E+
03 
5,09E+
03 
7,25E+
03 
4,36E+
03 
6,71E+
03 
7,23E+
03 
7,59E+
03 
8,99E+
03 
6,85E+
03 
6,51E+
03 
7,53E+
03 
6,24E+
03 
4,56E+
03 
6,20E+
03 
7,12E+
03 
Citric Acid 
4,98E+
04 
5,36E+
04 
5,45E+
04 
5,51E+
04 
5,49E+
04 
5,22E+
04 
5,21E+
04 
4,10E+
04 
5,38E+
04 
5,11E+
04 
5,07E+
04 
5,19E+
04 
5,60E+
04 
4,34E+
03 
5,15E+
04 
1,99E+
03 
5,39E+
04 
m-Inositol 
6,28E+
03 
5,43E+
04 
5,55E+
04 
5,74E+
04 
5,62E+
04 
5,08E+
04 
5,30E+
04 
5,43E+
04 
5,52E+
04 
5,32E+
04 
4,82E+
04 
5,14E+
04 
5,42E+
04 
5,30E+
04 
1,54E+
03 
4,96E+
04 
5,47E+
04 
D-Threonine 
9,45E+
02 
8,37E+
01 
3,62E+
02 
1,37E+
01 
2,77E+
02 
0,00E+
00 
3,13E+
01 
2,26E+
02 
3,26E+
02 
6,97E+
02 
3,40E+
02 
1,17E+
01 
1,86E+
02 
3,21E+
02 
5,40E+
01 
7,30E+
01 
3,33E-
01 
Fumaric Acid 
2,58E+
02 
6,67E-
01 
8,33E+
00 
3,33E-
01 
0,00E+
00 
0,00E+
00 
0,00E+
00 
6,00E+
00 
1,53E+
01 
0,00E+
00 
6,67E-
01 
0,00E+
00 
4,00E+
00 
1,67E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
Bromo-Succinic 
Acid 
4,28E+
04 
4,11E+
04 
4,61E+
04 
4,47E+
04 
4,43E+
04 
4,45E+
04 
4,25E+
04 
3,87E+
04 
4,62E+
04 
3,74E+
04 
4,13E+
04 
4,27E+
04 
4,57E+
04 
4,43E+
04 
3,33E+
04 
4,68E+
04 
4,66E+
04 
Propionic Acid 
1,29E+
04 
4,88E+
03 
7,93E+
03 
1,91E+
03 
1,02E+
04 
7,77E+
02 
7,69E+
03 
8,07E+
03 
4,05E+
03 
9,69E+
03 
6,37E+
03 
1,50E+
03 
3,84E+
03 
4,25E+
03 
1,87E+
03 
6,29E+
03 
7,27E+
03 
Mucic Acid 
3,61E+
03 
1,87E+
03 
1,03E+
04 
7,67E+
03 
1,19E+
04 
1,01E+
04 
2,53E+
03 
2,51E+
03 
1,17E+
04 
1,38E+
04 
1,55E+
04 
1,29E+
03 
1,16E+
04 
1,64E+
04 
5,63E+
02 
7,47E+
02 
1,96E+
03 
Glycolic Acid 
2,34E+
03 
2,40E+
03 
1,84E+
03 
1,13E+
03 
2,84E+
03 
6,76E+
02 
2,22E+
03 
2,24E+
03 
1,34E+
03 
2,46E+
03 
1,83E+
03 
9,13E+
02 
2,01E+
03 
2,35E+
03 
6,50E+
02 
2,51E+
03 
1,53E+
03 
Glyoxylic Acid 
2,78E+
03 
2,08E+
03 
1,28E+
03 
6,12E+
02 
2,53E+
03 
1,07E+
02 
2,20E+
03 
2,02E+
03 
1,28E+
03 
1,44E+
03 
2,60E+
03 
5,30E+
02 
2,01E+
03 
2,60E+
03 
6,59E+
02 
2,24E+
03 
1,32E+
03 
D-Cellobiose 
3,90E+
04 
3,76E+
04 
4,27E+
04 
4,63E+
04 
4,76E+
04 
4,02E+
04 
4,38E+
04 
4,56E+
04 
4,41E+
04 
4,03E+
04 
3,92E+
04 
4,06E+
04 
4,53E+
04 
4,58E+
04 
4,24E+
04 
5,18E+
04 
4,14E+
04 
Inosine 
3,36E+
04 
3,84E+
04 
4,30E+
04 
4,01E+
04 
4,44E+
04 
4,08E+
04 
4,29E+
04 
3,98E+
04 
4,26E+
04 
4,14E+
04 
4,00E+
04 
3,97E+
04 
4,45E+
04 
3,75E+
04 
3,68E+
04 
4,16E+
04 
3,46E+
04 
Glycyl-L-Glutamic 
Acid 
8,77E+
03 
8,30E+
03 
9,18E+
03 
8,38E+
03 
9,16E+
03 
6,10E+
03 
1,03E+
04 
8,75E+
03 
8,46E+
03 
8,70E+
03 
8,34E+
03 
7,56E+
03 
8,93E+
03 
9,35E+
03 
6,84E+
03 
8,15E+
03 
7,75E+
03 
Tricarballylic Acid 
2,65E+
03 
1,56E+
03 
2,09E+
03 
7,94E+
02 
2,95E+
03 
4,67E+
02 
2,08E+
03 
1,67E+
03 
1,54E+
03 
2,38E+
03 
2,08E+
03 
1,13E+
03 
1,79E+
03 
1,56E+
03 
5,47E+
02 
7,81E+
02 
1,63E+
03 
L-Serine 
6,68E+
03 
4,98E+
03 
3,83E+
03 
4,30E+
03 
4,30E+
03 
1,14E+
03 
4,15E+
03 
4,45E+
03 
4,73E+
03 
7,49E+
03 
5,29E+
03 
4,11E+
03 
3,22E+
03 
4,78E+
03 
3,95E+
03 
2,48E+
03 
3,31E+
03 
L-Threonine 
2,71E+
03 
1,64E+
03 
6,60E+
02 
7,30E+
02 
1,33E+
03 
2,43E+
01 
1,38E+
03 
1,35E+
03 
1,95E+
03 
2,69E+
03 
3,11E+
03 
3,53E+
02 
1,48E+
03 
1,91E+
03 
4,59E+
02 
2,06E+
02 
1,16E+
03 
L-Alanine 
2,27E+
03 
2,83E+
02 
2,23E+
02 
1,09E+
02 
6,78E+
02 
0,00E+
00 
4,19E+
02 
7,22E+
02 
7,56E+
02 
8,86E+
02 
1,35E+
03 
9,83E+
01 
4,63E+
02 
9,49E+
02 
1,22E+
02 
1,40E+
02 
4,67E+
01 
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Table 6.17: Aerobic utilization of carbon sources of Biolog MicroArray™ PM01 - Part V. 
C-source 
V
5
8
3
 
O
G
1
R
F
 
U
W
6
1
4
9
 
U
W
2
8
6
0
 
U
W
6
7
2
4
 
U
W
7
7
6
1
 
U
W
7
7
7
7
 
U
W
7
7
8
0
 
U
W
7
7
5
3
 
U
W
1
8
3
3
 
U
W
7
7
7
9
 
L
M
G
T
 2
3
3
3
 
A
T
C
C
 2
7
9
5
9
 
U
W
6
7
2
7
 
D
3
2
 
U
W
7
7
0
9
 
D
1
 
L-Alanyl-Glycine 
1,70E+
03 
4,84E+
02 
3,22E+
02 
1,24E+
02 
6,74E+
02 
3,33E-
01 
4,25E+
02 
9,81E+
02 
3,91E+
02 
8,18E+
02 
3,68E+
02 
5,47E+
01 
3,89E+
02 
9,56E+
02 
1,19E+
02 
1,51E+
02 
1,14E+
02 
Acetoacetic Acid 
2,80E+
04 
2,49E+
04 
2,32E+
04 
2,36E+
04 
1,98E+
04 
2,43E+
04 
2,61E+
04 
2,39E+
04 
2,57E+
04 
3,16E+
04 
2,74E+
04 
2,40E+
04 
2,24E+
04 
2,96E+
04 
2,29E+
04 
1,76E+
04 
2,57E+
04 
N-Acetyl-b-D-
Mannosamine 
4,85E+
04 
5,37E+
04 
5,17E+
04 
5,08E+
04 
5,53E+
04 
4,74E+
04 
5,24E+
04 
5,28E+
04 
5,09E+
04 
4,77E+
04 
4,68E+
04 
4,80E+
04 
5,04E+
04 
5,31E+
04 
5,03E+
04 
5,65E+
04 
4,83E+
04 
Mono Methyl 
Succinate 
5,07E+
03 
4,15E+
03 
4,49E+
03 
2,57E+
03 
5,25E+
03 
2,57E+
03 
5,11E+
03 
3,89E+
03 
3,89E+
03 
4,88E+
03 
9,15E+
03 
2,62E+
03 
5,07E+
03 
6,98E+
03 
1,71E+
03 
3,99E+
03 
3,25E+
03 
Methyl Pyruvate 
4,90E+
04 
5,29E+
04 
5,32E+
04 
5,21E+
04 
5,12E+
04 
4,95E+
04 
5,15E+
04 
5,01E+
04 
5,03E+
04 
4,97E+
04 
4,72E+
04 
9,09E+
03 
5,41E+
04 
5,16E+
04 
4,85E+
04 
5,24E+
04 
5,29E+
04 
D-Malic Acid 
2,61E+
04 
1,83E+
04 
3,16E+
04 
2,27E+
04 
2,61E+
04 
2,59E+
04 
2,95E+
04 
2,97E+
04 
2,77E+
04 
2,60E+
04 
2,74E+
04 
2,73E+
04 
2,47E+
04 
3,11E+
04 
2,22E+
04 
2,38E+
04 
3,20E+
04 
L-Malic Acid 
5,97E+
04 
6,30E+
04 
6,36E+
04 
6,33E+
04 
6,34E+
04 
6,10E+
04 
6,30E+
04 
6,07E+
04 
6,30E+
04 
5,91E+
04 
5,98E+
04 
6,05E+
04 
6,52E+
04 
6,22E+
04 
5,99E+
04 
6,33E+
04 
6,32E+
04 
Glycyl-L-Proline 
1,02E+
04 
1,05E+
04 
9,05E+
03 
1,05E+
04 
1,13E+
04 
8,42E+
03 
1,08E+
04 
1,12E+
04 
1,11E+
04 
1,05E+
04 
9,77E+
03 
8,85E+
03 
1,22E+
04 
1,04E+
04 
9,27E+
03 
1,05E+
04 
1,12E+
04 
p-Hydroxy-
Phenylacetic Acid 
5,45E+
03 
3,90E+
03 
4,04E+
03 
3,54E+
03 
5,63E+
03 
2,93E+
03 
4,54E+
03 
5,36E+
03 
4,99E+
03 
3,57E+
03 
4,84E+
03 
3,46E+
03 
5,87E+
03 
4,22E+
03 
2,69E+
03 
4,95E+
03 
5,38E+
03 
m-Hydroxy-
Phenylacetic Acid 
3,27E+
03 
3,43E+
03 
2,31E+
03 
2,35E+
03 
3,91E+
03 
1,37E+
03 
3,67E+
03 
4,10E+
03 
2,87E+
03 
2,37E+
03 
2,98E+
03 
1,73E+
03 
3,85E+
03 
3,15E+
03 
1,06E+
03 
3,40E+
03 
3,13E+
03 
Tyramine 
4,77E+
03 
4,27E+
03 
2,21E+
03 
3,56E+
03 
3,95E+
03 
2,34E+
03 
4,94E+
03 
4,93E+
03 
3,23E+
03 
3,87E+
03 
3,92E+
03 
1,60E+
03 
4,60E+
03 
8,25E+
03 
1,82E+
03 
3,19E+
03 
3,26E+
03 
D-Psicose 
3,18E+
04 
4,00E+
04 
5,05E+
04 
5,08E+
04 
3,94E+
04 
2,92E+
04 
4,29E+
04 
4,21E+
04 
3,42E+
04 
3,69E+
04 
3,76E+
04 
2,85E+
04 
3,45E+
04 
4,57E+
04 
3,91E+
04 
3,11E+
04 
2,83E+
04 
L-Lyxose 
4,44E+
04 
4,82E+
04 
4,47E+
04 
4,71E+
04 
5,41E+
04 
4,43E+
04 
4,84E+
04 
4,82E+
04 
4,65E+
04 
4,31E+
04 
5,01E+
04 
3,79E+
04 
4,62E+
04 
4,81E+
04 
4,68E+
04 
4,81E+
04 
4,52E+
04 
Glucuronamide 
9,05E+
03 
1,09E+
04 
8,78E+
03 
7,58E+
03 
9,43E+
03 
5,68E+
03 
1,07E+
04 
8,53E+
03 
7,79E+
03 
1,06E+
04 
8,30E+
03 
5,06E+
03 
9,28E+
03 
1,06E+
04 
7,05E+
03 
9,05E+
03 
8,07E+
03 
Pyruvic Acid 
5,38E+
04 
5,77E+
04 
5,90E+
04 
5,84E+
04 
5,43E+
04 
5,78E+
04 
5,81E+
04 
5,73E+
04 
5,78E+
04 
5,59E+
04 
5,59E+
04 
1,84E+
04 
6,08E+
04 
5,79E+
04 
5,48E+
04 
5,62E+
04 
5,97E+
04 
L-Galactonic Acid-g-
Lactone 
4,02E+
03 
4,46E+
03 
4,20E+
03 
2,41E+
03 
5,35E+
03 
1,92E+
03 
4,46E+
03 
3,43E+
03 
2,69E+
03 
4,75E+
03 
3,92E+
03 
1,90E+
03 
5,07E+
03 
5,50E+
03 
1,40E+
03 
4,47E+
03 
4,51E+
03 
D-Galacturonic Acid 
1,48E+
04 
1,18E+
04 
1,57E+
04 
7,34E+
03 
1,37E+
04 
1,24E+
04 
1,28E+
04 
9,39E+
03 
1,39E+
04 
1,93E+
04 
1,73E+
04 
1,17E+
04 
1,53E+
04 
1,28E+
04 
8,84E+
03 
1,90E+
04 
1,40E+
04 
b-Phenylethylamine 
1,90E+
04 
1,64E+
04 
1,51E+
04 
1,15E+
04 
1,72E+
04 
1,34E+
04 
1,81E+
04 
1,49E+
04 
1,41E+
04 
1,85E+
04 
1,75E+
04 
1,42E+
04 
1,64E+
04 
1,88E+
04 
1,34E+
04 
1,76E+
04 
1,48E+
04 
Ethanolamine 
1,58E+
04 
1,53E+
04 
1,45E+
04 
1,02E+
04 
1,52E+
04 
1,13E+
04 
1,45E+
04 
1,23E+
04 
1,28E+
04 
1,40E+
04 
1,59E+
04 
1,06E+
04 
1,56E+
04 
1,40E+
04 
1,05E+
04 
1,52E+
04 
1,21E+
04 
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Table 6.18: Standard derivations of Biolog MicroArray™ PM01 analyzes - Part I. 
C-source 
V
5
8
3
 
O
G
1
R
F
 
U
W
6
1
4
9
 
U
W
2
8
6
0
 
U
W
6
7
2
4
 
U
W
7
7
6
1
 
U
W
7
7
7
7
 
U
W
7
7
8
0
 
U
W
7
7
5
3
 
U
W
1
8
3
3
 
U
W
7
7
7
9
 
L
M
G
T
 2
3
3
3
 
A
T
C
C
 2
7
9
5
9
 
U
W
6
7
2
7
 
D
3
2
 
U
W
7
7
0
9
 
D
1
 
Negative Control 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
L-Arabinose 
2,4E+0
3 
1,4E+0
3 
1,3E+0
4 
5,8E+0
2 
2,5E+0
3 
6,6E+0
3 
1,1E+0
3 
1,3E+0
3 
5,4E+0
3 
4,9E+0
3 
4,1E+0
3 
9,8E+0
3 
6,7E+0
3 
8,9E+0
2 
7,2E+0
2 
9,7E+0
3 
6,7E+0
3 
N-Acetyl-D-
Glucosamine 
3,1E+0
3 
5,7E+0
3 
7,2E+0
2 
4,1E+0
3 
2,1E+0
3 
5,8E+0
3 
6,3E+0
2 
3,2E+0
3 
3,9E+0
3 
5,2E+0
3 
4,8E+0
3 
3,8E+0
3 
4,7E+0
3 
1,1E+0
3 
4,1E+0
3 
1,4E+0
3 
2,7E+0
3 
D-Saccharic Acid 
8,8E+0
2 
9,1E+0
0 
2,8E+0
2 
3,9E+0
0 
1,5E+0
2 
8,6E+0
0 
1,4E+0
1 
1,0E+0
2 
6,3E+0
2 
4,1E+0
2 
1,3E+0
2 
4,3E+0
1 
1,1E+0
2 
1,4E+0
2 
1,4E+0
1 
5,5E+0
1 
9,4E-
01 
Succinic Acid 
7,1E+0
2 
3,5E+0
1 
1,3E+0
2 
0,0E+0
0 
2,1E+0
2 
0,0E+0
0 
0,0E+0
0 
4,9E+0
1 
3,8E+0
2 
2,4E+0
2 
2,5E+0
2 
0,0E+0
0 
1,4E+0
2 
3,6E+0
2 
7,0E+0
1 
3,1E+0
1 
0,0E+0
0 
D-Galactose 
1,4E+0
3 
3,8E+0
3 
2,2E+0
3 
1,8E+0
3 
1,3E+0
3 
2,3E+0
2 
3,7E+0
3 
3,4E+0
3 
1,5E+0
3 
3,6E+0
3 
4,6E+0
3 
1,6E+0
3 
1,8E+0
3 
3,1E+0
3 
2,3E+0
3 
1,5E+0
3 
3,7E+0
3 
L-Aspartic Acid 
8,8E+0
2 
1,2E+0
2 
5,8E+0
2 
1,5E+0
1 
2,7E+0
2 
0,0E+0
0 
3,2E+0
2 
3,6E+0
2 
2,0E+0
2 
4,5E+0
2 
4,0E+0
2 
6,0E+0
1 
2,6E+0
2 
4,8E+0
2 
7,7E+0
1 
1,1E+0
2 
2,3E+0
1 
L-Proline 
7,4E+0
2 
3,3E+0
1 
7,0E+0
1 
8,2E-
01 
8,6E+0
1 
0,0E+0
0 
6,5E+0
0 
4,2E+0
1 
2,1E+0
2 
3,4E+0
2 
2,8E+0
2 
7,1E+0
0 
9,1E+0
1 
2,9E+0
2 
6,5E+0
1 
1,6E+0
1 
4,7E-
01 
D-Alanine 
9,1E+0
2 
7,6E+0
2 
2,8E+0
2 
6,1E+0
1 
4,1E+0
2 
6,1E+0
0 
9,9E+0
1 
1,5E+0
2 
3,5E+0
2 
2,6E+0
2 
6,2E+0
2 
3,6E+0
0 
1,9E+0
2 
4,8E+0
2 
1,2E+0
2 
1,5E+0
2 
1,3E+0
1 
D-Trehalose 
3,8E+0
2 
2,9E+0
3 
2,0E+0
3 
2,0E+0
3 
1,7E+0
3 
1,1E+0
3 
4,0E+0
3 
4,3E+0
3 
1,8E+0
3 
3,1E+0
3 
3,5E+0
3 
1,5E+0
3 
1,7E+0
3 
1,8E+0
3 
3,2E+0
3 
9,5E+0
2 
3,0E+0
3 
D-Mannose 
6,3E+0
2 
3,2E+0
3 
3,0E+0
3 
9,0E+0
2 
3,1E+0
3 
8,0E+0
2 
4,8E+0
3 
3,8E+0
3 
2,3E+0
3 
3,7E+0
3 
6,9E+0
3 
1,1E+0
3 
6,1E+0
3 
2,1E+0
3 
2,5E+0
3 
1,8E+0
3 
3,8E+0
3 
Dulcitol 
4,0E+0
3 
3,6E+0
3 
1,1E+0
3 
1,7E+0
3 
4,1E+0
3 
3,0E+0
3 
3,8E+0
3 
2,5E+0
3 
1,8E+0
3 
1,9E+0
3 
1,4E+0
3 
4,0E+0
3 
8,8E+0
2 
7,6E+0
2 
7,7E+0
2 
1,4E+0
3 
2,1E+0
3 
D-Serine 
2,8E+0
3 
1,5E+0
3 
4,8E+0
3 
2,0E+0
3 
2,6E+0
3 
7,2E+0
2 
1,5E+0
3 
1,7E+0
3 
2,7E+0
3 
1,4E+0
3 
9,5E+0
2 
2,9E+0
3 
1,0E+0
3 
1,4E+0
3 
1,2E+0
3 
2,7E+0
3 
2,4E+0
2 
D-Sorbitol 
1,7E+0
3 
3,6E+0
3 
2,0E+0
3 
1,4E+0
3 
3,2E+0
3 
2,6E+0
3 
3,4E+0
3 
3,8E+0
3 
1,4E+0
3 
3,0E+0
3 
2,9E+0
3 
9,4E+0
2 
1,4E+0
3 
1,5E+0
3 
4,0E+0
3 
1,7E+0
3 
5,7E+0
2 
Glycerol 
2,1E+0
3 
3,2E+0
3 
2,8E+0
3 
2,2E+0
3 
4,2E+0
2 
1,8E+0
3 
4,5E+0
3 
2,6E+0
3 
2,2E+0
3 
2,3E+0
3 
1,7E+0
3 
6,5E+0
3 
1,0E+0
3 
3,4E+0
3 
2,6E+0
3 
7,8E+0
2 
1,4E+0
3 
L-Fucose 
7,4E+0
2 
1,5E+0
3 
3,6E+0
3 
7,5E+0
2 
1,6E+0
3 
6,3E+0
1 
6,3E+0
2 
1,2E+0
3 
2,0E+0
3 
2,8E+0
3 
1,0E+0
3 
3,6E+0
2 
2,0E+0
3 
1,4E+0
3 
3,5E+0
2 
7,7E+0
2 
5,6E+0
2 
D-Glucuronic Acid 
7,8E+0
2 
7,3E+0
2 
1,1E+0
3 
3,3E+0
1 
7,9E+0
2 
0,0E+0
0 
5,0E+0
1 
9,0E+0
2 
6,7E+0
2 
6,9E+0
2 
8,0E+0
2 
3,9E+0
1 
5,9E+0
2 
4,3E+0
2 
1,9E+0
2 
1,7E+0
2 
7,1E+0
1 
D-Gluconic Acid 
1,4E+0
3 
2,4E+0
3 
1,8E+0
3 
1,1E+0
3 
2,8E+0
3 
1,4E+0
3 
3,0E+0
3 
3,7E+0
3 
2,0E+0
3 
2,3E+0
3 
4,7E+0
3 
2,1E+0
3 
1,7E+0
3 
1,3E+0
2 
3,8E+0
3 
3,0E+0
3 
2,5E+0
3 
D,L-a-Glycerol- 
Phosphate 
1,6E+0
3 
2,3E+0
3 
2,9E+0
3 
2,7E+0
3 
3,3E+0
3 
1,5E+0
3 
2,9E+0
3 
2,3E+0
3 
1,1E+0
3 
3,1E+0
3 
3,9E+0
3 
2,9E+0
3 
3,4E+0
3 
2,2E+0
3 
7,2E+0
2 
1,3E+0
3 
3,3E+0
3 
D-Xylose 
4,3E+0
3 
3,7E+0
3 
4,3E+0
3 
4,0E+0
2 
1,1E+0
4 
3,4E+0
3 
4,5E+0
3 
3,4E+0
3 
3,4E+0
3 
1,3E+0
3 
5,9E+0
3 
2,2E+0
3 
4,5E+0
3 
5,8E+0
2 
9,1E+0
2 
1,4E+0
3 
1,8E+0
3 
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Table 6.19: Standard derivations of Biolog MicroArray™ PM01 analyzes - Part II. 
C-source 
V
5
8
3
 
O
G
1
R
F
 
U
W
6
1
4
9
 
U
W
2
8
6
0
 
U
W
6
7
2
4
 
U
W
7
7
6
1
 
U
W
7
7
7
7
 
U
W
7
7
8
0
 
U
W
7
7
5
3
 
U
W
1
8
3
3
 
U
W
7
7
7
9
 
L
M
G
T
 2
3
3
3
 
A
T
C
C
 2
7
9
5
9
 
U
W
6
7
2
7
 
D
3
2
 
U
W
7
7
0
9
 
D
1
 
L-Lactic Acid 
1,1E+0
3 
6,0E+0
1 
1,2E+0
2 
0,0E+0
0 
6,9E+0
1 
0,0E+0
0 
2,9E+0
1 
7,1E+0
1 
1,1E+0
2 
4,2E+0
2 
8,4E+0
1 
5,2E+0
0 
7,9E+0
1 
7,7E+0
1 
2,8E+0
1 
6,9E+0
0 
1,4E+0
0 
Formic Acid 
1,8E+0
3 
4,6E+0
2 
9,9E+0
2 
4,7E-
01 
2,0E+0
3 
2,4E+0
0 
1,9E+0
2 
2,7E+0
2 
3,8E+0
2 
6,1E+0
2 
3,5E+0
2 
1,6E+0
1 
2,4E+0
2 
1,0E+0
2 
4,9E+0
1 
1,2E+0
2 
5,2E+0
1 
D-Mannitol 
2,3E+0
3 
2,3E+0
3 
3,0E+0
3 
3,6E+0
3 
2,5E+0
2 
1,2E+0
3 
1,6E+0
3 
4,7E+0
3 
3,4E+0
3 
3,4E+0
3 
8,1E+0
3 
1,6E+0
3 
7,3E+0
3 
2,8E+0
2 
3,7E+0
3 
2,5E+0
3 
3,5E+0
3 
L-Glutamic Acid 
2,1E+0
3 
2,5E+0
3 
1,4E+0
3 
1,7E+0
3 
2,0E+0
3 
2,8E+0
3 
2,8E+0
3 
2,3E+0
3 
2,7E+0
3 
2,3E+0
3 
2,1E+0
3 
3,4E+0
3 
1,8E+0
3 
1,5E+0
3 
1,9E+0
3 
1,5E+0
3 
1,3E+0
3 
D-Glucose-6-Phosphate 
1,0E+0
4 
2,1E+0
3 
1,7E+0
3 
1,6E+0
3 
1,5E+0
3 
4,2E+0
3 
3,1E+0
3 
3,3E+0
3 
5,3E+0
3 
3,6E+0
3 
1,6E+0
3 
4,9E+0
3 
2,0E+0
3 
2,0E+0
3 
2,3E+0
3 
7,2E+0
3 
3,2E+0
3 
D-Galactonic Acid-g-
Lactone 
8,9E+0
2 
0,0E+0
0 
4,8E+0
3 
7,2E+0
2 
1,7E+0
3 
5,1E+0
2 
3,5E+0
2 
4,9E+0
1 
3,7E+0
3 
2,6E+0
3 
4,6E+0
3 
0,0E+0
0 
3,5E+0
3 
2,7E+0
3 
0,0E+0
0 
1,9E+0
0 
0,0E+0
0 
D,L-Malic Acid 
1,2E+0
3 
2,3E+0
3 
2,5E+0
3 
2,2E+0
3 
1,6E+0
3 
1,1E+0
3 
3,1E+0
3 
2,1E+0
3 
1,2E+0
3 
2,2E+0
3 
3,1E+0
3 
1,5E+0
3 
2,2E+0
3 
1,9E+0
3 
1,2E+0
3 
1,1E+0
3 
1,1E+0
3 
D-Ribose 
1,5E+0
3 
3,8E+0
3 
2,6E+0
3 
1,7E+0
3 
2,7E+0
3 
2,2E+0
3 
4,1E+0
3 
3,9E+0
3 
1,0E+0
3 
2,8E+0
3 
1,9E+0
3 
7,7E+0
2 
2,0E+0
3 
1,9E+0
3 
1,9E+0
3 
5,3E+0
3 
8,8E+0
2 
Tween 20 
1,1E+0
3 
2,7E+0
3 
4,7E+0
3 
2,6E+0
3 
5,5E+0
3 
4,8E+0
3 
2,3E+0
3 
3,1E+0
3 
3,9E+0
3 
1,8E+0
3 
8,3E+0
3 
6,4E+0
3 
5,8E+0
3 
3,5E+0
3 
5,4E+0
2 
3,3E+0
3 
5,2E+0
3 
L-Rhamnose 
9,3E+0
2 
1,6E+0
3 
4,7E+0
3 
1,7E+0
3 
7,2E+0
3 
9,4E+0
2 
2,0E+0
3 
2,3E+0
3 
1,9E+0
3 
2,0E+0
3 
5,1E+0
2 
1,7E+0
3 
3,6E+0
3 
2,6E+0
3 
7,2E+0
2 
1,0E+0
3 
1,3E+0
3 
D-Fructose 
8,4E+0
2 
1,4E+0
3 
4,3E+0
3 
1,7E+0
3 
2,3E+0
3 
4,4E+0
2 
5,9E+0
3 
6,1E+0
3 
3,0E+0
3 
4,3E+0
3 
7,6E+0
3 
2,5E+0
3 
4,3E+0
3 
3,7E+0
3 
2,7E+0
3 
2,5E+0
3 
1,7E+0
3 
Acetic Acid 
2,8E+0
3 
4,7E+0
3 
1,9E+0
3 
3,2E+0
3 
1,7E+0
3 
1,8E+0
3 
3,1E+0
3 
2,8E+0
3 
2,8E+0
3 
2,8E+0
2 
7,0E+0
2 
5,2E+0
3 
2,1E+0
3 
1,1E+0
3 
4,5E+0
3 
3,1E+0
3 
2,8E+0
3 
a-D-Glucose 
2,0E+0
3 
2,2E+0
3 
2,5E+0
3 
3,1E+0
2 
1,4E+0
3 
1,8E+0
3 
4,0E+0
3 
6,2E+0
3 
1,7E+0
3 
3,8E+0
3 
4,2E+0
3 
5,9E+0
2 
2,5E+0
3 
3,9E+0
3 
2,4E+0
3 
1,6E+0
3 
1,7E+0
3 
Maltose 
2,5E+0
2 
2,0E+0
3 
1,5E+0
3 
1,9E+0
3 
2,0E+0
3 
1,1E+0
3 
4,1E+0
3 
4,8E+0
3 
2,5E+0
3 
2,4E+0
3 
4,7E+0
3 
2,5E+0
3 
2,4E+0
3 
3,0E+0
3 
3,4E+0
3 
1,7E+0
3 
2,4E+0
3 
D-Melibiose 
9,1E+0
2 
2,1E+0
3 
1,4E+0
3 
1,9E+0
3 
1,3E+0
3 
5,1E+0
2 
1,8E+0
3 
2,1E+0
3 
2,8E+0
2 
1,7E+0
3 
1,6E+0
3 
1,0E+0
3 
1,3E+0
3 
2,1E+0
3 
7,9E+0
2 
5,7E+0
2 
1,6E+0
3 
Thymidine 
1,0E+0
3 
3,4E+0
3 
3,2E+0
3 
2,7E+0
3 
2,9E+0
3 
4,5E+0
3 
3,5E+0
3 
2,8E+0
3 
3,4E+0
3 
1,7E+0
3 
1,3E+0
3 
4,3E+0
3 
1,5E+0
3 
1,7E+0
3 
4,7E+0
3 
7,2E+0
3 
2,9E+0
3 
L-Asparagine 
9,6E+0
2 
8,1E+0
2 
2,5E+0
3 
1,5E+0
3 
2,3E+0
3 
7,7E+0
2 
1,1E+0
3 
1,9E+0
3 
2,9E+0
3 
1,2E+0
3 
1,9E+0
3 
1,1E+0
3 
1,5E+0
3 
8,2E+0
2 
1,2E+0
3 
1,3E+0
3 
1,0E+0
3 
D-Aspartic Acid 
9,1E+0
2 
6,8E+0
2 
4,3E+0
2 
1,5E+0
2 
1,0E+0
3 
1,7E+0
1 
1,4E+0
2 
9,4E+0
2 
1,5E+0
3 
3,9E+0
2 
7,1E+0
2 
1,0E+0
2 
6,6E+0
2 
4,9E+0
2 
2,4E+0
2 
5,6E+0
2 
1,1E+0
2 
D-Glucosaminic Acid 
2,1E+0
3 
1,7E+0
3 
1,9E+0
3 
2,0E+0
3 
2,9E+0
3 
1,9E+0
3 
3,7E+0
3 
3,2E+0
3 
1,8E+0
3 
2,5E+0
3 
4,4E+0
3 
4,4E+0
2 
2,3E+0
3 
2,7E+0
3 
4,8E+0
2 
1,5E+0
3 
1,9E+0
3 
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Table 6.20: Standard derivations of Biolog MicroArray™ PM01 analyzes - Part III. 
C-source 
V
5
8
3
 
O
G
1
R
F
 
U
W
6
1
4
9
 
U
W
2
8
6
0
 
U
W
6
7
2
4
 
U
W
7
7
6
1
 
U
W
7
7
7
7
 
U
W
7
7
8
0
 
U
W
7
7
5
3
 
U
W
1
8
3
3
 
U
W
7
7
7
9
 
L
M
G
T
 2
3
3
3
 
A
T
C
C
 2
7
9
5
9
 
U
W
6
7
2
7
 
D
3
2
 
U
W
7
7
0
9
 
D
1
 
1,2-Propanediol 
8,6E+
02 
4,3E+
01 
2,0E+
02 
6,8E+
00 
1,3E+
02 
0,0E+
00 
1,2E+
01 
1,5E+
02 
1,8E+
02 
4,9E+
02 
3,1E+
02 
4,7E+
00 
4,2E+
02 
1,2E+
03 
2,9E+
01 
5,2E+
00 
0,0E+
00 
Tween 40 
2,4E+
02 
6,1E+
02 
1,3E+
02 
5,8E+
02 
8,6E+
02 
0,0E+
00 
5,7E+
02 
5,8E+
02 
3,3E+
02 
2,5E+
03 
2,0E+
03 
3,7E+
01 
5,1E+
02 
1,1E+
03 
8,4E+
01 
1,2E+
03 
1,6E+
01 
a-Keto-Glutaric Acid 
1,2E+
03 
2,0E+
02 
1,2E+
03 
2,8E+
01 
1,0E+
03 
2,8E+
00 
8,0E+
01 
5,7E+
02 
4,7E+
02 
3,9E+
02 
2,0E+
03 
2,1E+
01 
3,2E+
02 
6,3E+
02 
1,1E+
02 
2,2E+
02 
7,1E+
00 
a-Keto-Butyric Acid 
1,6E+
03 
3,2E+
03 
1,3E+
03 
2,1E+
03 
5,9E+
03 
1,4E+
03 
3,7E+
03 
5,7E+
03 
4,3E+
02 
3,8E+
03 
4,0E+
03 
1,8E+
03 
3,2E+
03 
1,2E+
03 
2,0E+
03 
7,5E+
02 
1,8E+
03 
a-Methyl-D-Galactoside 
4,2E+
02 
2,7E+
02 
4,5E+
02 
2,9E+
02 
6,9E+
02 
0,0E+
00 
8,7E+
02 
5,8E+
02 
5,0E+
02 
1,2E+
03 
1,8E+
03 
9,2E+
01 
5,8E+
02 
3,6E+
01 
8,7E+
01 
2,0E+
02 
3,7E+
02 
a-D-Lactose 
1,4E+
03 
4,4E+
03 
3,0E+
03 
1,4E+
03 
2,9E+
03 
1,8E+
03 
4,8E+
03 
5,0E+
03 
5,5E+
03 
3,4E+
03 
7,0E+
03 
1,7E+
03 
3,5E+
03 
3,8E+
03 
2,5E+
03 
4,0E+
03 
3,4E+
03 
Lactulose 
4,2E+
03 
5,1E+
03 
3,0E+
03 
1,5E+
03 
3,0E+
03 
2,1E+
03 
5,1E+
03 
6,1E+
03 
3,0E+
03 
2,8E+
03 
5,0E+
03 
2,2E+
03 
3,1E+
03 
2,8E+
03 
3,8E+
03 
1,8E+
03 
3,5E+
03 
Sucrose 
9,4E+
02 
4,4E+
03 
6,0E+
02 
1,4E+
03 
2,5E+
03 
2,7E+
02 
4,8E+
03 
6,1E+
03 
2,0E+
03 
3,5E+
03 
4,1E+
03 
2,8E+
03 
1,5E+
03 
2,9E+
03 
2,4E+
03 
2,3E+
03 
3,0E+
03 
Uridine 
1,0E+
03 
4,3E+
03 
3,8E+
03 
1,6E+
03 
4,5E+
03 
4,3E+
03 
2,9E+
03 
2,7E+
03 
3,2E+
03 
2,9E+
03 
2,3E+
03 
9,9E+
03 
3,0E+
03 
1,5E+
03 
4,2E+
03 
1,1E+
04 
2,9E+
03 
L-Glutamine 
1,3E+
03 
1,7E+
03 
7,8E+
02 
8,9E+
02 
2,1E+
03 
1,2E+
03 
6,8E+
02 
2,4E+
03 
1,7E+
03 
2,2E+
02 
1,5E+
03 
2,5E+
02 
6,9E+
02 
3,9E+
02 
1,4E+
03 
9,3E+
02 
7,9E+
02 
m-Tartaric Acid 
1,5E+
03 
2,1E+
02 
4,1E+
02 
3,7E+
01 
9,9E+
02 
4,0E+
00 
1,7E+
02 
6,7E+
02 
7,8E+
02 
4,2E+
02 
3,6E+
02 
1,5E+
02 
4,8E+
02 
1,3E+
02 
3,8E+
01 
1,4E+
02 
2,2E+
02 
D-Glucose-1-Phosphate 
8,1E+
02 
1,3E+
03 
1,4E+
03 
4,9E+
02 
1,6E+
03 
4,7E+
02 
7,2E+
02 
2,0E+
03 
1,3E+
03 
8,7E+
02 
1,7E+
03 
2,3E+
02 
9,1E+
02 
1,1E+
03 
5,3E+
02 
3,5E+
02 
7,1E+
02 
D-Fructose-6-Phosphate 
1,4E+
04 
3,7E+
03 
2,6E+
03 
1,7E+
03 
1,2E+
03 
1,3E+
03 
3,2E+
03 
3,5E+
03 
1,5E+
03 
3,0E+
03 
3,1E+
03 
1,1E+
03 
1,3E+
03 
1,4E+
03 
2,0E+
03 
3,6E+
03 
2,5E+
02 
Tween 80 
9,5E+
02 
2,1E+
03 
2,0E+
03 
2,0E+
03 
3,8E+
03 
2,3E+
03 
3,6E+
03 
2,9E+
03 
1,8E+
03 
2,7E+
03 
6,7E+
03 
2,8E+
03 
3,9E+
03 
2,2E+
03 
1,4E+
02 
1,9E+
03 
3,7E+
03 
a-Hydroxy Glutaric Acid-g-
Lactone 
1,1E+
03 
5,4E+
00 
8,1E+
01 
9,0E+
00 
1,6E+
02 
6,2E+
00 
1,4E+
01 
1,3E+
02 
7,9E+
01 
9,5E+
02 
1,9E+
02 
6,5E+
00 
1,1E+
02 
8,0E+
01 
2,4E+
00 
4,9E+
01 
5,8E+
00 
a-Hydroxy-Butyric Acid 
8,0E+
02 
3,7E+
02 
3,1E+
02 
8,8E+
01 
6,6E+
02 
7,1E+
00 
2,3E+
02 
7,7E+
02 
2,5E+
02 
1,7E+
02 
8,3E+
02 
1,0E+
02 
3,3E+
02 
2,1E+
02 
4,1E+
01 
3,9E+
01 
2,2E+
02 
b-Methyl-D-Glucoside 
1,2E+
03 
4,9E+
03 
4,1E+
03 
1,2E+
03 
2,9E+
03 
1,6E+
03 
5,4E+
03 
7,2E+
03 
2,6E+
03 
2,6E+
03 
5,7E+
03 
8,0E+
02 
3,5E+
03 
2,4E+
03 
4,4E+
03 
5,0E+
03 
4,1E+
03 
Adonitol 
1,5E+
03 
1,5E+
03 
7,5E+
02 
6,2E+
02 
2,2E+
03 
1,0E+
01 
1,2E+
02 
5,5E+
02 
1,3E+
03 
5,4E+
02 
1,8E+
03 
1,7E+
02 
2,2E+
03 
1,2E+
03 
3,2E+
02 
6,1E+
02 
1,3E+
03 
Maltotriose 
5,7E+
02 
2,9E+
03 
3,1E+
03 
2,1E+
03 
2,7E+
03 
1,1E+
03 
5,9E+
03 
5,7E+
03 
4,3E+
03 
3,4E+
03 
6,8E+
03 
2,9E+
03 
3,4E+
03 
3,2E+
03 
3,3E+
03 
2,5E+
03 
4,2E+
03 
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Table 6.21: Standard derivations of Biolog MicroArray™ PM01 analyzes - Part IV. 
C-source 
V
5
8
3
 
O
G
1
R
F
 
U
W
6
1
4
9
 
U
W
2
8
6
0
 
U
W
6
7
2
4
 
U
W
7
7
6
1
 
U
W
7
7
7
7
 
U
W
7
7
8
0
 
U
W
7
7
5
3
 
U
W
1
8
3
3
 
U
W
7
7
7
9
 
L
M
G
T
 2
3
3
3
 
A
T
C
C
 2
7
9
5
9
 
U
W
6
7
2
7
 
D
3
2
 
U
W
7
7
0
9
 
D
1
 
2`-Deoxy-
Adenosine 
1,5E+0
3 
3,5E+0
3 
2,2E+0
3 
1,8E+0
3 
3,3E+0
3 
2,7E+0
3 
3,7E+0
3 
5,9E+0
3 
2,5E+0
3 
2,7E+0
3 
2,8E+0
3 
5,5E+0
3 
3,0E+0
3 
1,8E+0
3 
1,8E+0
3 
8,7E+0
3 
2,2E+0
3 
Adenosine 
2,5E+0
3 
4,6E+0
3 
2,2E+0
3 
2,1E+0
3 
4,3E+0
3 
4,7E+0
3 
3,5E+0
3 
7,4E+0
3 
2,9E+0
3 
2,7E+0
3 
3,4E+0
3 
3,1E+0
3 
2,7E+0
3 
1,4E+0
3 
4,8E+0
3 
2,7E+0
3 
2,7E+0
3 
Glycyl-L-Aspartic 
Acid 
3,0E+0
3 
1,2E+0
3 
1,2E+0
3 
1,9E+0
3 
2,5E+0
3 
1,9E+0
3 
6,2E+0
2 
3,0E+0
3 
1,0E+0
3 
1,5E+0
3 
9,6E+0
2 
1,1E+0
3 
3,9E+0
2 
7,8E+0
2 
1,4E+0
3 
1,5E+0
3 
5,1E+0
2 
Citric Acid 
5,3E+0
2 
3,9E+0
3 
7,2E+0
2 
1,1E+0
3 
1,9E+0
3 
1,9E+0
3 
4,0E+0
3 
4,6E+0
3 
6,2E+0
2 
2,3E+0
3 
4,9E+0
2 
1,7E+0
3 
1,2E+0
3 
9,6E+0
2 
2,4E+0
3 
7,6E+0
2 
1,2E+0
3 
m-Inositol 
2,0E+0
3 
3,8E+0
3 
2,6E+0
3 
2,0E+0
3 
3,0E+0
3 
1,4E+0
3 
3,9E+0
3 
4,1E+0
3 
1,1E+0
3 
3,6E+0
3 
5,2E+0
3 
1,5E+0
3 
2,5E+0
3 
3,4E+0
3 
1,6E+0
3 
2,4E+0
3 
9,5E+0
2 
D-Threonine 
1,1E+0
3 
6,5E+0
1 
5,0E+0
2 
1,1E+0
1 
3,9E+0
2 
0,0E+0
0 
2,4E+0
1 
3,2E+0
2 
4,4E+0
2 
5,2E+0
2 
2,5E+0
2 
1,6E+0
1 
2,6E+0
2 
3,4E+0
2 
7,0E+0
1 
1,0E+0
2 
4,7E-
01 
Fumaric Acid 
3,6E+0
2 
9,4E-
01 
1,1E+0
1 
4,7E-
01 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
8,5E+0
0 
2,2E+0
1 
0,0E+0
0 
9,4E-
01 
0,0E+0
0 
5,7E+0
0 
2,4E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
Bromo-Succinic 
Acid 
1,1E+0
3 
3,8E+0
3 
3,5E+0
3 
2,1E+0
3 
6,6E+0
3 
5,7E+0
3 
4,4E+0
3 
6,5E+0
3 
5,1E+0
3 
3,3E+0
3 
2,8E+0
3 
6,5E+0
3 
6,2E+0
3 
1,2E+0
3 
1,6E+0
3 
2,7E+0
3 
7,4E+0
3 
Propionic Acid 
7,2E+0
3 
2,7E+0
3 
5,2E+0
3 
1,1E+0
3 
5,6E+0
3 
5,8E+0
2 
2,0E+0
3 
4,9E+0
3 
2,6E+0
3 
2,5E+0
3 
3,4E+0
3 
9,8E+0
2 
2,4E+0
3 
3,4E+0
3 
2,5E+0
3 
6,4E+0
3 
6,1E+0
3 
Mucic Acid 
7,3E+0
2 
1,9E+0
3 
4,0E+0
3 
5,7E+0
3 
3,2E+0
3 
4,0E+0
3 
1,8E+0
3 
2,2E+0
3 
2,2E+0
3 
6,5E+0
3 
3,6E+0
3 
5,8E+0
2 
5,4E+0
3 
1,5E+0
3 
5,9E+0
2 
4,2E+0
2 
2,0E+0
3 
Glycolic Acid 
1,8E+0
3 
2,2E+0
3 
6,0E+0
2 
1,1E+0
3 
2,5E+0
3 
4,4E+0
2 
1,5E+0
3 
2,6E+0
3 
1,3E+0
2 
6,7E+0
2 
1,4E+0
3 
5,2E+0
2 
1,2E+0
3 
6,3E+0
2 
6,7E+0
2 
2,9E+0
2 
1,1E+0
3 
Glyoxylic Acid 
2,1E+0
3 
2,1E+0
3 
9,2E+0
2 
4,3E+0
2 
1,6E+0
3 
5,7E+0
1 
1,5E+0
3 
2,6E+0
3 
7,2E+0
2 
5,1E+0
2 
1,6E+0
3 
4,1E+0
2 
1,2E+0
3 
7,8E+0
2 
7,3E+0
2 
7,2E+0
2 
1,5E+0
3 
D-Cellobiose 
1,3E+0
3 
2,2E+0
3 
1,1E+0
3 
1,2E+0
3 
2,9E+0
3 
1,3E+0
3 
4,4E+0
3 
6,4E+0
3 
2,5E+0
3 
2,5E+0
3 
3,7E+0
3 
1,7E+0
3 
2,1E+0
3 
3,6E+0
3 
3,1E+0
3 
1,2E+0
3 
2,0E+0
3 
Inosine 
5,4E+0
2 
4,0E+0
3 
3,0E+0
3 
1,5E+0
3 
2,7E+0
3 
2,6E+0
3 
2,8E+0
3 
3,5E+0
3 
2,0E+0
3 
1,9E+0
3 
2,6E+0
3 
1,8E+0
3 
2,3E+0
3 
1,8E+0
3 
5,4E+0
3 
3,1E+0
3 
3,3E+0
3 
Glycyl-L-Glutamic 
Acid 
1,1E+0
3 
1,5E+0
3 
2,6E+0
3 
1,3E+0
3 
3,1E+0
3 
1,4E+0
3 
1,7E+0
3 
3,3E+0
3 
3,0E+0
3 
1,7E+0
3 
2,5E+0
3 
2,1E+0
3 
1,6E+0
3 
8,6E+0
2 
1,9E+0
3 
2,1E+0
3 
1,3E+0
3 
Tricarballylic Acid 
8,4E+0
2 
1,1E+0
3 
1,1E+0
3 
6,1E+0
2 
2,4E+0
3 
4,7E+0
2 
1,9E+0
3 
1,4E+0
3 
1,2E+0
3 
9,8E+0
2 
1,6E+0
3 
3,9E+0
2 
4,2E+0
2 
5,0E+0
2 
6,8E+0
2 
7,4E+0
2 
5,7E+0
2 
L-Serine 
7,4E+0
2 
2,6E+0
3 
1,5E+0
3 
6,4E+0
2 
2,8E+0
3 
1,2E+0
3 
1,7E+0
3 
2,9E+0
3 
1,8E+0
3 
1,1E+0
3 
1,7E+0
3 
8,9E+0
2 
7,1E+0
2 
8,7E+0
2 
2,7E+0
3 
1,8E+0
3 
7,6E+0
2 
L-Threonine 
2,6E+0
2 
1,4E+0
3 
4,8E+0
2 
5,6E+0
2 
1,9E+0
3 
3,0E+0
1 
4,7E+0
2 
1,7E+0
3 
1,6E+0
3 
1,4E+0
3 
2,5E+0
3 
3,6E+0
2 
1,1E+0
3 
9,8E+0
2 
4,5E+0
2 
2,7E+0
2 
1,0E+0
3 
L-Alanine 
1,3E+0
3 
2,1E+0
2 
2,7E+0
2 
8,5E+0
1 
9,5E+0
2 
0,0E+0
0 
2,8E+0
2 
9,5E+0
2 
5,4E+0
2 
2,2E+0
2 
1,0E+0
3 
1,4E+0
2 
6,5E+0
2 
6,9E+0
2 
9,2E+0
1 
1,9E+0
2 
5,7E+0
1 
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Table 6.22: Standard derivations of Biolog MicroArray™ PM01 analyzes - Part V. 
C-source 
V
5
8
3
 
O
G
1
R
F
 
U
W
6
1
4
9
 
U
W
2
8
6
0
 
U
W
6
7
2
4
 
U
W
7
7
6
1
 
U
W
7
7
7
7
 
U
W
7
7
8
0
 
U
W
7
7
5
3
 
U
W
1
8
3
3
 
U
W
7
7
7
9
 
L
M
G
T
 2
3
3
3
 
A
T
C
C
 2
7
9
5
9
 
U
W
6
7
2
7
 
D
3
2
 
U
W
7
7
0
9
 
D
1
 
L-Alanyl-Glycine 
1,3E+0
3 
3,4E+0
2 
3,9E+0
2 
1,3E+0
2 
9,3E+0
2 
4,7E-
01 
1,9E+0
2 
1,4E+0
3 
2,8E+0
2 
2,0E+0
2 
3,5E+0
2 
5,2E+0
1 
4,4E+0
2 
4,8E+0
2 
1,1E+0
2 
1,2E+0
2 
1,6E+0
2 
Acetoacetic Acid 
2,2E+0
3 
1,7E+0
3 
2,6E+0
3 
3,4E+0
3 
8,0E+0
3 
2,5E+0
3 
4,0E+0
3 
5,6E+0
3 
1,3E+0
3 
4,0E+0
3 
1,2E+0
3 
3,3E+0
3 
2,4E+0
3 
2,6E+0
3 
3,9E+0
3 
7,4E+0
2 
3,0E+0
3 
N-Acetyl-b-D-
Mannosamine 
1,2E+0
3 
4,2E+0
3 
1,1E+0
3 
1,5E+0
3 
3,6E+0
3 
3,5E+0
3 
4,8E+0
3 
5,8E+0
3 
1,7E+0
3 
2,3E+0
3 
2,4E+0
3 
3,5E+0
3 
2,3E+0
3 
2,1E+0
3 
3,3E+0
3 
7,3E+0
2 
2,0E+0
3 
Mono Methyl Succinate 
7,7E+0
2 
3,7E+0
3 
2,7E+0
2 
1,9E+0
3 
3,8E+0
3 
9,4E+0
2 
2,2E+0
3 
3,8E+0
3 
4,0E+0
2 
1,9E+0
3 
2,7E+0
3 
1,2E+0
3 
2,1E+0
3 
5,4E+0
2 
1,5E+0
3 
3,5E+0
2 
2,0E+0
3 
Methyl Pyruvate 
1,5E+0
3 
5,0E+0
3 
6,3E+0
2 
1,9E+0
3 
4,9E+0
3 
2,8E+0
2 
4,3E+0
3 
5,3E+0
3 
1,8E+0
3 
3,7E+0
3 
3,5E+0
3 
6,4E+0
3 
1,7E+0
3 
2,3E+0
3 
3,8E+0
3 
4,3E+0
3 
2,4E+0
3 
D-Malic Acid 
2,9E+0
3 
1,0E+0
3 
2,6E+0
3 
1,1E+0
4 
6,4E+0
3 
3,4E+0
3 
5,8E+0
3 
8,3E+0
3 
1,4E+0
3 
5,6E+0
3 
3,4E+0
3 
2,4E+0
3 
8,2E+0
3 
5,5E+0
3 
5,2E+0
3 
1,1E+0
4 
4,0E+0
3 
L-Malic Acid 
1,4E+0
3 
3,7E+0
3 
1,9E+0
3 
2,2E+0
3 
1,8E+0
3 
1,7E+0
3 
3,8E+0
3 
3,8E+0
3 
7,3E+0
2 
1,6E+0
3 
1,8E+0
3 
2,1E+0
3 
1,7E+0
3 
5,8E+0
2 
4,2E+0
3 
2,7E+0
3 
2,6E+0
3 
Glycyl-L-Proline 
2,0E+0
3 
1,6E+0
3 
1,1E+0
3 
3,6E+0
3 
1,6E+0
3 
8,7E+0
2 
2,5E+0
3 
1,3E+0
3 
2,8E+0
3 
9,0E+0
2 
2,0E+0
3 
1,1E+0
3 
1,6E+0
3 
1,7E+0
3 
1,3E+0
3 
7,8E+0
2 
1,3E+0
3 
p-Hydroxy-Phenylacetic 
Acid 
1,4E+0
3 
2,5E+0
3 
7,8E+0
2 
2,4E+0
3 
2,5E+0
3 
2,1E+0
3 
1,9E+0
3 
2,9E+0
3 
7,5E+0
2 
1,6E+0
3 
9,2E+0
2 
7,0E+0
2 
7,9E+0
2 
1,0E+0
3 
7,9E+0
2 
5,5E+0
2 
6,9E+0
2 
m-Hydroxy-Phenylacetic 
Acid 
9,4E+0
2 
2,4E+0
3 
9,4E+0
2 
1,9E+0
3 
2,6E+0
3 
1,1E+0
3 
2,0E+0
3 
2,8E+0
3 
1,3E+0
3 
1,5E+0
3 
1,8E+0
3 
2,5E+0
2 
8,3E+0
2 
1,6E+0
3 
2,5E+0
2 
6,3E+0
2 
1,5E+0
2 
Tyramine 
6,4E+0
2 
3,1E+0
3 
4,8E+0
2 
2,7E+0
3 
3,5E+0
3 
1,4E+0
3 
2,8E+0
3 
3,8E+0
3 
2,0E+0
3 
1,4E+0
3 
2,8E+0
3 
8,3E+0
2 
1,2E+0
3 
2,1E+0
3 
1,4E+0
3 
1,4E+0
3 
1,2E+0
3 
D-Psicose 
5,3E+0
3 
2,8E+0
3 
1,0E+0
3 
1,3E+0
3 
5,2E+0
3 
1,4E+0
4 
8,4E+0
2 
2,9E+0
3 
1,3E+0
4 
4,1E+0
3 
1,1E+0
4 
1,2E+0
4 
1,6E+0
4 
5,5E+0
2 
4,1E+0
2 
1,5E+0
4 
1,3E+0
4 
L-Lyxose 
2,2E+0
3 
1,7E+0
3 
7,4E+0
3 
2,2E+0
3 
1,1E+0
4 
1,7E+0
3 
1,5E+0
3 
3,6E+0
3 
1,3E+0
3 
2,8E+0
3 
6,2E+0
3 
2,4E+0
3 
6,9E+0
3 
1,0E+0
3 
1,9E+0
3 
1,8E+0
3 
9,5E+0
2 
Glucuronamide 
1,6E+0
3 
2,3E+0
3 
2,9E+0
3 
2,1E+0
3 
3,3E+0
3 
8,9E+0
2 
4,0E+0
2 
3,7E+0
3 
1,5E+0
3 
2,0E+0
3 
2,2E+0
3 
3,8E+0
2 
2,2E+0
3 
1,3E+0
3 
1,7E+0
3 
2,3E+0
3 
2,0E+0
3 
Pyruvic Acid 
1,9E+0
3 
4,6E+0
3 
8,4E+0
2 
1,9E+0
3 
8,5E+0
3 
1,9E+0
3 
4,1E+0
3 
5,4E+0
3 
1,6E+0
3 
3,6E+0
3 
2,2E+0
3 
3,3E+0
3 
1,8E+0
3 
9,5E+0
2 
2,8E+0
3 
1,2E+0
3 
1,3E+0
3 
L-Galactonic Acid-g-
Lactone 
9,6E+0
2 
3,5E+0
3 
6,8E+0
2 
1,7E+0
3 
3,5E+0
3 
7,5E+0
2 
2,0E+0
3 
3,7E+0
3 
9,0E+0
2 
2,1E+0
3 
2,3E+0
3 
1,1E+0
3 
1,4E+0
3 
5,4E+0
2 
9,6E+0
2 
6,7E+0
2 
1,9E+0
3 
D-Galacturonic Acid 
3,0E+0
3 
4,0E+0
3 
3,4E+0
3 
2,7E+0
3 
4,8E+0
3 
7,0E+0
3 
1,7E+0
3 
5,4E+0
3 
7,0E+0
3 
8,2E+0
3 
6,9E+0
3 
7,7E+0
3 
4,9E+0
3 
1,4E+0
3 
2,7E+0
3 
8,0E+0
3 
6,3E+0
3 
b-Phenylethylamine 
2,6E+0
3 
3,2E+0
3 
4,6E+0
2 
2,5E+0
3 
2,9E+0
3 
2,0E+0
3 
2,0E+0
3 
5,4E+0
3 
2,4E+0
3 
9,8E+0
2 
4,7E+0
2 
3,1E+0
3 
2,1E+0
3 
1,3E+0
3 
1,9E+0
3 
3,2E+0
2 
1,6E+0
3 
Ethanolamine 
2,4E+0
3 
5,7E+0
3 
1,2E+0
3 
2,8E+0
3 
2,5E+0
3 
2,4E+0
3 
3,0E+0
3 
5,5E+0
3 
1,8E+0
3 
5,6E+0
2 
6,4E+0
2 
2,7E+0
3 
9,1E+0
2 
6,0E+0
2 
1,9E+0
3 
1,1E+0
3 
1,2E+0
3 
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Table 6.23: Aerobic utilization of carbon sources of Biolog MicroArray™ PM02 - Part I. 
C-source 
V
5
8
3
 
O
G
1
R
F
 
U
W
6
1
4
9
 
U
W
2
8
6
0
 
U
W
6
7
2
4
 
U
W
7
7
6
1
 
U
W
7
7
7
7
 
U
W
7
7
8
0
 
U
W
7
7
5
3
 
U
W
1
8
3
3
 
U
W
7
7
7
9
 
L
M
G
T
 2
3
3
3
 
A
T
C
C
 2
7
9
5
9
 
U
W
6
7
2
7
 
D
3
2
 
U
W
7
7
0
9
 
D
1
 
Negative Control 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
Chondroitin Sulfate 
C 
3,40E+
01 
1,98E+
02 
1,60E+
01 
5,23E+
01 
6,97E+
02 
9,50E+
01 
4,57E+
01 
6,33E+
00 
1,43E+
01 
3,43E+
01 
3,21E+
02 
9,20E+
01 
1,56E+
02 
4,04E+
02 
7,64E+
02 
2,67E+
00 
1,73E+
02 
a-Cyclodextrin 
4,41E+
04 
4,57E+
04 
4,57E+
04 
5,33E+
04 
5,08E+
04 
4,82E+
04 
4,77E+
04 
5,16E+
04 
4,86E+
04 
4,56E+
04 
4,48E+
04 
4,96E+
04 
4,89E+
04 
4,74E+
04 
4,92E+
04 
4,80E+
04 
4,78E+
04 
b-Cyclodextrin 
3,56E+
04 
3,41E+
04 
2,98E+
04 
3,57E+
04 
4,26E+
04 
2,88E+
04 
2,69E+
04 
3,46E+
04 
3,48E+
04 
3,67E+
04 
3,81E+
04 
3,81E+
04 
3,07E+
04 
3,81E+
04 
4,14E+
04 
4,91E+
03 
3,09E+
04 
g-Cyclodextrin 
5,57E+
02 
0,00E+
00 
1,67E+
00 
0,00E+
00 
1,58E+
03 
1,09E+
02 
0,00E+
00 
1,73E+
01 
1,76E+
02 
1,13E+
02 
1,67E+
02 
3,92E+
02 
5,02E+
02 
1,19E+
02 
6,69E+
02 
0,00E+
00 
1,10E+
02 
Dextrin 
4,85E+
04 
5,26E+
04 
4,77E+
04 
5,42E+
04 
5,27E+
04 
5,16E+
04 
5,16E+
04 
5,55E+
04 
5,03E+
04 
4,82E+
04 
4,76E+
04 
5,21E+
04 
5,40E+
04 
5,34E+
04 
5,44E+
04 
4,91E+
04 
5,19E+
04 
Gelatin 
1,62E+
03 
3,11E+
02 
2,96E+
02 
2,13E+
02 
7,52E+
02 
3,77E+
02 
6,46E+
02 
2,50E+
03 
4,28E+
02 
5,15E+
02 
8,71E+
02 
7,72E+
02 
8,21E+
02 
2,94E+
03 
4,47E+
02 
9,97E+
01 
2,28E+
02 
Glycogen 
1,15E+
04 
3,83E+
03 
3,05E+
03 
2,62E+
03 
6,38E+
03 
4,88E+
03 
5,61E+
03 
8,12E+
03 
4,69E+
03 
4,37E+
03 
7,56E+
03 
6,54E+
03 
5,25E+
03 
6,30E+
03 
5,87E+
03 
1,00E+
03 
5,96E+
03 
Inulin 
2,71E+
03 
1,31E+
03 
4,10E+
02 
6,33E+
00 
1,41E+
03 
7,73E+
02 
9,07E+
02 
3,72E+
03 
1,18E+
03 
1,52E+
03 
2,25E+
03 
7,87E+
02 
1,19E+
03 
4,31E+
03 
2,04E+
03 
1,29E+
02 
9,81E+
02 
Laminarin 
1,53E+
04 
1,06E+
04 
6,10E+
03 
5,66E+
03 
9,63E+
03 
8,72E+
03 
9,84E+
03 
1,60E+
04 
9,05E+
03 
1,30E+
04 
1,23E+
04 
2,68E+
03 
8,42E+
03 
1,50E+
04 
1,19E+
04 
7,40E+
03 
9,70E+
03 
Mannan 
1,08E+
04 
9,68E+
03 
5,55E+
03 
5,13E+
03 
9,35E+
03 
7,93E+
03 
7,65E+
03 
1,20E+
04 
8,45E+
03 
9,34E+
03 
1,06E+
04 
8,33E+
03 
9,57E+
03 
1,14E+
04 
9,75E+
03 
6,16E+
03 
9,97E+
03 
Pectin 
3,67E+
04 
3,08E+
04 
2,98E+
04 
3,11E+
04 
3,57E+
04 
3,39E+
04 
3,23E+
04 
3,62E+
04 
3,32E+
04 
3,44E+
04 
3,70E+
04 
3,67E+
04 
3,71E+
04 
3,75E+
04 
3,71E+
04 
3,10E+
04 
3,57E+
04 
N-Acetyl-D-
Galactosamine 
3,86E+
04 
4,53E+
04 
4,13E+
04 
4,80E+
04 
4,61E+
04 
4,31E+
04 
4,46E+
04 
4,47E+
04 
4,52E+
04 
3,99E+
04 
4,09E+
04 
4,15E+
04 
4,43E+
04 
4,02E+
04 
4,20E+
04 
4,71E+
04 
4,08E+
04 
N-Acetyl-Neuraminic 
Acid 
4,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
b-D-Allose 
1,69E+
04 
1,28E+
04 
1,19E+
04 
1,32E+
04 
1,02E+
04 
1,66E+
04 
1,38E+
04 
1,89E+
04 
7,82E+
03 
2,04E+
04 
1,59E+
04 
5,52E+
03 
6,54E+
03 
1,54E+
04 
2,08E+
04 
1,72E+
04 
1,79E+
04 
Amygdalin 
4,06E+
04 
4,81E+
04 
4,23E+
04 
5,17E+
04 
5,17E+
04 
4,92E+
04 
4,67E+
04 
5,04E+
04 
5,02E+
04 
4,54E+
04 
4,05E+
04 
3,78E+
04 
4,74E+
04 
5,10E+
04 
5,24E+
04 
4,07E+
04 
4,86E+
04 
D-Arabinose 
2,87E+
04 
3,70E+
04 
2,77E+
04 
3,57E+
04 
3,41E+
04 
2,80E+
04 
3,77E+
04 
3,94E+
04 
3,48E+
04 
3,16E+
04 
2,48E+
04 
2,75E+
04 
3,02E+
04 
3,68E+
04 
3,21E+
04 
3,08E+
04 
3,31E+
04 
D-Arabitol 
1,90E+
03 
1,70E+
03 
1,06E+
03 
1,30E+
01 
1,84E+
03 
1,84E+
02 
1,42E+
03 
3,82E+
03 
8,60E+
02 
6,72E+
02 
1,85E+
03 
3,53E+
02 
8,90E+
02 
2,82E+
03 
1,89E+
03 
5,73E+
01 
1,35E+
03 
L-Arabitol 
1,76E+
02 
1,69E+
02 
3,06E+
02 
6,67E-
01 
1,04E+
03 
8,27E+
01 
4,37E+
02 
2,16E+
03 
8,49E+
02 
4,80E+
01 
3,41E+
02 
9,23E+
01 
4,86E+
02 
2,43E+
03 
1,13E+
03 
3,30E+
01 
1,81E+
03 
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Table 6.24: Aerobic utilization of carbon sources of Biolog MicroArray™ PM02 - Part II. 
C-source 
V
5
8
3
 
O
G
1
R
F
 
U
W
6
1
4
9
 
U
W
2
8
6
0
 
U
W
6
7
2
4
 
U
W
7
7
6
1
 
U
W
7
7
7
7
 
U
W
7
7
8
0
 
U
W
7
7
5
3
 
U
W
1
8
3
3
 
U
W
7
7
7
9
 
L
M
G
T
 2
3
3
3
 
A
T
C
C
 2
7
9
5
9
 
U
W
6
7
2
7
 
D
3
2
 
U
W
7
7
0
9
 
D
1
 
Arbutin 
4,40E
+04 
3,76E
+04 
4,65E
+04 
5,32E
+04 
5,33E
+04 
4,82E
+04 
4,88E
+04 
5,13E
+04 
5,06E
+04 
4,44E
+04 
4,69E
+04 
5,14E
+04 
5,16E
+04 
5,18E
+04 
5,17E
+04 
5,20E
+04 
5,03E
+04 
2-Deoxy-D-Ribose 
2,71E
+04 
3,41E
+04 
2,34E
+04 
2,86E
+04 
2,93E
+04 
2,56E
+04 
3,25E
+04 
3,62E
+04 
2,80E
+04 
2,24E
+04 
2,51E
+04 
2,40E
+04 
2,90E
+04 
3,24E
+04 
3,02E
+04 
2,46E
+04 
2,86E
+04 
i-Erythritol 
3,87E
+03 
3,03E
+03 
1,84E
+03 
9,70E
+02 
4,68E
+03 
1,78E
+03 
3,57E
+03 
6,42E
+03 
2,51E
+03 
3,30E
+03 
3,40E
+03 
2,87E
+03 
2,26E
+03 
5,80E
+03 
3,32E
+03 
1,14E
+03 
2,86E
+03 
D-Fucose 
1,01E
+04 
1,33E
+04 
8,54E
+03 
1,01E
+04 
1,11E
+04 
7,26E
+03 
1,26E
+04 
1,61E
+04 
1,13E
+04 
9,17E
+03 
9,04E
+03 
9,69E
+03 
7,34E
+03 
1,43E
+04 
1,27E
+04 
7,35E
+03 
1,08E
+04 
3-0-b-D-Galactopyranosyl-
D-Arabinose 
3,34E
+04 
4,41E
+04 
4,98E
+04 
4,73E
+04 
5,27E
+04 
5,01E
+04 
4,77E
+04 
4,46E
+04 
4,75E
+04 
3,48E
+04 
4,51E
+04 
5,07E
+04 
5,32E
+04 
2,70E
+04 
5,19E
+04 
3,97E
+04 
5,10E
+04 
Gentiobiose 
3,60E
+04 
3,76E
+04 
3,99E
+04 
4,54E
+04 
4,70E
+04 
4,05E
+04 
4,20E
+04 
4,55E
+04 
4,63E
+04 
3,93E
+04 
4,12E
+04 
4,24E
+04 
4,35E
+04 
4,31E
+04 
4,10E
+04 
4,66E
+04 
4,38E
+04 
L-Glucose 
4,09E
+02 
1,47E
+02 
1,16E
+02 
6,67E-
01 
1,79E
+02 
5,63E
+01 
2,34E
+02 
7,65E
+02 
7,17E
+01 
1,90E
+02 
1,05E
+03 
1,28E
+02 
0,00E
+00 
2,04E
+03 
6,90E
+01 
0,00E
+00 
1,97E
+01 
D-Lactitol 
1,32E
+03 
4,68E
+02 
4,03E
+04 
4,59E
+04 
4,74E
+04 
4,29E
+04 
4,33E
+04 
4,52E
+04 
4,34E
+04 
4,13E
+04 
3,78E
+04 
4,49E
+04 
4,50E
+04 
4,30E
+04 
4,59E
+04 
3,33E
+04 
4,36E
+04 
D-Melezitose 
3,70E
+04 
3,23E
+04 
4,14E
+04 
4,98E
+04 
4,90E
+04 
4,38E
+04 
4,24E
+04 
4,63E
+04 
4,62E
+04 
4,20E
+04 
4,28E
+04 
4,66E
+04 
4,54E
+04 
4,66E
+04 
4,44E
+04 
4,80E
+04 
4,53E
+04 
Maltitol 
1,08E
+04 
3,29E
+03 
2,79E
+02 
1,36E
+02 
4,22E
+03 
1,95E
+03 
2,78E
+03 
7,77E
+03 
2,75E
+03 
4,14E
+03 
4,20E
+03 
2,88E
+03 
2,54E
+03 
8,66E
+03 
2,62E
+03 
2,35E
+03 
3,22E
+03 
a-Methyl-D-Glucoside 
2,04E
+03 
1,38E
+03 
1,27E
+03 
2,50E
+02 
2,42E
+03 
7,54E
+02 
7,46E
+02 
4,99E
+03 
7,44E
+02 
1,74E
+03 
1,62E
+03 
9,06E
+02 
1,03E
+03 
7,08E
+03 
3,22E
+03 
2,03E
+02 
1,65E
+03 
b-Methyl-D-Galactoside 
1,42E
+04 
2,53E
+04 
3,81E
+04 
4,11E
+04 
4,49E
+04 
4,07E
+04 
4,26E
+04 
4,69E
+04 
4,03E
+04 
4,14E
+04 
4,28E
+04 
4,75E
+04 
4,90E
+03 
1,07E
+04 
9,31E
+03 
3,39E
+04 
4,18E
+04 
3-O-Methyl-Glucose 
1,82E
+04 
2,29E
+04 
2,11E
+04 
2,10E
+04 
2,49E
+04 
2,68E
+04 
2,55E
+04 
3,09E
+04 
2,51E
+04 
2,70E
+04 
2,87E
+04 
2,73E
+04 
2,66E
+04 
3,34E
+04 
2,79E
+04 
1,33E
+04 
2,63E
+04 
b-Methyl-D-Glucuronic Acid 
3,09E
+03 
1,83E
+03 
6,78E
+02 
6,60E
+01 
1,74E
+03 
3,98E
+02 
9,39E
+02 
5,19E
+03 
9,17E
+02 
1,50E
+03 
3,20E
+03 
1,37E
+03 
1,33E
+03 
6,42E
+03 
3,29E
+03 
5,43E
+01 
1,99E
+03 
a-Methyl-D-Mannoside 
9,31E
+03 
8,65E
+03 
4,93E
+03 
3,17E
+03 
5,82E
+03 
4,41E
+03 
6,98E
+03 
1,20E
+04 
4,91E
+03 
8,20E
+03 
5,34E
+03 
5,40E
+03 
4,84E
+03 
3,37E
+04 
8,83E
+03 
1,42E
+03 
6,08E
+03 
b-Methyl-D-Xyloside 
3,58E
+03 
3,21E
+03 
1,04E
+03 
7,31E
+02 
2,85E
+03 
9,84E
+02 
2,25E
+03 
7,60E
+03 
1,79E
+03 
2,59E
+03 
2,78E
+03 
2,50E
+03 
1,70E
+03 
5,91E
+03 
2,87E
+03 
1,41E
+02 
2,60E
+03 
Palatinose 
2,92E
+04 
3,64E
+04 
1,94E
+04 
2,08E
+04 
2,60E
+04 
1,91E
+04 
2,95E
+04 
3,92E
+04 
2,71E
+04 
2,63E
+04 
2,18E
+04 
2,21E
+04 
2,40E
+04 
3,69E
+04 
3,12E
+04 
2,28E
+04 
2,56E
+04 
D-Raffinose 
9,36E
+03 
6,54E
+03 
3,92E
+03 
3,51E
+03 
1,15E
+04 
9,24E
+03 
1,03E
+04 
1,12E
+04 
8,79E
+03 
1,48E
+04 
1,21E
+04 
6,81E
+03 
8,85E
+03 
1,11E
+04 
6,07E
+03 
9,76E
+03 
9,39E
+03 
Salicin 
4,27E
+04 
4,53E
+04 
4,27E
+04 
4,99E
+04 
4,86E
+04 
4,53E
+04 
4,75E
+04 
4,82E
+04 
4,59E
+04 
4,24E
+04 
4,29E
+04 
4,68E
+04 
4,71E
+04 
4,85E
+04 
4,90E
+04 
4,70E
+04 
4,77E
+04 
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Table 6.25: Aerobic utilization of carbon sources of Biolog MicroArray™ PM02 - Part III. 
C-source 
V
5
8
3
 
O
G
1
R
F
 
U
W
6
1
4
9
 
U
W
2
8
6
0
 
U
W
6
7
2
4
 
U
W
7
7
6
1
 
U
W
7
7
7
7
 
U
W
7
7
8
0
 
U
W
7
7
5
3
 
U
W
1
8
3
3
 
U
W
7
7
7
9
 
L
M
G
T
 2
3
3
3
 
A
T
C
C
 2
7
9
5
9
 
U
W
6
7
2
7
 
D
3
2
 
U
W
7
7
0
9
 
D
1
 
Sedoheptulosan 
9,91E+
02 
1,07E+
03 
2,67E+
00 
7,77E+
01 
9,38E+
02 
9,17E+
01 
1,71E+
03 
2,47E+
03 
1,80E+
01 
1,22E+
03 
5,93E+
02 
3,33E+
01 
2,26E+
02 
6,52E+
03 
1,83E+
01 
0,00E+
00 
4,33E+
02 
L-Sorbose 
8,14E+
03 
1,38E+
04 
7,88E+
03 
1,08E+
04 
1,27E+
04 
7,03E+
03 
1,02E+
04 
1,56E+
04 
1,23E+
04 
1,45E+
04 
8,77E+
03 
8,65E+
03 
8,34E+
03 
1,42E+
04 
1,08E+
04 
7,77E+
03 
1,18E+
04 
Stachyose 
1,30E+
03 
4,15E+
02 
2,27E+
01 
1,03E+
01 
5,27E+
02 
7,57E+
01 
8,26E+
02 
3,39E+
03 
1,04E+
02 
1,16E+
03 
7,73E+
02 
4,41E+
02 
2,62E+
02 
5,34E+
03 
5,50E+
02 
1,40E+
01 
2,19E+
02 
D-Tagatose 
4,73E+
04 
4,95E+
04 
4,88E+
04 
5,30E+
04 
5,50E+
04 
4,75E+
04 
4,89E+
04 
5,35E+
04 
5,26E+
04 
4,75E+
04 
4,82E+
04 
5,30E+
04 
4,93E+
04 
5,19E+
04 
5,30E+
04 
5,41E+
04 
5,24E+
04 
Turanose 
4,15E+
04 
4,16E+
04 
3,39E+
04 
3,56E+
04 
4,00E+
04 
3,79E+
04 
3,95E+
04 
4,48E+
04 
3,85E+
04 
3,85E+
04 
3,72E+
04 
3,90E+
04 
3,95E+
04 
4,38E+
04 
3,95E+
04 
3,45E+
04 
3,95E+
04 
Xylitol 
9,26E+
03 
5,71E+
03 
1,52E+
03 
8,72E+
02 
5,12E+
03 
2,50E+
03 
3,73E+
03 
9,68E+
03 
3,08E+
03 
1,18E+
03 
3,94E+
03 
3,45E+
03 
2,98E+
03 
1,15E+
04 
4,45E+
03 
1,06E+
03 
3,43E+
03 
N-Acetyl-D-
Glucosaminitol 
9,91E+
03 
9,16E+
03 
4,26E+
03 
1,07E+
04 
8,33E+
03 
5,80E+
03 
8,72E+
03 
1,08E+
04 
5,18E+
03 
8,42E+
03 
8,05E+
03 
8,13E+
03 
4,87E+
03 
1,16E+
04 
9,92E+
03 
4,80E+
03 
6,74E+
03 
g-Amino-Butyric 
Acid 
3,26E+
03 
2,06E+
03 
9,19E+
02 
4,86E+
02 
2,30E+
03 
8,31E+
02 
2,04E+
03 
6,48E+
03 
1,11E+
03 
1,70E+
03 
2,53E+
03 
2,02E+
03 
1,55E+
03 
5,85E+
03 
2,78E+
03 
3,74E+
02 
1,69E+
03 
d-Amino-Valeric 
Acid 
3,93E+
01 
1,23E+
01 
9,23E+
01 
5,00E+
00 
5,86E+
02 
1,13E+
02 
9,67E+
00 
3,75E+
02 
1,08E+
02 
4,43E+
01 
1,14E+
02 
1,04E+
02 
3,63E+
01 
7,47E+
01 
1,50E+
02 
1,63E+
01 
3,03E+
02 
Butyric Acid 
1,06E+
04 
7,21E+
03 
1,24E+
04 
9,27E+
03 
1,20E+
04 
1,45E+
04 
8,36E+
03 
1,44E+
04 
1,59E+
04 
1,55E+
04 
9,85E+
03 
1,36E+
04 
1,19E+
04 
1,22E+
04 
1,38E+
04 
8,87E+
03 
1,08E+
04 
Capric Acid 
1,77E+
03 
8,74E+
02 
1,38E+
02 
6,30E+
01 
4,05E+
02 
1,93E+
02 
6,00E+
02 
1,32E+
03 
4,36E+
02 
1,57E+
02 
9,70E+
01 
1,72E+
03 
5,70E+
02 
2,86E+
03 
4,53E+
02 
8,93E+
01 
5,35E+
02 
Caproic Acid 
1,56E+
02 
0,00E+
00 
0,00E+
00 
0,00E+
00 
1,60E+
01 
2,58E+
02 
3,41E+
02 
7,29E+
02 
4,52E+
02 
4,10E+
01 
9,00E+
02 
1,39E+
03 
2,23E+
02 
4,36E+
03 
0,00E+
00 
0,00E+
00 
2,43E+
02 
Citraconic Acid 
1,33E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
9,33E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
1,95E+
02 
0,00E+
00 
0,00E+
00 
0,00E+
00 
D,L-Citramalic Acid 
1,67E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
5,77E+
01 
1,00E+
00 
0,00E+
00 
4,74E+
02 
3,33E-
01 
1,03E+
02 
2,90E+
01 
2,33E+
00 
3,33E-
01 
1,98E+
03 
3,67E+
00 
0,00E+
00 
2,87E+
01 
D-Glucosamine 
3,63E+
04 
2,81E+
04 
4,41E+
04 
5,40E+
04 
5,23E+
04 
4,36E+
04 
4,69E+
04 
4,82E+
04 
4,20E+
04 
4,01E+
04 
4,37E+
04 
4,63E+
04 
4,55E+
04 
5,16E+
04 
4,49E+
04 
5,24E+
04 
4,54E+
04 
2-Hydroxy-Benzoic 
Acid 
8,33E+
00 
3,33E-
01 
0,00E+
00 
0,00E+
00 
3,40E+
01 
0,00E+
00 
0,00E+
00 
4,50E+
02 
0,00E+
00 
5,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
1,74E+
02 
0,00E+
00 
4,67E+
00 
1,00E+
00 
4-Hydroxy-Benzoic 
Acid 
6,67E-
01 
0,00E+
00 
0,00E+
00 
0,00E+
00 
6,67E+
00 
0,00E+
00 
0,00E+
00 
2,67E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
2,33E+
00 
0,00E+
00 
3,67E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
b-Hydroxy-Butyric 
Acid 
3,97E+
03 
3,60E+
03 
1,30E+
03 
8,96E+
02 
2,53E+
03 
1,27E+
03 
2,15E+
03 
7,73E+
03 
1,02E+
03 
2,73E+
03 
4,25E+
03 
2,75E+
03 
1,07E+
03 
9,93E+
03 
4,07E+
03 
1,88E+
02 
2,12E+
03 
g-Hydroxy-Butyric 
Acid 
9,31E+
03 
6,15E+
03 
3,65E+
03 
3,82E+
03 
9,71E+
03 
5,61E+
03 
5,99E+
03 
1,26E+
04 
6,73E+
03 
7,78E+
03 
1,04E+
04 
8,45E+
03 
9,09E+
03 
1,06E+
04 
7,36E+
03 
4,42E+
03 
8,59E+
03 
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Table 6.26: Aerobic utilization of carbon sources of Biolog MicroArray™ PM02 - Part IV. 
C-source 
V
5
8
3
 
O
G
1
R
F
 
U
W
6
1
4
9
 
U
W
2
8
6
0
 
U
W
6
7
2
4
 
U
W
7
7
6
1
 
U
W
7
7
7
7
 
U
W
7
7
8
0
 
U
W
7
7
5
3
 
U
W
1
8
3
3
 
U
W
7
7
7
9
 
L
M
G
T
 2
3
3
3
 
A
T
C
C
 2
7
9
5
9
 
U
W
6
7
2
7
 
D
3
2
 
U
W
7
7
0
9
 
D
1
 
a-Keto-Valeric Acid 
4,38E+
04 
4,53E+
04 
4,09E+
04 
4,57E+
04 
4,77E+
04 
4,34E+
04 
4,61E+
04 
4,90E+
04 
4,36E+
04 
4,10E+
04 
4,38E+
04 
4,45E+
04 
4,60E+
04 
4,72E+
04 
4,86E+
04 
3,54E+
04 
4,42E+
04 
Itaconic Acid 
3,61E+
02 
2,27E+
01 
1,43E+
01 
5,67E+
00 
2,43E+
02 
6,83E+
01 
9,67E+
00 
1,13E+
02 
9,53E+
01 
1,47E+
02 
5,37E+
01 
1,58E+
02 
2,39E+
02 
5,17E+
01 
1,63E+
01 
1,47E+
01 
2,67E+
02 
5-Keto-D-Gluconic 
Acid 
3,35E+
04 
4,04E+
04 
2,91E+
04 
3,42E+
04 
3,28E+
04 
3,42E+
04 
4,06E+
04 
4,73E+
04 
3,63E+
04 
3,19E+
04 
2,45E+
04 
3,14E+
04 
3,62E+
04 
4,66E+
04 
3,82E+
04 
3,63E+
04 
3,71E+
04 
D-Lactic Acid Methyl 
Ester 
2,67E+
00 
1,67E+
00 
0,00E+
00 
0,00E+
00 
3,03E+
01 
1,93E+
01 
5,33E+
00 
6,53E+
01 
0,00E+
00 
5,33E+
00 
0,00E+
00 
3,00E+
00 
0,00E+
00 
9,79E+
02 
8,67E+
01 
0,00E+
00 
0,00E+
00 
Malonic Acid 
6,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
1,73E+
01 
0,00E+
00 
0,00E+
00 
1,87E+
01 
0,00E+
00 
3,19E+
02 
5,57E+
01 
1,47E+
01 
0,00E+
00 
2,79E+
02 
0,00E+
00 
0,00E+
00 
6,67E-
01 
Melibionic Acid 
1,21E+
04 
1,20E+
04 
3,56E+
03 
5,37E+
02 
3,28E+
03 
2,37E+
03 
2,71E+
03 
5,80E+
03 
1,24E+
03 
6,02E+
03 
4,59E+
03 
3,50E+
03 
7,87E+
01 
2,58E+
03 
1,25E+
03 
7,79E+
02 
2,41E+
03 
Oxalic Acid 
1,67E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
6,67E+
00 
0,00E+
00 
0,00E+
00 
6,00E+
00 
3,67E+
00 
0,00E+
00 
1,67E+
00 
0,00E+
00 
2,00E+
00 
6,07E+
01 
0,00E+
00 
0,00E+
00 
2,77E+
01 
Oxalomalic Acid 
2,18E+
04 
2,36E+
04 
1,62E+
04 
2,27E+
04 
2,30E+
04 
1,82E+
04 
2,37E+
04 
2,71E+
04 
1,97E+
04 
1,90E+
04 
1,71E+
04 
2,02E+
04 
2,05E+
04 
2,80E+
04 
2,23E+
04 
1,86E+
04 
2,01E+
04 
Quinic Acid 
3,60E+
01 
3,00E+
00 
0,00E+
00 
0,00E+
00 
3,93E+
01 
0,00E+
00 
6,67E-
01 
7,88E+
02 
0,00E+
00 
0,00E+
00 
8,00E+
00 
0,00E+
00 
3,00E+
00 
1,22E+
03 
0,00E+
00 
0,00E+
00 
3,33E+
00 
D-Ribono-1,4-
Lactone 
2,33E+
00 
5,00E+
00 
2,33E+
00 
0,00E+
00 
6,43E+
01 
3,33E-
01 
2,33E+
00 
1,89E+
02 
0,00E+
00 
1,33E+
00 
5,80E+
01 
8,33E+
00 
0,00E+
00 
2,10E+
02 
1,40E+
01 
0,00E+
00 
4,33E+
00 
Sebacic Acid 
6,45E+
02 
3,43E+
01 
1,74E+
02 
3,50E+
01 
9,50E+
02 
4,08E+
02 
2,01E+
02 
1,83E+
03 
5,26E+
02 
8,44E+
02 
1,03E+
03 
1,04E+
03 
2,78E+
02 
1,51E+
03 
8,39E+
02 
6,57E+
01 
2,59E+
02 
Sorbic Acid 
2,08E+
04 
2,15E+
04 
1,70E+
04 
2,26E+
04 
2,30E+
04 
2,02E+
04 
2,32E+
04 
2,55E+
04 
2,28E+
04 
1,70E+
04 
1,78E+
04 
1,90E+
04 
1,93E+
04 
2,49E+
04 
2,29E+
04 
2,06E+
04 
2,19E+
04 
Succinamic Acid 
1,37E+
03 
3,97E+
02 
3,63E+
02 
7,73E+
01 
1,26E+
03 
1,57E+
02 
4,63E+
02 
3,72E+
03 
4,24E+
02 
5,13E+
02 
8,90E+
02 
8,75E+
02 
3,73E+
02 
3,27E+
03 
1,17E+
03 
3,93E+
01 
3,21E+
02 
D-Tartaric Acid 
9,42E+
03 
6,83E+
03 
3,68E+
03 
2,37E+
03 
8,09E+
03 
5,08E+
03 
6,52E+
03 
8,29E+
03 
5,59E+
03 
8,11E+
03 
1,00E+
04 
8,04E+
03 
5,48E+
03 
8,68E+
03 
7,78E+
03 
2,79E+
03 
6,18E+
03 
L-Tartaric Acid 
9,60E+
03 
1,03E+
04 
5,73E+
03 
5,72E+
03 
9,74E+
03 
7,35E+
03 
8,80E+
03 
1,15E+
04 
8,19E+
03 
8,45E+
03 
1,04E+
04 
1,01E+
04 
8,13E+
03 
9,84E+
03 
1,68E+
04 
6,36E+
03 
9,41E+
03 
Acetamide 
1,20E+
01 
0,00E+
00 
0,00E+
00 
0,00E+
00 
1,11E+
02 
2,50E+
01 
3,20E+
01 
6,42E+
02 
0,00E+
00 
2,57E+
01 
0,00E+
00 
0,00E+
00 
0,00E+
00 
9,76E+
02 
0,00E+
00 
0,00E+
00 
1,30E+
01 
L-Alaninamide 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
2,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
6,67E-
01 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
N-Acetyl-L-Glutamic 
Acid 
1,00E+
00 
6,67E-
01 
1,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
2,00E+
00 
4,07E+
02 
0,00E+
00 
3,33E-
01 
2,67E+
00 
0,00E+
00 
8,33E+
00 
1,86E+
03 
0,00E+
00 
0,00E+
00 
0,00E+
00 
L-Arginine 
4,60E+
02 
2,93E+
03 
2,49E+
02 
3,09E+
02 
1,02E+
03 
5,74E+
02 
2,25E+
02 
1,70E+
03 
7,12E+
02 
8,19E+
02 
2,40E+
03 
6,14E+
02 
3,42E+
03 
5,28E+
03 
8,33E+
00 
3,19E+
02 
2,32E+
02 
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Table 6.27: Aerobic utilization of carbon sources of Biolog MicroArray™ PM02 - Part V. 
C-source 
V
5
8
3
 
O
G
1
R
F
 
U
W
6
1
4
9
 
U
W
2
8
6
0
 
U
W
6
7
2
4
 
U
W
7
7
6
1
 
U
W
7
7
7
7
 
U
W
7
7
8
0
 
U
W
7
7
5
3
 
U
W
1
8
3
3
 
U
W
7
7
7
9
 
L
M
G
T
 2
3
3
3
 
A
T
C
C
 2
7
9
5
9
 
U
W
6
7
2
7
 
D
3
2
 
U
W
7
7
0
9
 
D
1
 
Glycine 
1,43E+
01 
0,00E+
00 
0,00E+
00 
0,00E+
00 
3,33E-
01 
1,67E+
00 
0,00E+
00 
3,32E+
02 
6,67E-
01 
0,00E+
00 
0,00E+
00 
0,00E+
00 
2,00E+
03 
5,48E+
02 
0,00E+
00 
0,00E+
00 
1,00E+
01 
L-Histidine 
3,33E-
01 
1,33E+
00 
3,33E-
01 
0,00E+
00 
1,26E+
02 
0,00E+
00 
2,67E+
00 
2,71E+
02 
0,00E+
00 
1,67E+
00 
4,17E+
01 
3,33E-
01 
1,00E+
00 
6,00E+
02 
2,33E+
00 
0,00E+
00 
2,67E+
00 
L-Homoserine 
5,25E+
02 
1,37E+
02 
4,80E+
01 
1,33E+
00 
5,00E+
02 
5,33E+
01 
2,47E+
02 
3,04E+
03 
2,23E+
01 
7,89E+
02 
3,45E+
02 
1,13E+
02 
4,69E+
02 
3,63E+
03 
5,06E+
02 
3,67E+
00 
2,20E+
02 
4-Hydroxy-L-Proline 
(trans) 
6,14E+
02 
2,63E+
01 
1,90E+
01 
4,33E+
00 
3,02E+
02 
1,90E+
01 
1,23E+
01 
1,14E+
03 
3,50E+
01 
8,90E+
01 
3,62E+
02 
1,08E+
02 
5,87E+
01 
9,60E+
02 
1,33E+
02 
1,20E+
01 
7,73E+
01 
L-Isoleucine 
1,81E+
03 
2,13E+
03 
1,09E+
02 
7,00E+
00 
1,14E+
03 
1,86E+
02 
1,90E+
02 
2,25E+
03 
3,40E+
02 
4,34E+
02 
7,62E+
02 
6,44E+
02 
1,24E+
03 
2,08E+
03 
3,16E+
02 
4,67E+
01 
5,67E+
02 
L-Leucine 
6,96E+
03 
2,17E+
03 
3,43E+
03 
3,69E+
03 
5,27E+
03 
3,62E+
03 
3,58E+
03 
7,36E+
03 
1,93E+
03 
5,38E+
03 
6,71E+
03 
5,26E+
03 
2,56E+
03 
7,00E+
03 
6,29E+
03 
5,90E+
02 
4,33E+
03 
L-Lysine 
7,98E+
03 
6,36E+
03 
2,11E+
03 
1,54E+
03 
4,38E+
03 
2,47E+
03 
4,64E+
03 
8,24E+
03 
2,44E+
03 
3,60E+
03 
5,24E+
03 
3,68E+
03 
4,72E+
03 
8,65E+
03 
4,86E+
03 
1,94E+
03 
4,51E+
03 
L-Methionine 
1,04E+
04 
1,07E+
04 
7,54E+
03 
7,72E+
03 
1,11E+
04 
8,88E+
03 
1,10E+
04 
1,33E+
04 
7,96E+
03 
9,95E+
03 
1,16E+
04 
9,85E+
03 
8,63E+
03 
1,25E+
04 
1,13E+
04 
7,39E+
03 
9,52E+
03 
L-Ornithine 
5,33E+
00 
3,33E+
00 
0,00E+
00 
0,00E+
00 
2,97E+
01 
0,00E+
00 
0,00E+
00 
3,49E+
02 
6,67E-
01 
0,00E+
00 
0,00E+
00 
0,00E+
00 
1,67E+
00 
1,47E+
01 
0,00E+
00 
0,00E+
00 
1,47E+
01 
L-Phenylalanine 
1,80E+
01 
0,00E+
00 
1,00E+
00 
0,00E+
00 
8,47E+
01 
1,23E+
01 
0,00E+
00 
1,33E+
00 
0,00E+
00 
3,01E+
02 
1,67E+
00 
0,00E+
00 
0,00E+
00 
6,53E+
01 
2,00E+
00 
0,00E+
00 
0,00E+
00 
L-Pyroglutamic Acid 
3,33E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
3,33E+
00 
0,00E+
00 
0,00E+
00 
3,80E+
01 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
0,00E+
00 
3,78E+
02 
0,00E+
00 
0,00E+
00 
3,33E-
01 
L-Valine 
7,69E+
02 
1,45E+
02 
2,40E+
01 
6,67E-
01 
4,32E+
02 
9,17E+
01 
1,86E+
03 
1,36E+
03 
6,80E+
01 
1,37E+
01 
4,09E+
02 
1,27E+
01 
5,88E+
02 
2,39E+
03 
2,04E+
02 
1,00E+
01 
2,20E+
02 
D,L-Carnitine 
1,29E+
03 
1,57E+
01 
1,50E+
02 
2,33E+
00 
8,74E+
02 
1,41E+
02 
1,88E+
03 
2,33E+
03 
3,32E+
02 
2,47E+
02 
7,60E+
02 
4,33E+
02 
7,70E+
02 
3,42E+
03 
1,25E+
02 
1,57E+
01 
5,12E+
02 
Butylamine (sec) 
2,75E+
03 
5,26E+
02 
5,82E+
02 
1,69E+
02 
2,67E+
03 
1,81E+
02 
1,28E+
03 
3,13E+
03 
5,58E+
02 
2,10E+
03 
1,79E+
03 
2,93E+
02 
6,94E+
02 
2,40E+
03 
1,97E+
03 
3,00E+
01 
5,16E+
02 
D,L-Octopamine 
1,47E+
03 
1,77E+
02 
6,08E+
02 
1,25E+
02 
2,48E+
03 
7,76E+
02 
1,43E+
03 
2,85E+
03 
4,58E+
02 
5,02E+
02 
5,04E+
02 
4,63E+
02 
7,40E+
02 
2,30E+
03 
9,75E+
02 
2,64E+
02 
1,42E+
03 
Putrescine 
1,64E+
03 
5,73E+
01 
6,07E+
01 
2,25E+
02 
9,97E+
02 
5,80E+
01 
9,80E+
01 
2,38E+
03 
3,77E+
01 
9,93E+
01 
1,46E+
03 
9,50E+
01 
1,17E+
03 
2,24E+
03 
3,16E+
02 
3,23E+
01 
1,61E+
02 
Dihydroxy-Acetone 
4,23E+
04 
5,01E+
04 
3,78E+
04 
4,36E+
04 
4,34E+
04 
4,14E+
04 
4,60E+
04 
5,25E+
04 
4,18E+
04 
3,67E+
04 
3,71E+
04 
4,10E+
04 
4,64E+
04 
4,75E+
04 
4,70E+
04 
4,43E+
04 
4,31E+
04 
2,3-Butanediol 
7,96E+
03 
6,90E+
03 
3,33E+
03 
2,47E+
03 
6,97E+
03 
4,33E+
03 
6,22E+
03 
1,10E+
04 
3,51E+
03 
4,03E+
03 
7,61E+
03 
4,72E+
03 
4,84E+
03 
1,28E+
04 
7,44E+
03 
1,79E+
03 
6,08E+
03 
2,3-Butanone 
1,04E+
04 
9,38E+
03 
5,00E+
03 
4,70E+
03 
9,14E+
03 
5,10E+
03 
8,99E+
03 
1,25E+
04 
5,11E+
03 
5,51E+
03 
7,50E+
03 
8,65E+
03 
8,64E+
03 
1,14E+
04 
8,31E+
03 
5,19E+
03 
6,75E+
03 
3-Hydroxy-2-
Butanone 
1,05E+
04 
1,15E+
04 
7,62E+
03 
6,69E+
03 
9,88E+
03 
7,60E+
03 
8,76E+
03 
1,16E+
04 
6,64E+
03 
9,60E+
03 
1,11E+
04 
1,02E+
04 
8,61E+
03 
9,95E+
03 
9,98E+
03 
5,52E+
03 
8,79E+
03 
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Table 6.28: Standard derivations of Biolog MicroArray™ PM02 analyzes - Part I. 
C-source 
V
5
8
3
 
O
G
1
R
F
 
U
W
6
1
4
9
 
U
W
2
8
6
0
 
U
W
6
7
2
4
 
U
W
7
7
6
1
 
U
W
7
7
7
7
 
U
W
7
7
8
0
 
U
W
7
7
5
3
 
U
W
1
8
3
3
 
U
W
7
7
7
9
 
L
M
G
T
 2
3
3
3
 
A
T
C
C
 2
7
9
5
9
 
U
W
6
7
2
7
 
D
3
2
 
U
W
7
7
0
9
 
D
1
 
Negative Control 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
Chondroitin Sulfate C 
1,9E+0
1 
2,8E+0
2 
1,2E+0
1 
6,6E+0
1 
3,7E+0
2 
9,2E+0
1 
6,0E+0
1 
9,0E+0
0 
2,0E+0
1 
3,0E+0
1 
4,3E+0
2 
1,3E+0
2 
1,9E+0
2 
5,1E+0
2 
5,6E+0
2 
3,8E+0
0 
2,5E+0
2 
a-Cyclodextrin 
9,3E+0
2 
2,8E+0
3 
8,0E+0
3 
2,3E+0
3 
2,4E+0
3 
3,5E+0
3 
2,8E+0
3 
2,3E+0
3 
2,6E+0
3 
1,3E+0
3 
3,0E+0
3 
4,5E+0
2 
7,3E+0
2 
3,0E+0
3 
9,3E+0
2 
2,1E+0
3 
2,4E+0
3 
b-Cyclodextrin 
3,7E+0
3 
2,2E+0
3 
6,6E+0
3 
3,0E+0
3 
3,0E+0
3 
2,3E+0
3 
6,1E+0
2 
2,5E+0
3 
1,6E+0
3 
2,9E+0
3 
3,8E+0
3 
2,3E+0
3 
4,3E+0
3 
1,8E+0
3 
5,8E+0
2 
9,3E+0
2 
2,4E+0
3 
g-Cyclodextrin 
5,8E+0
2 
0,0E+0
0 
2,4E+0
0 
0,0E+0
0 
1,5E+0
3 
1,5E+0
2 
0,0E+0
0 
2,5E+0
1 
2,5E+0
2 
1,5E+0
2 
2,3E+0
2 
5,5E+0
2 
7,1E+0
2 
1,7E+0
2 
8,3E+0
2 
0,0E+0
0 
1,6E+0
2 
Dextrin 
3,1E+0
3 
1,1E+0
3 
7,4E+0
3 
1,6E+0
3 
1,8E+0
3 
2,9E+0
3 
1,0E+0
3 
8,3E+0
2 
1,4E+0
3 
1,8E+0
3 
4,5E+0
3 
2,3E+0
3 
6,9E+0
2 
3,1E+0
3 
1,8E+0
3 
1,9E+0
3 
2,6E+0
3 
Gelatin 
1,7E+0
3 
1,4E+0
2 
3,3E+0
2 
4,6E+0
1 
5,3E+0
2 
1,3E+0
2 
3,4E+0
2 
2,0E+0
3 
2,6E+0
2 
1,5E+0
2 
7,4E+0
2 
6,8E+0
2 
6,0E+0
2 
2,3E+0
3 
9,0E+0
1 
9,1E+0
1 
1,6E+0
2 
Glycogen 
2,1E+0
3 
1,3E+0
3 
2,2E+0
3 
1,1E+0
3 
1,4E+0
3 
2,6E+0
2 
5,7E+0
2 
3,8E+0
3 
1,9E+0
3 
3,7E+0
3 
1,6E+0
3 
1,3E+0
3 
2,4E+0
3 
4,5E+0
3 
2,0E+0
3 
5,9E+0
2 
1,5E+0
3 
Inulin 
1,6E+0
3 
1,4E+0
3 
4,5E+0
2 
4,9E+0
0 
8,6E+0
2 
6,0E+0
2 
6,6E+0
2 
2,3E+0
3 
1,0E+0
3 
1,1E+0
3 
5,9E+0
2 
5,6E+0
2 
1,4E+0
3 
4,5E+0
3 
2,2E+0
3 
1,4E+0
2 
8,6E+0
2 
Laminarin 
6,0E+0
2 
2,3E+0
3 
4,6E+0
3 
2,8E+0
3 
5,1E+0
2 
9,1E+0
2 
1,7E+0
3 
4,2E+0
3 
2,9E+0
3 
5,7E+0
3 
3,2E+0
3 
2,0E+0
3 
3,6E+0
2 
5,8E+0
3 
2,8E+0
3 
3,5E+0
3 
1,1E+0
3 
Mannan 
2,9E+0
3 
1,5E+0
3 
3,4E+0
3 
9,9E+0
2 
1,6E+0
3 
1,9E+0
3 
6,4E+0
2 
3,4E+0
3 
2,3E+0
3 
1,0E+0
3 
1,5E+0
3 
2,0E+0
3 
2,1E+0
3 
4,3E+0
3 
2,6E+0
3 
3,3E+0
3 
2,2E+0
3 
Pectin 
2,6E+0
3 
1,4E+0
3 
7,6E+0
3 
2,4E+0
3 
1,1E+0
3 
2,3E+0
3 
3,5E+0
3 
3,0E+0
3 
2,2E+0
3 
4,9E+0
3 
3,2E+0
3 
4,0E+0
3 
4,4E+0
3 
9,7E+0
2 
2,9E+0
3 
2,9E+0
3 
2,0E+0
3 
N-Acetyl-D-
Galactosamine 
2,6E+0
3 
2,3E+0
3 
7,3E+0
3 
1,3E+0
3 
2,8E+0
2 
1,6E+0
3 
4,2E+0
3 
5,3E+0
3 
2,9E+0
3 
3,9E+0
3 
4,6E+0
3 
3,7E+0
3 
8,3E+0
2 
2,1E+0
3 
4,4E+0
3 
2,7E+0
3 
2,8E+0
2 
N-Acetyl-Neuraminic 
Acid 
5,7E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
b-D-Allose 
4,1E+0
3 
7,5E+0
3 
7,0E+0
3 
6,9E+0
3 
6,5E+0
3 
2,0E+0
3 
7,6E+0
3 
3,3E+0
3 
6,7E+0
3 
4,5E+0
3 
7,5E+0
2 
7,6E+0
3 
8,9E+0
3 
9,6E+0
3 
3,3E+0
3 
1,6E+0
3 
1,1E+0
3 
Amygdalin 
9,4E+0
3 
3,2E+0
3 
5,8E+0
3 
1,8E+0
3 
2,8E+0
3 
3,2E+0
3 
4,3E+0
3 
3,1E+0
3 
3,7E+0
3 
3,8E+0
3 
7,9E+0
3 
2,0E+0
4 
2,5E+0
3 
1,1E+0
3 
1,5E+0
3 
1,8E+0
4 
1,6E+0
3 
D-Arabinose 
1,0E+0
4 
6,2E+0
2 
1,2E+0
4 
2,0E+0
3 
9,1E+0
3 
3,0E+0
3 
1,3E+0
3 
1,4E+0
3 
3,7E+0
3 
5,5E+0
3 
4,9E+0
3 
8,5E+0
3 
6,1E+0
3 
3,6E+0
3 
4,6E+0
3 
3,8E+0
3 
4,7E+0
3 
D-Arabitol 
2,1E+0
3 
1,9E+0
3 
1,4E+0
3 
1,4E+0
1 
1,6E+0
3 
1,8E+0
2 
8,9E+0
2 
2,9E+0
3 
9,7E+0
2 
7,6E+0
2 
2,4E+0
3 
2,1E+0
2 
7,3E+0
2 
3,3E+0
3 
4,8E+0
2 
1,5E+0
1 
1,0E+0
3 
L-Arabitol 
1,5E+0
2 
7,8E+0
1 
3,9E+0
2 
9,4E-
01 
1,3E+0
3 
7,6E+0
1 
5,2E+0
2 
1,6E+0
3 
7,5E+0
2 
5,8E+0
1 
4,3E+0
2 
6,0E+0
1 
3,5E+0
2 
2,4E+0
3 
1,2E+0
3 
4,4E+0
1 
8,7E+0
2 
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Table 6.29: Standard derivations of Biolog MicroArray™ PM02 analyzes - Part II. 
C-source 
V
5
8
3
 
O
G
1
R
F
 
U
W
6
1
4
9
 
U
W
2
8
6
0
 
U
W
6
7
2
4
 
U
W
7
7
6
1
 
U
W
7
7
7
7
 
U
W
7
7
8
0
 
U
W
7
7
5
3
 
U
W
1
8
3
3
 
U
W
7
7
7
9
 
L
M
G
T
 2
3
3
3
 
A
T
C
C
 2
7
9
5
9
 
U
W
6
7
2
7
 
D
3
2
 
U
W
7
7
0
9
 
D
1
 
Arbutin 
1,6E+
03 
2,0E+
03 
8,3E+
03 
2,4E+
03 
1,7E+
03 
2,4E+
03 
4,7E+
03 
4,3E+
03 
3,3E+
03 
5,7E+
03 
5,1E+
03 
2,0E+
03 
1,4E+
03 
1,6E+
03 
3,7E+
02 
3,5E+
03 
3,0E+
03 
2-Deoxy-D-Ribose 
9,1E+
03 
1,6E+
03 
9,8E+
03 
4,6E+
03 
6,7E+
03 
3,5E+
03 
2,0E+
03 
2,4E+
03 
3,3E+
03 
3,4E+
03 
6,2E+
03 
4,6E+
03 
2,5E+
03 
2,8E+
03 
1,5E+
03 
3,2E+
03 
4,2E+
03 
i-Erythritol 
1,6E+
03 
6,4E+
02 
1,6E+
03 
4,3E+
02 
1,5E+
03 
1,3E+
03 
1,3E+
03 
2,3E+
03 
7,1E+
02 
2,6E+
03 
2,9E+
03 
1,4E+
03 
6,4E+
02 
3,5E+
03 
7,4E+
02 
8,1E+
02 
2,5E+
02 
D-Fucose 
7,4E+
03 
4,5E+
02 
6,2E+
03 
1,7E+
03 
4,8E+
03 
3,1E+
03 
1,6E+
03 
1,4E+
03 
4,4E+
03 
5,5E+
03 
5,1E+
03 
4,9E+
03 
4,3E+
03 
4,3E+
03 
1,5E+
03 
4,6E+
03 
3,4E+
03 
3-0-b-D-Galactopyranosyl-D-
Arabinose 
9,3E+
03 
6,5E+
03 
7,1E+
03 
2,2E+
03 
5,7E+
02 
2,6E+
03 
6,7E+
03 
2,3E+
03 
1,3E+
03 
9,1E+
03 
4,2E+
03 
4,4E+
03 
6,2E+
02 
5,9E+
03 
4,4E+
03 
1,8E+
03 
2,6E+
03 
Gentiobiose 
4,2E+
03 
5,9E+
03 
7,0E+
03 
1,4E+
03 
1,5E+
03 
1,1E+
03 
4,1E+
03 
5,4E+
03 
2,8E+
03 
3,0E+
03 
4,9E+
03 
4,1E+
03 
2,0E+
02 
2,7E+
03 
3,5E+
03 
3,5E+
03 
1,4E+
03 
L-Glucose 
5,5E+
02 
1,3E+
02 
1,6E+
02 
9,4E-
01 
2,0E+
02 
8,0E+
01 
3,3E+
02 
8,1E+
02 
7,1E+
01 
2,7E+
02 
1,5E+
03 
1,8E+
02 
0,0E+
00 
2,7E+
03 
4,9E+
01 
0,0E+
00 
1,8E+
01 
D-Lactitol 
8,9E+
02 
3,7E+
02 
8,2E+
03 
4,3E+
02 
3,3E+
03 
3,6E+
03 
4,7E+
03 
4,1E+
03 
3,3E+
03 
3,5E+
03 
4,6E+
03 
2,4E+
03 
9,8E+
02 
6,5E+
02 
1,7E+
03 
1,6E+
03 
3,2E+
03 
D-Melezitose 
4,2E+
03 
4,7E+
03 
8,8E+
03 
7,6E+
02 
2,9E+
03 
2,3E+
03 
7,0E+
03 
7,6E+
03 
2,7E+
03 
4,6E+
03 
4,4E+
03 
1,7E+
03 
2,9E+
03 
2,8E+
03 
3,2E+
03 
3,3E+
03 
2,4E+
03 
Maltitol 
1,6E+
03 
2,6E+
03 
1,8E+
02 
1,4E+
02 
2,3E+
03 
1,6E+
03 
3,5E+
03 
3,7E+
03 
3,7E+
03 
2,7E+
03 
2,1E+
03 
1,7E+
03 
2,5E+
03 
7,6E+
03 
3,0E+
03 
3,1E+
03 
3,6E+
03 
a-Methyl-D-Glucoside 
1,7E+
03 
4,9E+
02 
9,2E+
02 
1,8E+
02 
1,9E+
03 
7,2E+
02 
7,8E+
02 
2,3E+
03 
6,0E+
02 
1,8E+
03 
1,6E+
03 
1,1E+
03 
3,6E+
02 
4,3E+
03 
1,4E+
03 
2,6E+
02 
1,4E+
02 
b-Methyl-D-Galactoside 
5,8E+
03 
2,6E+
03 
8,1E+
03 
2,8E+
03 
3,1E+
03 
4,8E+
03 
2,0E+
03 
2,5E+
03 
3,1E+
03 
4,5E+
03 
4,5E+
03 
4,4E+
03 
1,1E+
03 
5,6E+
03 
2,4E+
03 
3,6E+
03 
4,4E+
03 
3-O-Methyl-Glucose 
1,2E+
04 
4,2E+
03 
7,3E+
03 
4,7E+
03 
2,1E+
03 
2,2E+
03 
3,2E+
03 
4,7E+
03 
2,1E+
03 
4,5E+
03 
4,7E+
03 
3,5E+
03 
1,9E+
03 
5,1E+
03 
2,8E+
03 
6,0E+
03 
1,2E+
03 
b-Methyl-D-Glucuronic Acid 
3,6E+
03 
9,8E+
02 
7,4E+
02 
2,8E+
01 
1,5E+
03 
3,4E+
02 
8,6E+
02 
2,4E+
03 
9,2E+
02 
1,3E+
03 
2,0E+
03 
1,2E+
03 
7,3E+
02 
4,0E+
03 
3,0E+
03 
2,4E+
01 
8,4E+
02 
a-Methyl-D-Mannoside 
7,1E+
03 
2,5E+
03 
3,5E+
03 
1,4E+
03 
3,1E+
03 
2,4E+
03 
2,0E+
03 
3,8E+
03 
2,0E+
03 
5,2E+
03 
6,2E+
03 
3,7E+
03 
3,4E+
03 
4,5E+
03 
2,3E+
03 
9,6E+
02 
2,5E+
03 
b-Methyl-D-Xyloside 
3,5E+
03 
9,2E+
02 
1,1E+
03 
6,7E+
02 
7,9E+
02 
8,3E+
01 
8,4E+
02 
3,1E+
03 
8,2E+
02 
1,6E+
03 
2,7E+
03 
1,5E+
03 
1,3E+
03 
4,7E+
03 
1,8E+
03 
6,0E+
01 
5,5E+
02 
Palatinose 
8,8E+
03 
1,8E+
03 
1,1E+
04 
8,1E+
03 
6,1E+
03 
4,1E+
03 
8,3E+
03 
5,5E+
03 
1,8E+
03 
3,7E+
03 
4,5E+
03 
4,3E+
03 
6,0E+
03 
1,2E+
04 
6,4E+
03 
3,6E+
03 
4,9E+
03 
D-Raffinose 
4,4E+
03 
2,0E+
03 
2,8E+
03 
7,9E+
02 
1,6E+
03 
3,9E+
03 
9,3E+
02 
3,7E+
03 
5,8E+
03 
5,5E+
03 
2,4E+
03 
8,8E+
02 
3,1E+
03 
6,5E+
03 
1,5E+
03 
4,6E+
03 
5,0E+
03 
Salicin 
4,0E+
03 
1,7E+
03 
8,7E+
03 
8,6E+
02 
3,6E+
03 
3,4E+
03 
3,3E+
03 
3,3E+
03 
3,3E+
03 
2,7E+
03 
4,1E+
03 
2,8E+
03 
2,0E+
03 
1,4E+
03 
1,7E+
03 
4,2E+
03 
4,1E+
03 
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Table 6.30: Standard derivations of Biolog MicroArray™ PM02 analyzes - Part III. 
C-source 
V
5
8
3
 
O
G
1
R
F
 
U
W
6
1
4
9
 
U
W
2
8
6
0
 
U
W
6
7
2
4
 
U
W
7
7
6
1
 
U
W
7
7
7
7
 
U
W
7
7
8
0
 
U
W
7
7
5
3
 
U
W
1
8
3
3
 
U
W
7
7
7
9
 
L
M
G
T
 2
3
3
3
 
A
T
C
C
 2
7
9
5
9
 
U
W
6
7
2
7
 
D
3
2
 
U
W
7
7
0
9
 
D
1
 
Sedoheptulosan 
8,2E+0
2 
1,5E+0
3 
3,8E+0
0 
1,1E+0
2 
1,2E+0
3 
1,3E+0
2 
1,3E+0
3 
3,1E+0
3 
2,5E+0
1 
1,7E+0
3 
8,3E+0
2 
3,0E+0
1 
2,5E+0
2 
5,1E+0
3 
2,3E+0
1 
0,0E+0
0 
3,4E+0
2 
L-Sorbose 
3,0E+0
3 
9,7E+0
2 
5,1E+0
3 
3,0E+0
3 
3,6E+0
3 
2,8E+0
3 
2,5E+0
3 
2,5E+0
3 
1,4E+0
3 
5,0E+0
3 
4,0E+0
3 
1,5E+0
3 
7,2E+0
2 
5,8E+0
3 
1,9E+0
3 
1,5E+0
3 
2,4E+0
3 
Stachyose 
1,5E+0
3 
3,7E+0
2 
2,3E+0
1 
1,4E+0
1 
6,0E+0
2 
4,4E+0
1 
8,6E+0
2 
2,1E+0
3 
7,0E+0
1 
1,5E+0
3 
8,5E+0
2 
6,0E+0
2 
3,1E+0
2 
5,3E+0
3 
6,7E+0
2 
1,5E+0
1 
1,7E+0
2 
D-Tagatose 
2,7E+0
3 
5,4E+0
3 
1,0E+0
4 
6,5E+0
3 
3,2E+0
3 
4,6E+0
3 
7,6E+0
3 
5,0E+0
3 
2,9E+0
3 
3,9E+0
3 
5,2E+0
3 
1,7E+0
3 
5,7E+0
3 
4,0E+0
3 
3,8E+0
3 
4,0E+0
3 
2,8E+0
3 
Turanose 
4,4E+0
3 
1,6E+0
3 
6,2E+0
3 
2,7E+0
3 
1,7E+0
3 
2,0E+0
3 
1,6E+0
3 
2,8E+0
3 
1,3E+0
3 
3,3E+0
3 
2,4E+0
3 
8,4E+0
2 
1,2E+0
3 
5,5E+0
3 
1,9E+0
3 
2,2E+0
3 
1,4E+0
3 
Xylitol 
3,9E+0
3 
3,3E+0
3 
1,1E+0
3 
1,2E+0
3 
2,2E+0
3 
1,4E+0
3 
1,8E+0
3 
3,4E+0
3 
1,4E+0
3 
1,6E+0
3 
4,3E+0
3 
2,3E+0
3 
5,4E+0
2 
5,2E+0
3 
4,3E+0
2 
8,6E+0
2 
9,3E+0
2 
N-Acetyl-D-
Glucosaminitol 
6,1E+0
3 
1,0E+0
3 
3,3E+0
3 
2,7E+0
3 
5,1E+0
3 
3,4E+0
3 
1,5E+0
3 
1,8E+0
3 
2,4E+0
3 
5,3E+0
3 
4,4E+0
3 
5,1E+0
3 
1,8E+0
3 
3,1E+0
3 
1,4E+0
3 
3,4E+0
3 
3,3E+0
3 
g-Amino-Butyric Acid 
3,0E+0
3 
1,1E+0
3 
1,0E+0
3 
3,3E+0
2 
1,9E+0
3 
7,6E+0
2 
1,0E+0
3 
2,3E+0
3 
7,3E+0
2 
1,8E+0
3 
2,3E+0
3 
1,4E+0
3 
5,9E+0
2 
4,8E+0
3 
1,1E+0
3 
1,9E+0
2 
9,8E+0
2 
d-Amino-Valeric Acid 
2,3E+0
1 
9,5E+0
0 
1,1E+0
2 
4,1E+0
0 
4,2E+0
2 
1,6E+0
2 
9,7E+0
0 
5,0E+0
2 
1,4E+0
2 
5,0E+0
1 
1,1E+0
2 
1,1E+0
2 
3,9E+0
1 
1,0E+0
2 
1,8E+0
2 
1,9E+0
1 
3,2E+0
2 
Butyric Acid 
4,2E+0
3 
1,1E+0
3 
8,0E+0
3 
1,5E+0
3 
5,2E+0
3 
2,0E+0
3 
8,0E+0
2 
3,6E+0
3 
8,8E+0
3 
5,0E+0
3 
4,3E+0
3 
2,8E+0
3 
4,4E+0
3 
3,2E+0
3 
5,1E+0
3 
5,2E+0
3 
4,5E+0
3 
Capric Acid 
2,3E+0
3 
7,6E+0
2 
4,8E+0
1 
4,5E+0
1 
4,1E+0
2 
1,6E+0
2 
8,1E+0
2 
6,5E+0
2 
5,3E+0
2 
8,1E+0
1 
8,1E+0
1 
2,3E+0
3 
6,2E+0
2 
4,0E+0
3 
4,8E+0
2 
1,2E+0
2 
6,6E+0
2 
Caproic Acid 
1,4E+0
2 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
1,4E+0
1 
3,6E+0
2 
4,8E+0
2 
9,5E+0
2 
6,4E+0
2 
3,7E+0
1 
9,5E+0
2 
2,0E+0
3 
3,0E+0
2 
2,7E+0
3 
0,0E+0
0 
0,0E+0
0 
3,4E+0
2 
Citraconic Acid 
1,9E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
1,3E+0
1 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
2,7E+0
2 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
D,L-Citramalic Acid 
2,4E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
7,7E+0
1 
1,4E+0
0 
0,0E+0
0 
6,6E+0
2 
4,7E-
01 
1,5E+0
2 
3,6E+0
1 
1,7E+0
0 
4,7E-
01 
2,7E+0
3 
2,6E+0
0 
0,0E+0
0 
4,1E+0
1 
D-Glucosamine 
4,3E+0
3 
2,2E+0
3 
1,1E+0
4 
5,0E+0
2 
4,4E+0
3 
6,2E+0
3 
7,5E+0
3 
6,3E+0
3 
6,5E+0
3 
5,4E+0
3 
6,5E+0
3 
5,8E+0
3 
2,6E+0
3 
2,8E+0
3 
5,2E+0
3 
5,2E+0
3 
6,1E+0
3 
2-Hydroxy-Benzoic 
Acid 
1,2E+0
1 
4,7E-
01 
0,0E+0
0 
0,0E+0
0 
4,8E+0
1 
0,0E+0
0 
0,0E+0
0 
6,3E+0
2 
0,0E+0
0 
7,1E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
2,4E+0
2 
0,0E+0
0 
6,6E+0
0 
1,4E+0
0 
4-Hydroxy-Benzoic 
Acid 
9,4E-
01 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
9,4E+0
0 
0,0E+0
0 
0,0E+0
0 
3,8E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
3,3E+0
0 
0,0E+0
0 
5,2E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
b-Hydroxy-Butyric Acid 
3,5E+0
3 
1,4E+0
3 
1,1E+0
3 
5,6E+0
2 
2,1E+0
3 
1,1E+0
3 
7,5E+0
2 
3,5E+0
3 
6,9E+0
2 
3,0E+0
3 
3,1E+0
3 
2,7E+0
3 
9,9E+0
2 
4,4E+0
3 
2,1E+0
3 
2,1E+0
2 
1,2E+0
3 
g-Hydroxy-Butyric Acid 
2,2E+0
3 
8,4E+0
2 
2,4E+0
3 
2,2E+0
3 
2,4E+0
3 
1,9E+0
3 
1,5E+0
3 
3,5E+0
3 
3,3E+0
3 
3,8E+0
3 
3,7E+0
3 
6,4E+0
2 
4,0E+0
3 
3,8E+0
3 
1,2E+0
3 
2,9E+0
3 
2,8E+0
3 
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Table 6.31: Standard derivations of Biolog MicroArray™ PM02 analyzes - Part IV. 
C-source 
V
5
8
3
 
O
G
1
R
F
 
U
W
6
1
4
9
 
U
W
2
8
6
0
 
U
W
6
7
2
4
 
U
W
7
7
6
1
 
U
W
7
7
7
7
 
U
W
7
7
8
0
 
U
W
7
7
5
3
 
U
W
1
8
3
3
 
U
W
7
7
7
9
 
L
M
G
T
 2
3
3
3
 
A
T
C
C
 2
7
9
5
9
 
U
W
6
7
2
7
 
D
3
2
 
U
W
7
7
0
9
 
D
1
 
a-Keto-Valeric Acid 
3,7E+0
3 
1,9E+0
3 
7,2E+0
3 
2,0E+0
3 
3,2E+0
3 
3,1E+0
3 
3,2E+0
3 
3,2E+0
3 
2,4E+0
3 
3,2E+0
3 
5,6E+0
3 
4,9E+0
3 
8,2E+0
2 
4,3E+0
3 
1,5E+0
3 
1,8E+0
3 
1,4E+0
3 
Itaconic Acid 
4,6E+0
2 
3,3E+0
0 
9,0E+0
0 
8,0E+0
0 
2,7E+0
2 
6,1E+0
1 
1,4E+0
1 
1,1E+0
2 
1,3E+0
2 
1,9E+0
2 
6,5E+0
1 
2,2E+0
2 
3,3E+0
2 
7,2E+0
1 
1,2E+0
1 
2,0E+0
1 
3,7E+0
2 
5-Keto-D-Gluconic 
Acid 
1,0E+0
4 
2,3E+0
3 
1,1E+0
4 
1,8E+0
3 
6,6E+0
3 
3,7E+0
3 
6,3E+0
3 
3,6E+0
3 
9,7E+0
2 
4,4E+0
3 
1,2E+0
4 
6,4E+0
3 
1,0E+0
4 
8,6E+0
3 
4,0E+0
3 
1,0E+0
3 
1,5E+0
3 
D-Lactic Acid Methyl 
Ester 
3,8E+0
0 
2,4E+0
0 
0,0E+0
0 
0,0E+0
0 
4,3E+0
1 
1,6E+0
1 
7,5E+0
0 
9,2E+0
1 
0,0E+0
0 
7,5E+0
0 
0,0E+0
0 
3,6E+0
0 
0,0E+0
0 
1,3E+0
3 
1,1E+0
2 
0,0E+0
0 
0,0E+0
0 
Malonic Acid 
8,5E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
2,3E+0
1 
0,0E+0
0 
0,0E+0
0 
2,6E+0
1 
0,0E+0
0 
4,5E+0
2 
7,9E+0
1 
2,1E+0
1 
0,0E+0
0 
3,9E+0
2 
0,0E+0
0 
0,0E+0
0 
9,4E-
01 
Melibionic Acid 
4,4E+0
3 
4,1E+0
3 
3,8E+0
3 
6,9E+0
2 
2,2E+0
3 
2,0E+0
3 
1,4E+0
3 
1,3E+0
3 
4,5E+0
2 
6,7E+0
3 
3,7E+0
3 
2,9E+0
3 
6,6E+0
1 
3,0E+0
3 
1,6E+0
3 
7,9E+0
2 
8,3E+0
2 
Oxalic Acid 
1,2E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
9,4E+0
0 
0,0E+0
0 
0,0E+0
0 
8,5E+0
0 
5,2E+0
0 
0,0E+0
0 
2,4E+0
0 
0,0E+0
0 
2,8E+0
0 
8,6E+0
1 
0,0E+0
0 
0,0E+0
0 
3,9E+0
1 
Oxalomalic Acid 
6,3E+0
3 
7,2E+0
2 
9,7E+0
3 
2,2E+0
3 
8,3E+0
3 
6,5E+0
3 
1,4E+0
3 
2,5E+0
3 
5,3E+0
3 
7,2E+0
3 
5,1E+0
3 
4,7E+0
3 
4,1E+0
3 
1,6E+0
3 
2,9E+0
3 
5,9E+0
3 
5,7E+0
3 
Quinic Acid 
5,1E+0
1 
4,2E+0
0 
0,0E+0
0 
0,0E+0
0 
5,1E+0
1 
0,0E+0
0 
9,4E-
01 
1,1E+0
3 
0,0E+0
0 
0,0E+0
0 
9,3E+0
0 
0,0E+0
0 
4,2E+0
0 
1,7E+0
3 
0,0E+0
0 
0,0E+0
0 
4,7E+0
0 
D-Ribono-1,4-Lactone 
3,3E+0
0 
7,1E+0
0 
3,3E+0
0 
0,0E+0
0 
9,0E+0
1 
4,7E-
01 
3,3E+0
0 
2,6E+0
2 
0,0E+0
0 
1,9E+0
0 
7,9E+0
1 
1,0E+0
1 
0,0E+0
0 
2,9E+0
2 
1,9E+0
1 
0,0E+0
0 
5,4E+0
0 
Sebacic Acid 
3,2E+0
2 
4,4E+0
1 
1,3E+0
2 
3,6E+0
1 
1,1E+0
3 
4,2E+0
2 
2,2E+0
2 
1,4E+0
3 
3,1E+0
2 
1,2E+0
3 
9,9E+0
2 
1,2E+0
3 
3,3E+0
2 
1,8E+0
3 
5,4E+0
2 
4,8E+0
1 
2,5E+0
2 
Sorbic Acid 
5,5E+0
3 
4,5E+0
3 
9,2E+0
3 
3,4E+0
3 
4,2E+0
3 
2,9E+0
3 
1,7E+0
3 
2,5E+0
3 
2,4E+0
3 
2,7E+0
3 
4,7E+0
3 
5,6E+0
3 
1,4E+0
3 
3,6E+0
3 
1,1E+0
3 
2,1E+0
3 
2,5E+0
3 
Succinamic Acid 
1,5E+0
3 
1,7E+0
2 
4,1E+0
2 
7,8E+0
1 
1,5E+0
3 
1,2E+0
2 
3,9E+0
2 
2,4E+0
3 
4,6E+0
2 
6,9E+0
2 
1,1E+0
3 
8,0E+0
2 
3,4E+0
2 
3,5E+0
3 
6,9E+0
2 
2,0E+0
1 
1,2E+0
2 
D-Tartaric Acid 
8,2E+0
2 
2,2E+0
2 
2,6E+0
3 
8,4E+0
2 
2,0E+0
3 
1,3E+0
3 
1,1E+0
3 
2,2E+0
3 
1,4E+0
3 
4,3E+0
3 
1,9E+0
3 
2,3E+0
3 
8,3E+0
2 
3,4E+0
3 
1,3E+0
3 
1,4E+0
3 
2,3E+0
2 
L-Tartaric Acid 
4,5E+0
2 
6,3E+0
2 
3,9E+0
3 
1,1E+0
3 
1,2E+0
3 
2,3E+0
2 
1,8E+0
2 
1,7E+0
3 
1,2E+0
3 
4,1E+0
3 
1,4E+0
3 
1,5E+0
3 
1,0E+0
3 
3,9E+0
3 
9,3E+0
3 
6,4E+0
2 
3,6E+0
2 
Acetamide 
1,4E+0
1 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
1,6E+0
2 
3,4E+0
1 
4,5E+0
1 
9,1E+0
2 
0,0E+0
0 
3,6E+0
1 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
1,4E+0
3 
0,0E+0
0 
0,0E+0
0 
1,8E+0
1 
L-Alaninamide 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
2,8E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
9,4E-
01 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
N-Acetyl-L-Glutamic 
Acid 
1,4E+0
0 
9,4E-
01 
1,4E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
2,8E+0
0 
5,8E+0
2 
0,0E+0
0 
4,7E-
01 
3,8E+0
0 
0,0E+0
0 
1,2E+0
1 
2,2E+0
3 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
L-Arginine 
2,5E+0
2 
1,2E+0
3 
7,1E+0
1 
3,8E+0
2 
7,7E+0
2 
7,8E+0
2 
2,4E+0
2 
1,8E+0
3 
9,0E+0
2 
6,5E+0
2 
1,4E+0
3 
4,8E+0
2 
2,3E+0
3 
3,6E+0
3 
1,0E+0
1 
4,3E+0
2 
3,2E+0
2 
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Table 6.32: Standard derivations of Biolog MicroArray™ PM02 analyzes - Part V. 
C-source 
V
5
8
3
 
O
G
1
R
F
 
U
W
6
1
4
9
 
U
W
2
8
6
0
 
U
W
6
7
2
4
 
U
W
7
7
6
1
 
U
W
7
7
7
7
 
U
W
7
7
8
0
 
U
W
7
7
5
3
 
U
W
1
8
3
3
 
U
W
7
7
7
9
 
L
M
G
T
 2
3
3
3
 
A
T
C
C
 2
7
9
5
9
 
U
W
6
7
2
7
 
D
3
2
 
U
W
7
7
0
9
 
D
1
 
Glycine 
1,2E+0
1 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
4,7E-
01 
2,4E+0
0 
0,0E+0
0 
4,7E+0
2 
9,4E-
01 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
2,8E+0
3 
7,8E+0
2 
0,0E+0
0 
0,0E+0
0 
1,4E+0
1 
L-Histidine 
4,7E-
01 
1,9E+0
0 
4,7E-
01 
0,0E+0
0 
1,7E+0
2 
0,0E+0
0 
1,9E+0
0 
3,8E+0
2 
0,0E+0
0 
2,4E+0
0 
5,7E+0
1 
4,7E-
01 
1,4E+0
0 
8,4E+0
2 
2,1E+0
0 
0,0E+0
0 
2,5E+0
0 
L-Homoserine 
5,0E+0
2 
8,0E+0
1 
3,4E+0
1 
1,9E+0
0 
4,6E+0
2 
4,7E+0
1 
2,4E+0
2 
3,1E+0
3 
1,8E+0
1 
1,1E+0
3 
2,6E+0
2 
1,1E+0
2 
3,3E+0
2 
3,9E+0
3 
5,3E+0
2 
3,3E+0
0 
2,1E+0
2 
4-Hydroxy-L-Proline 
(trans) 
4,3E+0
2 
2,7E+0
1 
2,5E+0
1 
6,1E+0
0 
3,9E+0
2 
2,0E+0
1 
7,9E+0
0 
1,5E+0
3 
1,3E+0
1 
1,2E+0
2 
4,1E+0
2 
1,1E+0
2 
4,3E+0
1 
1,2E+0
3 
8,3E+0
1 
1,4E+0
1 
9,4E+0
1 
L-Isoleucine 
1,6E+0
3 
2,8E+0
3 
9,3E+0
1 
2,2E+0
0 
8,1E+0
2 
2,2E+0
2 
1,3E+0
2 
2,5E+0
3 
3,9E+0
2 
5,5E+0
2 
2,7E+0
2 
5,6E+0
2 
1,2E+0
3 
2,0E+0
3 
1,8E+0
2 
4,8E+0
1 
6,9E+0
2 
L-Leucine 
2,9E+0
3 
5,3E+0
2 
2,4E+0
3 
4,5E+0
2 
2,9E+0
3 
2,4E+0
3 
2,1E+0
3 
1,5E+0
3 
1,2E+0
3 
4,4E+0
3 
4,2E+0
3 
4,1E+0
3 
4,1E+0
2 
4,0E+0
3 
8,1E+0
2 
3,0E+0
2 
2,3E+0
3 
L-Lysine 
2,6E+0
3 
1,3E+0
3 
1,6E+0
3 
9,9E+0
2 
1,8E+0
3 
8,1E+0
2 
1,4E+0
3 
2,3E+0
3 
1,3E+0
3 
2,9E+0
3 
2,6E+0
3 
1,8E+0
3 
2,6E+0
3 
5,0E+0
3 
1,5E+0
3 
9,1E+0
2 
1,0E+0
3 
L-Methionine 
1,8E+0
3 
1,6E+0
3 
5,4E+0
3 
1,6E+0
3 
2,3E+0
3 
2,5E+0
3 
2,9E+0
3 
2,0E+0
3 
3,2E+0
3 
3,4E+0
3 
3,6E+0
3 
2,8E+0
3 
8,2E+0
2 
3,0E+0
3 
1,3E+0
3 
1,1E+0
3 
2,3E+0
3 
L-Ornithine 
7,5E+0
0 
4,7E+0
0 
0,0E+0
0 
0,0E+0
0 
4,2E+0
1 
0,0E+0
0 
0,0E+0
0 
4,9E+0
2 
9,4E-
01 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
2,4E+0
0 
2,1E+0
1 
0,0E+0
0 
0,0E+0
0 
2,1E+0
1 
L-Phenylalanine 
2,5E+0
1 
0,0E+0
0 
1,4E+0
0 
0,0E+0
0 
1,1E+0
2 
1,7E+0
1 
0,0E+0
0 
1,2E+0
0 
0,0E+0
0 
4,3E+0
2 
2,4E+0
0 
0,0E+0
0 
0,0E+0
0 
9,2E+0
1 
2,8E+0
0 
0,0E+0
0 
0,0E+0
0 
L-Pyroglutamic Acid 
4,7E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
4,7E+0
0 
0,0E+0
0 
0,0E+0
0 
5,4E+0
1 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
0,0E+0
0 
5,4E+0
2 
0,0E+0
0 
0,0E+0
0 
4,7E-
01 
L-Valine 
7,3E+0
2 
1,9E+0
2 
2,3E+0
1 
9,4E-
01 
2,2E+0
2 
1,3E+0
2 
2,6E+0
3 
1,8E+0
3 
9,6E+0
1 
1,9E+0
1 
5,1E+0
2 
1,3E+0
1 
6,6E+0
2 
3,3E+0
3 
2,8E+0
2 
1,3E+0
1 
3,1E+0
2 
D,L-Carnitine 
1,1E+0
3 
1,4E+0
1 
1,9E+0
2 
3,3E+0
0 
7,5E+0
2 
2,0E+0
2 
2,6E+0
3 
2,2E+0
3 
3,9E+0
2 
2,5E+0
2 
8,3E+0
2 
3,9E+0
2 
6,2E+0
2 
3,4E+0
3 
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